Covalent Protein Adduction by Drugs of Abuse by Schneider, Kevin
Florida International University
FIU Digital Commons
FIU Electronic Theses and Dissertations University Graduate School
2-27-2013
Covalent Protein Adduction by Drugs of Abuse
Kevin Schneider
Florida International University, kevinjschneider@gmail.com
Follow this and additional works at: http://digitalcommons.fiu.edu/etd
This work is brought to you for free and open access by the University Graduate School at FIU Digital Commons. It has been accepted for inclusion in
FIU Electronic Theses and Dissertations by an authorized administrator of FIU Digital Commons. For more information, please contact dcc@fiu.edu.
Recommended Citation
Schneider, Kevin, "Covalent Protein Adduction by Drugs of Abuse" (2013). FIU Electronic Theses and Dissertations. Paper 816.
http://digitalcommons.fiu.edu/etd/816
 FLORIDA INTERNATIONAL UNIVERSITY 
Miami, Florida 
 
 
 
 
 
 
 
COVALENT PROTEIN ADDUCTION BY DRUGS OF ABUSE 
 
 
 
 
 
 
A dissertation submitted in partial fulfillment of 
the requirements for the degree of 
DOCTOR OF PHILOSOPHY 
in 
CHEMISTRY 
by 
Kevin J. Schneider 
 
2013 
  
ii 
To: Dean Kenneth G. Furton 
 College of Arts and Sciences 
 
This dissertation, written by Kevin J. Schneider, and entitled Covalent Protein Adduction by Drugs of 
Abuse, having been approved in respect to style and intellectual content, is referred to you for judgment. 
 
We have read this dissertation and recommend that it be approved. 
 
______________________________________________ 
Kenneth Furton 
 
______________________________________________ 
Bruce McCord 
 
______________________________________________ 
Alexander Mebel 
 
______________________________________________  
Berrin Serdar 
 
______________________________________________ 
Anthony DeCaprio, Major Professor 
 
Date of Defense: February 27, 2013 
The dissertation of Kevin J. Schneider is approved. 
 
______________________________________________ 
Dean Kenneth G. Furton 
College of Arts and Sciences 
 
______________________________________________ 
Dean Lakshmi N. Reddi 
University Graduate School 
 
 
Florida International University, 2013 
 
 
iii 
 
 
 
 
 
 
 
 
 
 
 
© Copyright 2013 by Kevin J. Schneider 
All rights reserved. 
  
iv 
ABSTRACT OF THE DISSERTATION 
COVALENT PROTEIN ADDUCTION BY DRUGS OF ABUSE 
by 
Kevin J. Schneider 
Florida International University, 2013 
Miami, Florida 
Professor Anthony DeCaprio, Major Professor 
 Recreational abuse of the drugs cocaine, methamphetamine, and morphine continues to be 
prevalent in the United States of America and around the world.  While numerous methods of detection 
exist for each drug, they are generally limited by the lifetime of the parent drug and its metabolites in the 
body.  However, the covalent modification of endogenous proteins by these drugs of abuse may act as 
biomarkers of exposure and allow for extension of detection windows for these drugs beyond the lifetime 
of parent molecules or metabolites in the free fraction.  Additionally, existence of covalently bound 
molecules arising from drug ingestion can offer insight into downstream toxicities associated with each of 
these drugs. 
 This research investigated the metabolism of cocaine, methamphetamine, and morphine in 
common in vitro assay systems, specifically focusing on the generation of reactive intermediates and 
metabolites that have the potential to form covalent protein adducts.  Results demonstrated the formation of 
covalent adduction products between biological cysteine thiols and reactive moieties on cocaine and 
morphine metabolites.  Rigorous mass spectrometric analysis in conjunction with in vitro metabolic 
activation, pharmacogenetic reaction phenotyping, and computational modeling were utilized to 
characterize structures and mechanisms of formation for each resultant thiol adduction product.  For 
cocaine, data collected demonstrated the formation of adduction products from a reactive arene epoxide 
intermediate, designating a novel metabolic pathway for cocaine.  In the case of morphine, data expanded 
on known adduct-forming pathways using sensitive and selective analysis techniques, following the known 
reactive metabolite, morphinone, and a proposed novel metabolite, morphine quinone methide.  Data 
collected in this study describe novel metabolic events for multiple important drugs of abuse, culminating 
v 
in detection methods and mechanistic descriptors useful to both medical and forensic investigators when 
examining the toxicology associated with cocaine, methamphetamine, and morphine.  
vi 
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1. INTRODUCTION 
 The toxicological fate of ingested xenobiotics, while extremely complex, is vital to understanding 
the downstream impact a drug will impart.  Covalent adducts formed between products of drug metabolism 
and endogenous biomolecules (including proteins and DNA) represent a largely unexamined branch of 
toxicology that is a key factor mediating the overall toxicokinetic and toxicodynamic properties of a drug.  
While playing a diverse role in the apparent pharmacology of a substance, these permanent modifications 
to existing biomolecules act as biomarkers of exposure and, in certain cases, are unequivocal evidence of 
xenobiotic intake that persist even after the free fraction is cleared from the body.  Mechanistic and 
analytical designation of covalent biomolecular adduction is of particular interest to forensic and medical 
specialists, granting insight into toxicity mechanisms (for acute, chronic, and idiosyncratic toxicities), 
carcinogenicity, teratogenicity, bioaccumulation, bioavailability, addiction pathology, and exposure 
assessment.  While these properties are examined by myriad assays and models during clinical 
development of pharmaceuticals, illicit substances lack the rigorous testing milieu afforded to regulated 
drugs.  This research examined the metabolic fate of three commonly abused drugs (cocaine, 
methamphetamine, and morphine), specifically illustrating structures and mechanisms associated with the 
formation of currently uncharacterized irreversible protein modifications. 
 Distinct protein adducts described by this research were generated using various metabolic model 
systems employed by pharmaceutical companies and characterized using liquid chromatography tandem 
mass spectrometry (LC-MS/MS) for structural designation.  In conjunction with experimental design, these 
structural analyses were the basis for mechanistic description of the adduction process and were used as 
physiochemical estimators of in vivo environments.  This research provides a more complete depiction of 
the metabolic fate of cocaine, methamphetamine, and morphine in the human body in addition to forming 
the foundation for the future development of assays to designate past drug use based on detection of 
covalent protein adducts.  
2 
2. LITERATURE REVIEW 
2.1. Xenobiotic Biotransformation 
Pharmacokinetically, the lifetime of a xenobiotic in vivo can be characterized by the absorption, 
distribution, metabolism, and elimination (ADME) scheme.  While each of these four stages is imperative 
in considering the fate of a drug in vivo, perhaps the most complex is the metabolism phase.  Involving the 
synchronization of numerous enzymes, cofactors, and other biochemical processes, xenobiotic 
transformation significantly influences the potency, activity, and lifetime of drugs and other exogenous 
chemicals in the body.  While the process of metabolism is unique to each individual because of biological 
and physiochemical factors, general trends in biotransformation are able to be characterized.   
The process of xenobiotic metabolism in the body is a complex system of modification and 
conjugation in order to produce a product that is readily eliminated from the body (i.e., a polar, water-
soluble product).  The extent of xenobiotic metabolism is dependent on numerous factors, including innate 
hydrophilicity, the number of functional groups amenable to biotransformation, and half-life.  In addition to 
conventional Phase I and Phase II biotransformation processes, subsequent interaction with endogenous 
biomolecules or other xenobiotics shape the metabolic and elimination schemes for certain compounds.  
These events include protein binding (reversible and irreversible), pooling of drugs or metabolites in 
specific tissues, multiple drug interactions, and co-metabolic production of unique metabolites.   
Within the category of biotransformation are two major subdividing classifications: Phase I and 
Phase II metabolism.  Phase I metabolism pertains to several “functionalizing” reactions including 
oxidation, reduction, and hydrolysis.1  While Phase I metabolism is pervasive throughout cellular tissues 
including brain and kidney and has also been detected in extracellular environments, the epicenter of Phase 
I biotransformation in the human body is within liver tissue.2,3  The workhorses behind “non-synthetic” 
Phase I reactions in the liver are various mixed function oxidases, primarily cytochrome P450 (CYP) and 
flavin monooxygenase (FMO) families.4   
Among the numerous enzymes responsible for xenobiotic modification, the CYP enzymes are 
capable of catalyzing myriad oxidative biotransformation reactions on a multitude of compounds with 
3 
diverse chemical structures and physiological actions.  The membrane-bound CYP superfamily of enzymes 
is characterized by incorporation of an iron-containing heme cofactor (Figure 1).   
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Figure 1: Iron-containing heme cofactor in CYP enzymes 
When these hemoproteins are reduced and a complex is formed between heme iron and carbon monoxide, 
the resultant structure absorbs light at 450 nm, justifying their classification as “P450” enzymes.  While the 
CYP superfamily of enzymes shares commonality in the iron-containing heme group, there are numerous 
CYP isoforms that differ in enzymatic structure, substrate specificity, efficiency, and tissue localization 
(more detail on CYP isozymes is reported in Section 2.2).  Cytochrome P450-catalyzed oxidation is 
uncharacteristic of typical oxidative processes because these enzymes succeed in facilitating reactions that 
are energetically unfavorable at ambient temperatures (e.g., hydroxylation of non-functionalized alkyl 
groups).   
Cytochrome P450 enzymes are able to oxidatively modify xenobiotics by generating highly 
reactive intermediates through cycling the oxidative state of the iron heme group and introducing molecular 
oxygen.5  While the exact mechanics behind CYP-catalyzed oxidations are still being researched, a brief 
outline is presented in Figure 2.6-8  In the substrate-free form, most CYP hemes exist in a hexa-ligated low-
spin state via H2O coordination (Figure 2a).  Introduction of substrate into the catalytic site of the enzyme 
displaces the coordinated water molecule, resulting in a modified geometry for the penta-ligated high-spin 
iron complex (Figure 2b).  Acceptance of an electron from the cofactor flavoprotein NADPH cytochrome 
P450 reductase reduces the iron to the reactive FeII species (Figure 2c), which is able to bind molecular 
oxygen (Figure 2d).  A second reduction step by a cofactor flavoprotein (NADPH cytochrome P450 
reductase or cytochrome b5) (Figure 2e) and input of protons (Figure 2f) results in the heterolytic cleavage 
of the O-O bond, loss of H2O, and production of the reactive “oxenoid” species (Figure 2g).  Substrate 
4 
oxidation (Figure 2h) and release followed by water coordination regenerates the substrate-free hexa-
ligated low-spin iron ensemble.  Dashed arrows in Figure 2 represent “leaky” reactive oxygen species-
producing branches of the CYP catalytic cycle (including the “peroxide shunt” (b)↔(f) pathway).  
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Figure 2: Cytochrome P450 catalytic cycle 
(a) H2O coordinated hexa-ligated low-spin heme, (b) penta-ligated high-spin iron complex, 
(c) reduced FeII species, (d) FeII heme with bound molecular oxygen, (e) peroxy ion heme 
complex, (f) hydroperoxo iron heme complex, (g) FeIV reactive oxenoid, (h) coordinated 
oxidized substrate, (i) hydroxyl iron heme complex.  Dashed arrows represent “leaky” 
reactive oxygen species-producing branches. 
While there are many considerations in assigning mechanisms to CYP oxidation reactions, a 
system in which there are two electrophilic oxidants and a reactive two-state ensemble for the oxo-iron 
intermediate seems to explain many inconsistencies that have been observed between previous theories and 
empirical data.5  In this model, the early oxidants (i.e., hydroperoxo-iron (Figure 2f), iron-complexed 
hydrogen peroxide) react via the insertion of OH+ to produce protonated alcohols, which are the species 
responsible for cationic rearrangement products (Figure 3, Scheme 1).  On the other hand, a two-state 
5 
reaction model for the action of the oxo-iron reactive species divides the mechanism of this intermediate 
between the low-spin and high-spin ensembles capable of abstracting hydrogen from the substrate followed 
by oxygen-rebound (Figure 3, Scheme 2).  Previously considered a mechanism for CYP oxidation, 
concerted oxene insertion (Figure 3, Scheme 3) has since been dismissed on the basis of empirical data 
demonstrating large intramolecular kinetic isotope effects, loss of stereochemistry, and substrate 
rearrangements inconsistent with this mechanism.8 
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Figure 3: CYP oxidation schemes.   
Scheme 1: Insertion of OH+ by hydroperoxo-iron or iron-complexed hydrogen peroxide.   
Scheme 2: Iron-oxo hydrogen atom abstraction and oxygen-rebound.   
Scheme 3: Oxene insertion. 
 In addition to CYP biotransformation, the FMO enzyme family plays a diverse role in xenobiotic 
biotransformation.  Membrane-bound, FMOs utilize an oxidized flavin moiety to elicit oxidation of 
xenobiotics from molecular oxygen (Figure 4).6  Primary action of FMOs includes the oxidation of 
nucleophilic nitrogen, sulfur, and phosphorus heteroatoms, generating many biotransformation products 
analogous to CYP activity.  While similar in substrate and action, FMOs account for only a small 
percentage of overall xenobiotic metabolic activity (<5%) compared to CYP isoforms (~75%).9  Aside 
from the CYP and FMO families, there are various additional oxidases, peroxidases, dehydrogenases, 
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esterases, reductases, and hydrolases that contribute to the complex web of Phase I metabolic processes in 
the human body.10 
N
N
N
-
NH
H O
R
O
N
N
N
NH
H O
R
O
O
O
-
N
N
N
NH
H O
R
O
O
OH
N
N
N
NH
H O
R
O
O
H
N
N
N
NH
O
R
O
oxidized flavin
reduced flavin
4α-peroxyflavin4α-hydroperoxyflavin
4α-hydroxyflavin
NADPH
O2
H+
X
XO
-H2O
 
Figure 4: Flavin monooxygenase oxidation mechanism 
 Acting concurrently with Phase I functionalization reactions, conjugative Phase II metabolic 
events contribute to the biotransformation of many drugs in vivo.  Phase II conjugation reactions involve 
the addition of an endogenous moiety to existing or induced/exposed functional groups on xenobiotics, 
encompassing glucuronidation, sulfonation (sulfation), acetylation, methylation, and conjugation to 
glutathione or amino acids (e.g., glycine, taurine, glutamic acid).11  With the notable exception of 
methylation, Phase II conjugative activities increase the overall polarity of target molecules, facilitating 
elimination in one or more biological excretions (e.g., urine, bile, sweat, feces).  Biochemical pathways will 
often favor the removal of certain Phase II conjugates via a preferred matrix.  For example, it has been 
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demonstrated in rats that glucuronides formed with aglycones (parent molecules or unconjugated 
metabolites) of molecular weight (MW) <250 Da are preferentially excreted via urine while aglycones 
>350 Da are primarily excreted in bile, making the biliary excretion MW cutoff in rats ~325 Da.12,13  While 
similar patterns in high MW glucuronide biliary excretion are documented across species, MW cutoffs for 
excretion matrix preference vary among mammalian species (e.g., ~400 Da in guinea pigs, ~500 Da in 
rabbits). 
 Several classes of Phase II conjugative enzymes exist in humans, each facilitating a single 
conjugative activity and requiring distinct cofactors as summarized in Table 1.6,11,14  Similar to CYP 
enzymes, many Phase II enzyme families contain several isoforms, each with distinct substrate 
selectivity/specificity.   
Table 1: Phase II enzyme class information 
Conjugative 
Process Enzyme Family Cofactor(s) 
Glucuronidation 
Uridine diphosphoglucuronosyltransferase 
(UGT) 
Uridine diphosphoglucuronic acid 
(UDP-GlcUA) 
Sulfation 
Sulfotransferase 
(SULT) 
Phosphoadenosine-phosphosulfate 
(PAPS) 
Acetylation 
N-acetyltransferase 
(NAT) 
Acetyl-coenzyme A 
(AcCoA) 
Methylation Various 
S-adenosylmethionine 
(SAM) 
Glutathione 
Conjugation 
Glutathione-S-transferase 
(GST) 
Glutathione 
(GSH) 
Amino Acid 
Conjugation Various Gly, Glu, Tau 
While some Phase II biotransformation products do not undergo further metabolism, certain 
classes of conjugates are further modified to aid in elimination.  Some conjugative products can undergo 
subsequent Phase I or Phase II processes depending on substrate structure and enzyme selectivity.  
Successive modifications to the conjugated moiety are also a viable pathway with other conjugated 
products.   This process is sometimes termed “Phase III” metabolism.15  The most pervasive of Phase III 
metabolic events in humans is the continued metabolism of GSH-bound xenobiotics to form N-
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acetylcysteine (mercapturic acid) conjugates, which are excreted in the urine.  Subsequent to GSH 
conjugation by GST or non-enzymatic reaction, a cascade of additional enzymatic processes is necessary to 
biosynthesize mercapturates (Figure 5).16  Removal of glutamate and glycine by γ-glutamyltransferase (γ-
GT) and dipetidases, respectively, leaves the cysteine-bound electrophile available for N-acetylation via 
typical NAT/AcCoA activity. 
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Figure 5: Biodegradation of glutathione conjugates to mercapturic acids 
 The extent of xenobiotic metabolism within an individual relies on a series of factors associated 
with that individual.  While the metabolic events described above are generally conserved among 
individuals within a species, there are myriad factors that impact the biochemical processes associated with 
enzymatic xenobiotic metabolism.  Genetic factors, epigenetics, sex, age, biological rhythms, pregnancy, 
stress, nutritional factors, enzyme induction and inhibition, and disease state are all mediating factors in 
enzyme expression, function, and efficiency.3   
 
2.2. Cytochrome P450 Isozymes 
While oxidative mechanisms are maintained across the CYP superfamily, there are myriad 
subclasses, each with preferential substrate, activity, and body tissue distribution.  Fifty-seven of these 
distinct enzymes (known as isoforms) have been classified by the human genome project and the general 
substrate activity for major enzymes has been cataloged; however, individual reaction phenotyping is 
required to designate isoform action on a specific substrate.10  Reaction phenotyping is of great importance 
for both medical and forensic analyses involving a given xenobiotic.  Specific metabolism by a given 
isoform can influence a substance’s toxicology in combination with other xenobiotics or modify 
pharmacokinetics based on genetic factors. 
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 Induction or inhibition of a specific isoform by a secondary xenobiotic can drastically modify the 
pharmacokinetic (and therefore pharmacodynamic) properties of a drug.  For example, the antibiotic 
ciprofloxacin is a potent inhibitor of isoform CYP1A2, the enzyme responsible for metabolism of 
imipramine (an anti-depressant).17,18  Co-administration of ciprofloxacin with imipramine would disrupt 
conventional imipramine therapeutics and could potentially lead to toxicity.  Specific knowledge of 
enzymes responsible for a drug’s metabolism (or even those responsible for an individual biotransformation 
pathway) may grant insight into an individual’s reaction to a specific dose of the drug.  Stimulation of a 
metabolic pathway that produces a toxic metabolite can account for individual toxicities not normally 
encountered with a given dose (i.e., idiosyncratic toxicities).  Synergistic effects caused by co-
administration can be better understood with knowledge of reaction phenotyping. 
Similarly, genetically determined expression of CYP enzymes can also mediate toxicokinetic and 
toxicodynamic parameters.  Aside from inter-individual differences in base enzyme expression, the 
existence of numerous polymorphisms among the CYP isoforms (i.e., CYPs 1A1, 1A2, 2C19, 2D6, and 
2E1) can significantly impact xenobiotic metabolite profiles.  For example, CYP2D6 has multiple known 
variant alleles leading to polymorphic enzyme expression.  Each allelic variation influences enzymatic 
function, leading to phenotypes characterized by increased enzyme activity (CYP2D6 × 2 × n), inactive 
enzyme (CYP2D6 × 4), absent enzyme (CYP2D6 × 5), unstable enzyme (CYP2D6 × 10), and reduced 
enzyme activity (CYP2D6 × 17).2  Genetic influences on drug biotransformation via modifications of 
enzymatic expression represent a subset of a group known as “biomarkers of susceptibility.”  Biomarkers 
of susceptibility represent conditions that modify an organism’s response to molecular exposure.19  Marked 
shifts in the qualitative or quantitative response to chemical exposure can account for genotype-specific 
toxicities. 
Each of the 57 CYP isoforms designated by the human genome project maintains individual 
substrate specificities and expression in various tissues and matrices throughout the human body.  
Responsible for myriad synthetic, metabolic, and catabolic events for both endogenous and exogenous 
agents, only a subset of the know CYP enzymes are relevant to drug metabolism in humans.  Even within 
this subset of CYP isoforms, factors such as protein concentration, tissue distribution, enzyme kinetics, 
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substrate specificity, and substrate affinity mediate the ultimate impact of each isoform.  The most 
influential among these enzymes are presented in Figure 6 according to their concentration within liver 
tissue and relevance to xenobiotic metabolism (the latter is estimated as a factor of cataloged substrates for 
each isoform).6 
 
Figure 6: Distribution of cytochrome P450 enzymes and relevance to xenobiotic metabolism  
(from reference 6) 
 
2.3. Drug of Abuse Metabolism: Cocaine, Methamphetamine, and Morphine 
While most drugs of abuse undergo a degree of metabolism, the three examined in this study 
(cocaine, methamphetamine, and morphine) are modified in very different ways by metabolic enzymes and 
processes.  In addition to their distinct metabolism, each drug possesses unique clinical manifestations 
resultant from the drug’s pharmacology.  
Cocaine (Figure 7, 1) is a psychotropic stimulant extracted from the plant Erythroxylon coca that 
has been used for over 2000 years.20  Pharmacological activity of cocaine is induced via blockage of 
dopamine, norepinephrine, and serotonin reuptake in the central nervous system (CNS) while 
simultaneously stimulating release of dopamine from storage vesicles.21  Flooding of synapses with 
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neurotransmitters results in extreme stimulation of CNS pathways, generating feelings of euphoria, psychic 
energy, and self-confidence.  Pharmacokinetic data for cocaine have demonstrated a very short plasma half-
life of 0.7-1.5 h with a low volume of distribution (1-3 L/kg), demonstrating little cocaine sequestering by 
tissues.22 
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Figure 7: Chemical structures of cocaine [1], methamphetamine [2], and morphine [3] 
Once ingested, cocaine undergoes extensive Phase I biotransformation in vivo (Appendix 1).  The 
majority of these metabolic steps involve aromatic oxidation, N-dealkylation, N-oxidation, and ester 
hydrolysis.  The hydrolysis of the methyl ester to yield benzoylecgonine is the predominant pathway for ex 
vivo degradation of cocaine (however, human liver carboxylesterase 1 (hCE-1) promotes the hydrolytic 
cleavage in vivo).23,24  In the body, enzymatic cleavage of the benzoyl ester to form ecgonine methyl ester is 
catalyzed by plasma pseudocholinesterase and human liver carboxylesterase 2 (hCE-2).20,23,24  Co-
administration of cocaine with ethanol results in the production of cocaethylene via transesterification by 
hCE-1 and fatty acid ethyl synthase (FAES).20,24  If cocaine is smoked, the pyrolysis products of cocaine, 
anhydroecgonine methyl ester and associated metabolites (e.g., anhydroecgonine), can be detected in the 
blood.20  In addition to Phase I metabolism, research has suggested that products of cocaine 
biotransformation are amenable to Phase II modification (e.g., methylation, sulfation, glucuronidation) at 
the sites of Phase I hydroxylation (i.e., aromatic hydroxyl(s), N-hydroxyl), although identification of such 
conjugation products has yet to be reported in the literature.23,25  While the majority of these metabolites are 
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pharmacologically deactivated by Phase I and II biotransformation, the transesterification product 
cocaethylene has been shown to maintain similar physiochemical properties to cocaine.20   
Methamphetamine (Figure 7, 2) is a sympathomimetic amine with CNS stimulant properties 
whose pharmacological action is a result of dopamine release from storage vesicles.  Methamphetamine 
itself is also an agonist for neurotransmitter transporters, causing serotonin, norepinephrine, and dopamine 
release.26  Similar to cocaine pharmacology, release of neurotransmitters causes a general feeling of 
euphoria.  However, the long half-life of methamphetamine (~9 h) leads to lengthened clinical experience 
of symptoms compared to cocaine and other designer sympathomimetic amines with shorter in vivo half-
lives.22  The lipid solubility of methamphetamine can cause minor sequestering in fatty tissues, leading to a 
volume of distribution of 3-7 L/kg.26 
Methamphetamine biotransformation involves Phase I processes (Appendix 2); however, the 
metabolic steps involved are slightly different from those seen in cocaine metabolism.  Phase I metabolism 
of methamphetamine is a result of aromatic oxidation, N-dealkylation, N-oxidation, and aliphatic oxidation 
with the primary route of biotransformation being N-demethylation to amphetamine and aromatic oxidation 
to the hydroxymethamphetamine isomers.  Unlike cocaine, the metabolism of methamphetamine is 
relatively slow, with the majority of the elimination product being the parent compound (40-50% of 
ingested dose).26  The numerous hydroxylated products produced allow for subsequent conjugation of 
methamphetamine metabolic products via Phase II conjugation to glucuronide or sulfate moieties.27  As a 
result of the chemical nature of sympathomimetic amines, the metabolism of methamphetamine produces 
numerous pharmacologically active metabolites such as amphetamine. 
 Morphine (Figure 7, 3) is a naturally occurring opiate narcotic analgesic extracted from the opium 
poppy, Papaver somniferum.28  Pharmacological properties of morphine and its congeners are mediated by 
the μ, κ, and δ opioid receptors.  Morphine is a strong agonist of μ opioid receptors, which are responsible 
for CNS depression clinically manifested as analgesia, miosis, euphoria, and hypothermia.  Conversely, 
morphine only acts as a weak agonist of κ and δ receptors, which mediate analgesia, sedation, diuresis, 
delusions, and hallucinations.28  While possessing a relatively short half-life (2-3 h) and a volume of 
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distribution of 3-5 L/kg, morphine is known to bind to proteins (20-35% plasma protein binding), 
complicating pharmacokinetic estimations.22 
Unlike cocaine and methamphetamine, morphine’s primary biotransformation pathway involves 
the Phase II glucuronidation and sulfation of the parent drug (Appendix 3).  While a minor amount of Phase 
I metabolism can occur (by means of N-dealkylation, dehydrogenation, and reduction), the free hydroxyl 
groups at the 3- and 6- positions are the primary active sites for conjugation.  The pharmacological activity 
of morphine is reliant on the free hydroxyl group at the 3-position; consequently morphine-6-glucuronide 
maintains opioid receptor agonist properties while morphine-3-glucuronide is not active as an opioid 
agonist.  Therefore, even with a relatively short half-life, morphine is able to maintain its pharmacological 
effects through the continued action of pharmacologically active metabolites.  It is noteworthy in 
consideration of total biotransformation that complete mass balance of morphine metabolism has not yet 
been achieved, suggesting the existence of unidentified morphine metabolites.29 
 
2.4. In Vitro Metabolic Assays 
In vitro metabolic assays are typically employed by the pharmaceutical industry to assess the 
extent and rate of xenobiotic metabolism and examine the formation of active or toxic products.30  Other 
researchers have employed metabolic assays in pharmaceutical protein binding studies.31  While the assays 
used for these purposes are numerous and varied, toxicologists must balance the effectiveness, 
applicability, ease of use, and overall cost of each assay to determine the optimal system for their individual 
aims.  The most common in vitro model metabolic systems utilize one of the following as the primary 
contributor of Phase I and Phase II metabolic activity:  hepatocyte cultures, liver homogenate fractions 
(including microsomes, cytosol, and S9 fraction), horseradish peroxidase, and individual heterologously 
expressed enzymes.  While the addition of cofactors and trapping agents may impact the effectiveness of 
each assay, the base activity and fundamental enzymatic ability of each metabolic model is mediated by the 
selection of one of the systems above.   
Hepatocyte-based assays (e.g., cultured hepatocytes, liver slices) are the most biologically relevant 
of the in vitro assays because of their innate representation of the hepatic microenvironment.  However, the 
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need for fresh harvesting of live hepatocytes and the risk of decreased viability arising from 
cryopreservation processes limits the use of hepatocyte-based assays.  Non-human peroxidase substitutes 
(e.g., horseradish peroxidase) are sometimes used as models for non-P450 mediated oxidative activity by 
various endogenous peroxidases.10  Recently, recombinant complimentary DNA (cDNA) technology has 
allowed for the insertion of genetic material coding for individual enzymes into simple organisms (e.g., 
bacteria, insects), facilitating single enzyme/isoform assay systems.  The cDNA-based assays have found 
particular use in CYP isoform reaction phenotyping, allowing researchers the ability to assign individual 
enzymatic contribution to metabolic events and calculation of specific enzyme-substrate kinetics.  
However, these assays only offer a unilateral view of a xenobiotic’s metabolism, limiting their 
effectiveness as comprehensive metabolic model systems.  The advantages and disadvantages of the above-
mentioned assay systems have been reviewed by Brandon et al.32 
By far, the sub-cellular fractions of liver homogenate are the most commonly utilized metabolic 
model systems.  Of the fractions that can be obtained by differential centrifugation, the three most common 
utilized for in vitro assay protocols are the S9, cytosol, and microsome fractions.  After homogenizing liver 
tissue, centrifugation at 9,000 × g removes intact cells, nuclei, and large organelles such as mitochondria.  
The remaining supernatant, known as the “S9” fraction, is a suspension of soluble proteins and remnants of 
organelles such as endoplasmic reticulum (ER) and Golgi.  The S9 fraction contains many of the enzymes 
responsible for the Phase I and Phase II biotransformation of xenobiotics including the CYP isoforms, 
FMOs, and UGTs.  Further centrifugation of the S9 fraction at 100,000 × g produces a pellet containing 
microsomes (vesicle-like artifacts formed from the ER when eukaryotic cells undergo homogenization 
procedures in the laboratory).  Microsomal fractions contain a concentrated suspension of membrane-
associated enzymes including the CYP isoforms, FMOs, and UGTs.  The S9 fraction has only 20-25% of 
the ER-bound enzymatic activity as microsomal fractions because the microsomes make up approximately 
one-fifth of the S9 fraction.33  The supernatant remaining after removal of the microsomes is the cytosolic 
fraction, which contains soluble proteins and enzymes.  Table 2 lists the enzymatic components found in 
each differential centrifugation fraction.33 
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Table 2: Enzymatic components of microsomal, cytosolic, and S9 liver fractions 
Metabolic Enzymes Microsomes Cytosol S9 
Alcohol dehydrogenase 
 
× × 
Aldehyde dehydrogenase 
 
× × 
Amino acid conjugations × 
 
× 
CYP × 
 
× 
Esterases × × × 
FMO × 
 
× 
GST × × × 
Methyltransferases × × × 
NAT 
 
× × 
Reductases × × × 
SULT 
 
× × 
UGT × 
 
× 
Unlike the self-sustained system present in cultured hepatocytes, assays utilizing microsomal, 
cytosolic, and S9 fractions require the addition of various cofactors to facilitate enzyme function or provide 
precursor molecules necessary for certain metabolic processes (e.g., glucuronidation, sulfation, glutathione 
conjugation).  Typical cofactors introduced include nicotinamide dinucleotide phosphate (NADPH), 
MgCl2, NADPH regeneration systems, alamethicin, and Phase II conjugate donor molecules.  NADPH is 
required for the function of many enzymes responsible for Phase I metabolism, including CYPs and FMOs.  
The addition of a divalent metal ion (e.g., Mg+2, Ca+2,  Sr+2) has been found to increase the activity of 
systems containing CYP enzymes by stimulating the electron transfer from NADPH cytochrome P450 
reductase to cytochrome b5 and CYP enzymes.34  The addition of a NADPH regeneration system allows for 
the cyclic regeneration of the activating cofactor NADPH.  Typical regeneration systems include an 
enzymatic component capable of reducing NADP+ back to NADPH by oxidizing a substrate additive.  
Common NADPH regeneration systems are glucose-6-phosphate/glucose-6-phosphate dehydrogenase and 
isocitrate/isocitrate dehydrogenase. 
 Phase II conjugation can be performed using in vitro systems by supplementation with additives 
containing conjugate moieties (see Table 1 for cofactors corresponding to Phase II processes).  Typically, 
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no additional cofactors beyond those listed in Table 1 are necessary to facilitate conjugation; however, 
glucuronidation processes are enhanced by the addition of alamethicin (Alm) as a cofactor.  UGTs are 
membrane-bound proteins with active sites localized inside the lumen of the ER.35,36  To facilitate substrate 
access to UGT binding sites for glucuronidation, Alm is added to the reaction mixture.  Alm is a 20-residue 
antibiotic fungal peptide that forms multiconductance channels across lipid bilayers.  The well-defined 
pores are formed by the introduction of a hexameric bundle of the largely α-helical Alm across the lipid 
bilayer of the ER, thereby decreasing the observed enzymatic latency arising from the ER membrane acting 
as a diffusional barrier for substrates, cofactors, and products.35-38 
 While the above describes a complete in vitro metabolic system capable of producing Phase I and 
Phase II biotransformation products, further supplementation with additional nucleophilic “trapping 
molecules” expands the breadth of data obtained from in vitro metabolic assays.  A large subset of these 
trapping agents are biomolecules of varying complexity employed to approximate interactions between 
substrates and endogenous biomolecules in vivo.  Such trapping agents include single nucleophilic amino 
acids, synthetic and natural peptides, purified proteins, GSH, cyanide, semicarbazide, methoxylamine, and 
2’-deoxyguanosine.31,39-49 
 
2.5. Biomarkers of Exposure, Protein Adduction, and Adduction Mechanisms 
The term “biomarker of exposure” refers to a group of molecules that provide physiochemical 
evidence of exposure to a xenobiotic.19  Often, these biomarkers are generated by the modification of an 
endogenous biomolecule such as DNA or protein.  There are two classes of biomarkers of exposure.  The 
first is a biomarker that is indicative of, but not unique to, exposure to a given molecule.  For example, the 
addition of methyl groups to DNA bases can arise from exposure to methylmethane sulfonate (a cancer 
treatment agent); however, dimethylsulfate (a chemical warfare agent) is also a potent methylating agent of 
DNA bases (Figure 8a).50,51   While useful as corroborating evidence of exposure, these non-unique entities 
are not unequivocal proof of exposure on their own.  The second type of exposure biomarker is one that 
contains a moiety unique to the analyte of interest (typically a portion of the analyte molecule itself).  These 
biomarkers provide unequivocal evidence of exposure, as their mechanism of formation precludes 
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generation by any other analyte.  Both clozapine and diclofenac are examples of xenobiotics that form 
unique adducts with cysteine thiols on proteins (Figure 8b).43 
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Figure 8: Examples of (a) non-unique and (b) unique biomarkers of exposure 
Unique biomarkers of exposure are commonly the result of xenobiotic adduction to endogenous 
biomolecules.  Adduction refers to the irreversible covalent modification of reactive nucleophilic sites on 
biomolecules by inherently reactive electrophilic xenobiotics or metabolically activated moieties (either 
reactive metabolites or short-lived intermediates).  Biomolecular adduction typically occurs on reactive 
nucleophilic functional groups within DNA or protein structure.  The reactivity of individual biological 
nucleophiles is attributed to a combination of physiochemical factors including electron density, 
polarizability, the nature of the interacting xenobiotic species (electrophile), and steric factors that influence 
reactive site availability.  In recent years, great progress has been made in modeling these interactions, with 
the goal of predicting the nature and extent of reaction of electrophilic xenobiotics with biological 
nucleophiles.  These concepts are discussed below. 
The hard and soft acid and base (HSAB) theory is a compendium of calculations, estimators, and 
chemical properties that characterize the thermodynamic and physical interactions between electrophilic 
and nucleophilic entities that can bring about the formation of adducts.  In 1963, Pearson first described 
HSAB theory, stating that hard (i.e., nonpolarizable) acids preferentially bind to hard bases while soft (i.e., 
polarizable) acids prefer to bind to soft bases, in consideration of both thermodynamic and kinetic 
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properties.52  “Hardness” is a measure of resistance to change of an electron cloud, either by means of gain 
or loss of electrons or by polarization.53  While the hardness (and by association, softness) of a species 
mediates its reactivity (both global and localized), the property itself cannot be directly measured 
quantitatively.  In a simplified form, chemical hardness (η) can be related to electronegativity (χ) (described 
in Equation (1)) by expressing it as a function of ionization energy (I) and electron affinity (EA), as in 
Equation (2). 
Equation (1)  
2
χ
EAI +
=  
Equation (2)  EAI −=η  
Chemical softness (σ) can, therefore, be described as the inverse of hardness, as shown in Equation (3). 
Equation (3)  
EAI −
==
1
η
1
σ  
However, these equations represent only the surface of the complex calculations that are used by chemists 
to theoretically estimate the quantitative role of such parameters in reaction thermodynamics.   
 Additional advances have been made in recent years with the application of density functional 
theory (DFT) calculations to estimations of chemical hardness.  Frontier orbital theory (FOT) is an 
approximation of chemical exchange which asserts that interactions between frontier molecular orbitals 
(and the valence electrons they hold) are the primary contributors to inter-molecular interactions.  FOT 
maintains the basic principles of HSAB theory, purporting that adduct formation occurs when a soft 
nucleophile donates its highest energy electron to the lowest unoccupied molecular orbital (LUMO) of a 
soft electrophile.  In consideration of FOT, useful descriptor calculations regarding reactivity of 
electrophile-nucleophile interactions only require the estimation of LUMO energy (ELUMO) and highest 
occupied molecular orbital (HOMO) energy (EHOMO), which can be performed by commercially available 
computational programs (e.g., Spartan and Gaussian).  From these values, basic parameters including 
hardness (η), softness (σ), and chemical potential (µ) can be calculated as follows: 
 Equation (4)  
2
η HOMOLUMO
EE −
=  
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 Equation (5)  
HOMOLUMO
2
η
1
σ
EE −
==  
 Equation (6)  
2
μ HOMOLUMO
EE +
=  
FOT also facilitates the calculation of higher order descriptors that combine the above lower order 
parameters to deliver multifaceted summaries of chemical reactivity.  Sensitive measures of electrophilic 
(ω) and nucleophilic (φ) reactivity involve mathematical combinations of chemical hardness (η) and 
chemical potential (µ): 
 Equation (7)  
η2
μ
ω
2
=  
 Equation (8) 2μ
2η
ω
1
==ϕ  
While the above parameters are useful in examining the relative reactivity of substances within a class, they 
are not sufficient to examine the interaction that occurs between a nucleophile and an electrophile during 
the adduction process.  In contrast, the reaction index (ω-) summarizes the reactivity of two species as a 
function of their respective hardness and chemical potential as shown in Equation (9) (“A” refers to the 
nucleophile, “B” refers to the electrophile). 
 Equation (9)  2
BA
2
BAA-
)ηη(2
)μμ(η
ω
−
−
=  
When comparing reactivities between electrophile-nucleophile pairs, the higher the ω- value, the more 
favorable adduct formation is within the system on the basis of electronic factors.  
 Qualitatively, HSAB theory is a lens through which the covalent adduction of xenobiotics to 
biomolecules can be viewed.  Two common targets of biomolecular adduction are DNA and proteins.  
DNA is composed of four subunit bases (adenine, cytosine, guanine, and thymine) held together via 
hydrogen bonding and linked in strands by a phosphate-deoxyribose backbone.  Covalent adduction to 
nucleophilic sites on the subunit bases or the phosphate moiety of the backbone chain has been 
characterized for numerous reactive xenobiotics.  Generally, reactive sites on DNA are hard nucleophiles, 
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making DNA a reservoir for the preferential adduction by hard electrophilic species (see Table 3).44,54  
Clear implications exist for the downstream impact of covalent DNA modifications, especially concerning 
epigenetic and carcinogenic factors.  Disruption of any pathway vital to transcription or DNA replication 
can generate a cascade of ill effects at cellular (e.g., mutation, apoptosis) or tissue (e.g., carcinoma 
formation, necrosis, teratogenesis) levels. 
Table 3: Examples of hard and soft electrophilic and nucleophilic functional groups 
Type Electrophiles Nucleophiles 
Hard alkyl carbonium ions oxygen atoms of DNA bases 
 benzylic carbonium ions endocyclic nitrogens of bases in DNA 
 iminium ions oxygen atoms of serine and threonine 
 aldehydes  
Soft epoxides thiol group of cysteine 
 enones thiol group of glutathione 
 quinone imides amine groups of lysine and histidine 
 quinone methides  
 imine methides  
 isocyanates  
 isothiocyanates  
 aziridinium ions  
 episulfonium ions  
Unlike DNA, proteins are polymeric chains of amino acids connected by peptide amide linkages.  
While cofactors including heme groups and functional metal ions can be incorporated into protein structure, 
higher order structural characteristics of proteins are typically associated with amino acid sequence and 
structure.  Each of the 20 naturally occurring amino acids has a distinct side-chain structure, imparting 
physiochemical properties to the parent protein and immediate microenvironment.  Among these amino 
acids are nucleophilic residues that have the potential to form covalent adducts with electrophiles 
depending on individual electronic and steric factors.  Among the nucleophilic amino acids, some of the 
most reactive are the harder nucleophiles serine and threonine as well as the softer nucleophiles lysine and 
histidine, with cysteine being the softest and generally most reactive biological nucleophile.  Additionally, 
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the free amino terminus is a highly reactive nucleophile in proteins (although it is often blocked in cellular 
proteins).   
Reactivity of amino acid residues within proteins is a product not only of innate reactivity arising 
from structure, but is also a function of positioning within a protein and electronic influences resulting from 
adjacent residues.55,56  Variability in amino acid reactivity can be exemplified by nucleophilic lysine and 
cysteine residues.  Nucleophilic reactivity of both residues is mediated by their ionization state.  Maximal 
reactivity of lysine residues requires the ε-amino group to be in the unprotonated state, while the anionic 
thiolate form of the sulfhydryl is the more reactive form for cysteine.  Both residues rely on their respective 
pKa values to determine ionization state.  Even though lysine has a base pKa of ~10.4, it has been 
demonstrated that apparent lysine pKa values can vary greatly within a single protein.55  At physiological 
pH (7.4), lysine residues with low apparent pKa values are largely in the reactive nucleophilic unionized 
state.   
Cysteine has a base pKa of ~8.3; therefore, at physiological pH, deprotonation of the sulfhydryl to 
form the thiolate is not favored.  However, the occurrence of catalytic diads can significantly modify 
cysteine pKa values, promoting thiolate formation.56  Catalytic diads are cysteine residues adjacent to basic 
residues (i.e., lysine, histidine, arginine) that facilitate in the formation of thiolates from cysteine 
sulfhydryls.  Figure 9 shows the influence of adjacent basic residues in forming thiolate ions from cysteine 
sulfhydryl moieties.56  An example of one such catalytic diad is Cys-25 in the proteinase ficin.57  Cys-25 
interacts with a basic histidine moiety (His-159), imbuing Cys-25 with a depressed pKa of 2.5, creating a 
hyper-reactive nucleophilic center, likely prone to adduction by soft electrophiles. 
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Figure 9: Mechanism of cysteine thiolate formation in catalytic diad configurations 
As functional biomolecules, proteins experience a series of consequences arising from covalent 
modification by reactive electrophiles.  The site of covalent modification on a protein can be a factor 
mediating downstream impact.  Binding to non-essential domains within a protein’s structure may leave the 
22 
protein fully functional and unaffected.  However, it is more likely that structural deformation resultant 
from adduction or binding at an enzymatic active site can decrease or completely inhibit protein function.  
Well-characterized acetaldehyde adducts arising from ethanol metabolism have been shown to 
detrimentally impact the function of numerous proteins, particularly those containing critical reactive lysine 
residues.58-60  There are even documented cases where covalent protein binding has elicited immunological 
responses in humans, causing accelerated catabolism of adducted (often functionally inhibited) proteins.  
Consumption of alcohol has been found to cause the generation of antibodies with acetaldehyde adduct 
specificity, with the highest titer of such antibodies found in patients with alcoholic liver disease.61-63   
It is noteworthy that unlike DNA adducts, there is not a mechanism in place for the repair of 
adducted proteins.64  Consequently, protein adducts are persistent until the protein itself is degraded or 
replaced, which makes them excellent long-term exposure markers.  While the length of time a protein 
adduct can be detected is strictly dependent on the lifetime of the target protein in vivo, certain proteins are 
particularly advantageous to act as molecular dosimeters of xenobiotic exposure.  For example, hemoglobin 
is removed from circulation with erythrocytes after approximately 120 days in humans, allowing it to act as 
a cumulative dosimeter for xenobiotic exposure.65  While other protein targets may have shorter lifetimes in 
the body, they may find utility on the basis of other considerations.  Serum albumin has a relatively shorter 
in vivo half-life of ~20 days, but is biosynthesized in hepatocytes, making it an ideal target for short-lived 
reactive metabolites produced in the liver.65,66  Utilizing a battery of exposure indicators can allow for 
estimation of retrospective dose reconstruction, differentiating complex scenarios such as chronic vs. single 
dose exposure.67 
While numerous hypotheses exist regarding relative toxicity of covalently bound protein adducts, 
effective methods for determination of protein adduct mediated toxicity do not yet exist.54  However, even 
though specific mechanisms of toxicity cannot always be established, evidence and characterization of 
covalent protein adduction can give insight into downstream xenobiotic pathology including occurrences of 
idiosyncratic toxicity and target organ system toxicities.61,63,68,69 
From the standpoint of both the forensic and medical disciplines, unique biomarkers of exposure 
are preferred because of their inherent ability to confirm exposure to specific xenobiotics.  Development of 
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analytical assays to detect unique biomarkers could assist in designating exposure beyond the lifetime of 
the parent drug or metabolites in common matrices (e.g., blood, urine).  Biomarkers could also be of 
potential use in examining multiple-drug interactions and to give insight into toxicity and adverse 
interactions arising from drug exposure.  Furthermore, biomarkers of exposure specific to illicit drugs could 
benefit law enforcement officials by extending detection timelines, a tool that can be useful when exposure 
determination is critical (e.g., in parole monitoring).  Methods developed for adduct analysis may range 
from more complex direct analysis of modified endogenous proteins to simpler, less invasive measures 
such as examination of mercapturates in urine or GSH conjugates in blood.  Laying the groundwork for 
such assays requires the complete characterization of protein adducts formed by the analyte of interest and 
includes studies into their mechanism of formation.   
 
2.6. Protein Adduction by Drugs of Abuse 
While licit pharmaceuticals undergo protein binding studies amidst the rigorous milieu of safety 
testing required prior to approval within the USA, similar studies are not afforded to illicit drugs.  
Consequently, few investigations into protein adduction by drugs of abuse, either to identify potential 
biomarkers or possible mediators of drug toxicity, have been reported in the literature.  For the latter, even 
minor biotransformation pathways leading to irreversible protein adduction may have severe consequences 
for drug abusers because of the tendency to co-abuse multiple drugs simultaneously and to use higher doses 
that result in depletion of cellular defense against reactive electrophilic species (i.e., GSH), as chronic 
abusers develop tolerance to their habitual drug(s) of choice.   
One of the most investigated drugs of abuse (although licit for recreational use) has been ethanol, 
or more specifically, ethanol’s reactive metabolite, acetaldehyde.70  Acetaldehyde has been found to form 
numerous adduction products with endogenous biomolecules with severe implications into the resultant 
toxicity experienced by alcohol abusers.  Acetaldehyde is known to form Schiff base adduction products 
with Lys residues in proteins71, functionally inhibiting proteins reliant on Lys residues at the catalytic site.60  
In conjunction with protein inactivation, these adducts have also been linked to downstream immunogenic 
and histopathological detriments impacting chronic alcoholics.61,63,72  Supplemental to toxicological 
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implications, acetaldehyde adducts are also biomarkers of ethanol exposure.  Detection of known Schiff 
base adduction products on Lys residues is indicative of ethanol exposure.  While some of the acetaldehyde 
adducts are unstable in vivo, others are stable and are useful in retrospective exposure assessment.73,74  
Among illicit drugs, phencyclidine (PCP) is one of the most studied for its protein binding 
properties.  Protein adduction resultant from PCP exposure is the result of several reactive metabolites 
including a cyclic iminium ion as well as epoxide and quinone methide intermediates.75-77  Research has 
demonstrated the direct impact of these reactive compounds via the adduct-induced inactivation of human 
CYP enzymes (specifically CYPs 2B6 and 2C19) as a direct result of PCP exposure.78,79 
Protein binding elicited by morphine metabolism has also been examined to a limited extent.  
Oxidation of morphine by morphine-6-dehydrogenase or free hydroxyl radicals to yield the reactive α,β-
unsaturated carbonyl, morphinone, has been shown to lead to binding with biomolecular thiols, including 
GSH and 2-mercaptoethanol via covalent attachment at the 8-C of morphinone in numerous species 
including humans (Pathway (a), Figure 10).80-84  Specific structural examination by Ishida et al. determined 
the formation of the distinct 8α- stereospecific product.85  Further in vivo and in vitro studies with mice and 
rats by Nagamatsu and colleagues have demonstrated that macromolecular binding of morphinone directly 
correlated with hepatotoxicity.86,87  Indeed, previous research has shown that total morphinone produced 
(measured as the sum of GSH-bound and free fraction) exceeded that of normorphine in both the rat and 
guinea pig, suggesting morphinone production as the secondary major biotransformation route of morphine 
metabolism after Phase II conjugative events.80,81   
A second set of morphine-based adduction products relies on the formation of an unknown 
electrophilic metabolite that binds to protein thiol models (i.e., N-acetylcysteine, GSH) at the 10-C position 
in rats and humans (Pathway (b), Figure 10).88-90  Correia and colleagues have specifically designated the 
formation of a CYP-mediated oxidative product that is an electrophilic species capable of reacting with 
nucleophilic thiols, forming the distinct 10α- stereospecific product.  While these results are encouraging in 
accounting for incongruence in the mass balance of morphine metabolism, further investigations into the 
identity and mechanism of formation for the responsible unknown metabolite have not been pursued to date 
(since 1986). 
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Figure 10: Mechanisms for irreversible protein adduction by morphine 
As with morphine, cocaine ingestion is known to result in measurable levels of irreversible protein 
binding, as demonstrated by numerous histopathological studies, investigations utilizing radiolabeled drug, 
and analysis of immunogenic antibodies present in the blood of cocaine abusers.91-96  While these studies 
demonstrate the existence of cocaine protein adducts and correlate their formation with cocaine toxicity, 
little conclusive data exists for the direct analysis of cocaine-derived adduction products.  Numerous 
hypotheses have been proposed as to the reactive species responsible for cocaine-derived irreversible 
protein binding, including nitrosonium ions resultant from tropane oxidation (Pathway (a), Figure 11)23,95-97 
and intramolecular acid-catalyzed activation of the methyl ester with subsequent adduction to ε-amine 
groups on Lys residues (Pathway (b), Figure 11)98.  A third pathway for cocaine protein adduction was 
more recently investigated, involving the adduction potential the of pyrolysis product anhydroecgonine 
methyl ester (AEME) with biological thiol models (Pathway (c), Figure 11)99.  Work performed by Myers 
and colleagues demonstrated the production and toxicity of thiol conjugates arising from AEME, 
suggesting a potential role of such metabolic pathways in the sequelae of abused cocaine related toxicities.  
However, as with research into the pathways responsible for protein binding in morphine, investigations 
into mechanisms responsible for irreversible cocaine protein binding have remained dormant since the mid 
2000s.  
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Figure 11: Hypothesized mechanisms of irreversible protein modification by cocaine 
Aside from those drugs listed above, there have been few data collected on protein adduction by 
drugs of abuse.  Formation of melanin-amphetamine irreversible adducts generated during the enzymatic 
production of melanin in hair has been examined.100  Unlike the typical formation of irreversible covalent 
adduction products, melanin-amphetamine adduction requires the enzymatic activation of melanin 
prototype molecules in order to generate an electrophile capable of reacting with amphetamine molecules.  
Examinations into another phenethylamine, 3,4-methylenedioxymethamphetamine (MDMA), have 
demonstrated the formation of covalent adduction products resultant from catechol metabolite conversion 
to an ortho-quinone and subsequent reaction with biological thiols (i.e., GSH and N-acetylcysteine).101  
Such MDMA-adducted thiols are suspected of playing a mechanistic role in observed MDMA-induced 
neurotoxicity.102  While phenethylamines and other nascent designer drug classes are currently receiving 
great attention from the toxicology community, the majority of research is focused on parent drug and 
metabolite detection while virtually no data are available on the protein binding potential of these and other 
drugs of abuse. 
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2.7. Research Objectives 
This research was conducted to test three main hypotheses: 
Hypothesis I:  In vitro assay systems can be used as effective models of in vivo human hepatic metabolism 
for drugs of abuse. 
Hypothesis II:  Specific enzymes in the human body are responsible for biotransformation pathways that 
result in the formation of reactive metabolites and unstable intermediates. 
Hypothesis III:  Drugs of abuse form irreversible covalent adduction products with endogenous proteins 
and biomolecules. 
 
The primary objective of this research was to employ sensitive and specific scientific methods to 
examine the fate of cocaine, methamphetamine, and morphine during and after biotransformation in the 
human body.  The content of this report presents data obtained via instrumental evaluation of in vitro assay 
samples modeling the metabolism of each important drug of abuse.  The different tasks addressed are listed 
below: 
a. Optimization of methods for the comprehensive analysis of cocaine, methamphetamine, and 
morphine metabolic products by LC-MS/MS separation and identification using multiple reaction 
monitoring, including: 
i. Absolute quantification performed where possible. 
ii. Individual optimization of ionization and MS/MS parameters for each analyte where 
possible. 
iii. Synthesis of metabolic products for parameter optimization purposes where synthetic 
methods were available and procedures were feasible within the scope of the project. 
b. Optimization of in vitro metabolic assay parameters for the rapid generation of major metabolic 
products from xenobiotics: 
i. Assay system additives 
ii. Incubation time 
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iii. Component concentrations 
c. Evaluation of metabolic profiles of drugs of abuse across different in vitro assay systems. 
d. Optimization of bactosome-based in vitro assays for single-isozyme metabolism of xenobiotics. 
e. Determination of specific cytochrome P450 isoforms responsible for production of primary 
metabolic products of cocaine, methamphetamine, and morphine using data from bactosome-based 
assays. 
f. Screening of assays containing nucleophilic trapping agents in the presence of active metabolism 
mechanisms for hypothesized adduction products arising from cocaine, methamphetamine, 
morphine, or their metabolites: 
i. Trapping agents:  N-acetylcysteine, N-acetylhistidine, N-acetyllysine. 
ii. Product confirmation via MS/MS product ion scans of suspected adduction products. 
g. Optimization of LC-MS/MS separation and identification methods for confirmed adduction 
products. 
h. Characterization of metabolic processes associated with adduction products: 
i. Enzyme class determination. 
ii. Cytochrome P450 isoform designation. 
iii. Mechanism of electrophile/nucleophile interaction. 
iv. Binding potential with complex biomolecules. 
i. Correlation of in vitro generated adduction products with in silico predictions of 
electrophile/nucleophile reactivity. 
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3. METHODOLOGY 
3.1. Instrumentation 
Analysis of samples by LC-QQQ-MS was performed on an Agilent 6460 triple quadrupole mass 
spectrometer while samples analyzed by LC-QTOF-MS employed an Agilent 6530 quadrupole time-of-
flight system.  Both mass spectrometers were coupled to an Agilent 1290 Infinity ultra-high performance 
liquid chromatography (UHPLC) system using Jet Streaming electrospray ionization (ESI) technology.  All 
chromatographic separations were elicited using an Agilent ZORBAX Rapid Resolution HD Eclipse Plus 
C18 column (50 mm × 2.1 mm, 1.8 μm particle size) maintained at 40°C.  Data acquisition and analysis 
were performed using the Agilent MassHunter software package for both systems.   
 
3.2. Synthesis of Monohydroxylated Cocaine Metabolite Isomers 
Chromatographic peak assignments as well as ionization and fragmentation parameters for select 
aromatic oxidation isomers were determined by in-house synthesis and analysis of nine metabolic products 
of cocaine containing monohydroxylated arene moieties (2-, 3-, and 4-hydroxybenzoylecgonine; 2-, 3-, and 
4-hydroxycocaine; and 2-, 3-, and 4-hydroxycocaethylene), using the previously reported Steglich 
esterification method (see Appendix 4 for reaction mechanism).103,104  Briefly, 0.1 mg of drug precursor, 
0.5 mg of hydroxybenzoic acid, 1 mg of 1,3-dicyclohexylcarbodiimide, and 2 drops of pyridine in 1 mL of 
methylene chloride were added to a 5 mL reaction vial.  The solution was stirred at 50°C for 2 h.  After 
cooling to room temperature, the reaction mixture was washed with 2 mL of water and extracted with 2 mL 
of 2 M HCl.  The acidic solution was washed with 2 mL of methylene chloride to remove non-basic 
components.  The aqueous solution was adjusted to pH 8.5 using 1 M NH4OH and extracted with two 2 mL 
volumes of chloroform/2-propanol (3:1), and the combined organic extracts were evaporated to dryness 
using vacuum centrifugation and reconstituted in 100 μL of dimethyl sulfoxide (DMSO).  The drug 
precursors utilized for synthesis were as follows:  ecgonine for hydroxybenzoylecgonine isomers, ecgonine 
methyl ester for hydroxycocaine isomers, and ecgonine ethyl ester for hydroxycocaethylene isomers.  2-,  
3-, and 4-hydroxybenzoic acids were utilized to generate isomers substituted at the 2-, 3-, and 4- positions, 
respectively. 
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Thorough characterization of individual isomers utilized MS/MS examination on the LC-QQQ-
MS system.  In order to better understand the structural characteristics of some MS/MS fragment ions, 
pseudo-MS3 was performed via an in-source decay method.  In-source decay of hydroxycocaine isomers 
was elicited by increase of optimized fragmentor voltage from 135 to 200 V.  Quadrupole filtering for 
MS/MS fragments of interest followed by subsequent fragmentation in the collision cell yielded pseudo-
MS3 spectra allowing for in-depth structural analyses. 
 
3.3. Comprehensive Drug Metabolite Analysis 
Targeted metabolites for cocaine, methamphetamine, and morphine were identified by an 
examination of the literature for metabolites reported in authentic human samples and biotransformation 
products that were hypothesized in published literature based on postulated metabolic pathways.  
Comprehensive tables of the metabolites examined for cocaine, methamphetamine, and morphine are found 
in Appendices 5, 6, and 7, respectively.  Gradient elution of drug metabolites and standards of cocaine, 
methamphetamine, and morphine utilized a biphasic system of eluents according to the parameters 
described in Appendix 8.  When possible, ionization and MS/MS fragmentation parameters were 
individually optimized for parent drugs and metabolites using the Agilent Optimizer software.  For 
instances where reference standards were unavailable and optimization could not be performed, the 
ionization and fragmentation parameters of a structurally similar metabolite were applied (e.g., conditions 
optimized for benzoylnorecgonine were applied to N-hydroxybenzoylnorecgonine because no reference 
standard for N-hydroxybenzoylnorecgonine was available). 
Individual analytes were monitored by LC-QQQ-MS using two multiple reaction monitoring 
(MRM) transitions (one primary quantifier and one secondary qualifier).  MRM transitions as well as 
ionization and fragmentation parameters for each metabolic analyte are summarized in Appendix 5 
(cocaine), Appendix 6 (methamphetamine), and Appendix 7 (morphine).  When possible, absolute 
quantification of metabolite formation was performed by generating calibration curves using reference 
standards.  A series of calibrators (5000, 4000, 2000, 1000, 500, 100, 10 and 1 ng/mL in DMSO for 
cocaine; 5000, 2000, 1000, 500, 100, 10, 1, and 0.1 ng/mL in water for methamphetamine and morphine) 
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was utilized to generate each standard curve and individual sample quantification was performed utilizing 
Agilent MassHunter Quantitative Analysis software (Table 4 lists analytes for which absolute 
quantification was performed).  For instances where calibrated reference standards were not available, data 
analysis was performed by converting raw peak areas into ratios relative to the internal standard in order to 
account for instrumental variation.  While no absolute quantitative assessment could be determined for 
these compounds, inter-assay comparisons revealed the ability of individual systems to mediate specific 
biotransformation pathways.   
Table 4: Analytes quantified using standard calibration curves 
Cocaine Methamphetamine Morphine 
benzoylecgonine amphetamine hydromorphone 
cocaethylene ephedrine morphine-3-glucuronide 
ecgonine norephedrine normorphine 
ecgonine ethyl ester   
ecgonine methyl ester   
norcocaine   
 
DMSO (a polar aprotic substance) was utilized as a solvent for cocaine samples in order to avoid 
the passive hydrolysis of cocaine and certain metabolites.  It was experimentally determined that 1 μL 
injections of DMSO did not significantly impact analyte retention or peak shape.  In order to compensate 
for decreased method sensitivity brought on by injection volume reduction, sample and calibration 
concentrations were increased for cocaine analysis.  Methamphetamine and morphine were not observed to 
undergo analogous passive hydrolytic events; therefore water was utilized as a solvent for 
methamphetamine and morphine metabolism samples. 
 
3.4. Metabolic Assays 
In order to examine the ability of in vitro assays to produce metabolites for cocaine, 
methamphetamine, and morphine, various systems modeled after those employed in pharmaceutical 
evaluations were compared.31  These assays contained a mixture of biotransformation enzymes, cofactors, 
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and test compound according to the specifications detailed in Table 5.  The system containing no metabolic 
enzymes or cofactors was utilized to examine the passive biotransformation of each drug (e.g., non-
enzymatic hydrolysis).  Human liver microsomes (HLM), human liver cytosol (CYT), and human liver S9 
fraction (S9) assays examined the Phase I biotransformation and Phase II conjugative activity of each 
compound.  Horseradish peroxidase (HRP) provided a system to model non-CYP mediated oxidative 
metabolism.  Positive controls for Phase I and Phase II metabolism were performed by incubating zolpidem 
and nicotine, respectively, according to identical procedures as drug substrates. 
Table 5: Summary of sample preparation for metabolic assay incubations 
Component 
Metabolic System 
No 
Enzyme 
HLM, CYT, or S9 HRP 
+1 +2 +1/2 - + - 
Activating 
cofactors N/A 
2.0 mM 
NADPH 
2.0 mM 
UDP-GlcUA 
2.0 mM 
NADPH  
2.0 mM  
UDP-GlcUA 
N/A 500 µM H2O2 
N/A 
Buffer 10 mM pH 7.4 sodium phosphate buffer 
Substrate 200 µM cocaine, methamphetamine, morphine, or positive control 
Enzyme N/A 2.0 mg/mL HLM, CYT, or S9 0.1 µg/mL HRP 
Non-
activating 
cofactors 
N/A 
50 µg/mL alamethicin 
3.0 mM MgCl2 
N/A 
Regeneration 
system N/A 
0.4 U/mL glucose-6-phosphate dehydrogenase 
3.0 mM glucose-6-phosphate 
N/A 
All in vitro incubations were performed in 10 mM sodium phosphate buffer (pH 7.4) at 37°C to 
model physiological conditions.  All components except the activating cofactor(s) were added to an 
Eppendorf tube and pre-incubated for 5 min to bring the system to appropriate temperature.  The activating 
cofactor(s) were then added to each reaction vessel (50 μL final sample volume), which was then mixed 
and incubated for up to 24 h.  At 0.5 and 24 h, 25 μL aliquots of each sample were withdrawn and 
processed for LC-QQQ-MS analysis.  To each 25 μL aliquot, 25 μL of ice-cold acetonitrile were added to 
precipitate proteins and cease metabolism.  Samples were centrifuged at 15,000  at 4°C for 30 min to 
pellet protein.  The supernatant was recovered, evaporated to dryness, and reconstituted in the appropriate 
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solvent with added internal standard (DMSO with benzoylecgonine-D3 for cocaine, water with 
methamphetamine-D5 for methamphetamine, water with morphine-D3 for morphine) for subsequent LC-
QQQ-MS analysis. 
Determination of assay enzymatic activity was performed by subtracting analyte concentrations 
found in control samples from active systems.  For example, the analyte concentration determined in HLM 
preparations without added NADPH or UDP-GlcUA (i.e., HLM-) was subtracted from that in HLM with 
added NADPH (i.e., HLM+1), HLM with added UDP-GlcUA (i.e., HLM+2), or HLM with both cofactors 
added (i.e., HLM+1/2) (see Table 5).  When absolute concentrations were not determined due to lack of 
calibrated standards, analogous corrections were performed by subtracting ratios relative to internal 
standard.  Consequently, all comparative data are presented as “deviation from control” in either ng/mL 
(where calibrated standards were available) or relative ratio to internal standard (where calibrated standards 
were not available). 
 
3.5. Cytochrome P450 Isoform Metabolic Assays for Reaction Phenotyping 
Designation of individual CYP isoform contributions to specific biotransformation pathways was 
performed with the aid of bactosomes (microsomes harvested from Escherichia coli heterologously 
expressing human genes that code for CYP isoform production co-expressed with human NADPH-
cytochrome P450 reductase).  The individual isoforms examined included CYPs 1A2, 2B6, 2C8, 2C9, 
2C19, 2D6, and 3A4.  Samples were created according to the specifications given in Table 6 and following 
the same procedures for preparation as detailed in Section 3.4.  Final sample volumes were 50 µL each and 
were incubated at 37ºC for 30 min.  Metabolism was ceased by addition of 50 μL of ice-cold acetonitrile 
followed by centrifugation at 15,000 × g for 30 min at 4°C to pellet proteins.  Supernatants were evaporated 
to dryness, reconstituted in solvent, and subjected to LC-QQQ-MS analysis by the appropriate “Drug 
Metabolite Analysis” method (see Appendix 8).   
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Table 6: Summary of sample components for metabolic reaction phenotyping assays 
Component 
rhCYP System 
Control (-) Positive (+) 
Activating 
cofactor N/A 2.0 mM NADPH 
Buffer 10 mM sodium phosphate buffer (pH 7.4) 
Substrate 200 µM cocaine, methamphetamine, or morphine 
Enzyme 2.0 mg/mL rhCYP bactosome 
Non-
activating 
cofactors 
5.0 mM MgCl2 
Regeneration 
system 
0.4 U/mL glucose-6-phosphate dehydrogenase 
3.0 mM glucose-6-phosphate 
The viability of each isoform was evaluated using a modified cocktail assay containing six probes 
incubated according to the sample preparation procedures outlined above.105  Metabolic probe 
concentrations within each positive control sample were as follows: 4 μg/mL melatonin, 2 μg/mL 
bupropion, 2 μg/mL amodiaquine, 6 μg/mL tolbutamide, 20 μg/mL omeprazole, and 2 μg/mL 
dextromethorphan.  Chromatographic separation of positive control probe compounds and metabolites 
monitored as evidence of isoform activity was elicited by a biphasic system according to the gradient 
described in Appendix 8.  Optimized MS/MS parameters were determined using Agilent MassHunter 
Optimizer software and one MRM transition was selected to monitor the presence of positive control 
compounds and resultant metabolites (optimized MS/MS parameters and retention times listed in Table 7).   
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Table 7: Summary of positive control probe information and LC-MS/MS parameters for CYP 
isoform viability assay 
Probe/Monitored 
Metabolite Ion Transition Fragmentor
 Collision Energy Retention Time 
CYP1A2     
melatonina 233  174 100 V 8 V 2.37 min 
6-hydroxymelatonin 249  190 100 V 8 V 1.64 min 
CYP2B6     
bupropion 240  184 100 V 8 V 2.34 min 
hydroxybupropion 256  238 100 V 8 V 1.93 min 
CYP2C8     
amodiaquine 356  283 110 V 12 V 1.33 min 
desethylamodiaquine 328  283 110 V 12 V 1.21 min 
CYP2C9     
tolbutamide 271  91 100 V 32 V 3.90 min 
hydroxytolbutamide 287  171 100 V 12 V 2.59 min 
CYP2C19     
omeprazole 346  198 100 V 4 V 2.37 min 
desmethylomeprazole 332  198 100 V 4 V 2.19 min 
CYP2D6     
dextromethorphan 272  171 130 V 40 V 2.74 min 
dextorphan 258  199 130 V 28 V 1.84 min 
CYP3A4     
omeprazole 346  198 100 V 4 V 2.37 min 
omeprazole sulfone 362  150 100 V 36 V 2.19 min 
a Positive control probes are listed in bold; metabolic products characteristic of isoform activity are listed in 
plain text 
As heterologously expressed recombinant enzymes, recombinant human CYP (rhCYP) 
bactosomes do not maintain the same relative isoform concentration distribution as human liver tissue.  
However, rhCYP bactosomes purchased for this study (“EasyCYP” bactosomes, Cypex) are standardized 
to contain specific CYP content at 100 pmol/mg total protein.  Assuming that CYP activity within 
bactosomes is analogous to the human hepatic microenvironment in conjunction with standardized 
“EasyCYP” bactosome preparations from Cypex, only basic data transformation is necessary to 
approximate the influence of relative isoform concentrations within human liver tissue.106  Raw data were 
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multiplied by literature values for relative isoform concentrations in human liver samples6,38,106 (Table 8) 
and normalized to the highest contributing isoform (i.e., highest contributing isoform was set to 100%).  
Relative assignments of isoform contributions to individual biotransformation events were ranked 
according to the following criteria: major contribution, 60-100%; moderate contribution, 20-60%; minor 
contribution, 10-20%; any contribution below 10% was not considered significant and was not reported as 
a mediating isoform in that oxidative pathway. 
Table 8: CYP isoform distribution in human liver tissue 
Isoform Percent of Total CYP Content in Liver 
CYP1A2 9.8% 
CYP2B6 4.6% 
CYP2C8 8.3% 
CYP2C9 17.7% 
CYP2C19 3.3% 
CYP2D6 2.0% 
CYP3A4 21.5% 
 
3.6. Reactive Metabolite Trapping and Protein Adduction Model Systems 
Reactive metabolites were generated using in vitro assay incubations for cocaine, 
methamphetamine, and morphine supplemented with a biomolecular model trapping agent.  While reaction 
systems were similar to those employed for metabolite analysis, total protein content (i.e., HLM 
concentration and NADPH regeneration system) was decreased in order to minimize protein nucleophile 
reservoirs within the assay system to ensure maximal adduction to trapping molecules.   
Preliminary screenings were performed for each drug‒ trapping agent combination on the basis of 
expected adduct structures formed between the trapping molecules and predicted reactive functional groups 
within each parent drug and/or major metabolites (Table 9).107  Trapping molecules examined for screening 
purposes included N-acetylcysteine (NAC), N-acetyllysine (NAK), and N-acetylhistidine (NAH).  Analytes 
detected via LC-MS screening and suspected of being the result of covalent adduction between drugs and 
trapping agents were subjected to MS/MS analysis for structural clarification.  Positive control incubations 
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using the known reactive drugs clozapine and benzyl bromide as substrates were performed to confirm 
active mechanisms for reactive metabolite production and subsequent trapping by biomolecular models. 
Table 9: Theoretical adduction products for preliminary screening methods 
 Metabolite Base MW (as [M+H]+) 
NAC Adduct 
+161 (+163)a 
NAK Adduct 
+186 (+188) 
NAH Adduct 
+195 (+197) 
C
O
C
 
Pb 304 465 (467) 490 (492) 499 (501) 
P+O 320 481 (483) 506 (508) 515 (517) 
P-CH2 290 451 (453) 476 (478) 485 (487) 
P-COC6H4 200 361 (363) 386 (388) 395 (397) 
P+2O 336 497 (499) 522 (524) 531 (533) 
P-2CH2 276 437 (439) 462 (464) 471 (473) 
P-CH2+O 306 467 (469) 492 (494) 501 (503) 
P-CH2+2O 322 483 (485) 508 (510) 517 (519) 
P+O-H 319 480 (482) 505 (507) 514 (516) 
P-O-CH3c 273 N/A 460 N/A 
M
E
T
 
P 150 311 (313) 336 (338) 345 (347) 
P-CH2 136 297 (299) 322 (324) 331 (333) 
P+O 166 327 (329) 352 (354) 361 (363) 
P+2O 182 343 (345) 368 (370) 377 (379) 
P-CH2+O 152 313 (315) 338 (340) 347 (349) 
P-CH2+2O 168 329 (331) 354 (356) 363 (365) 
M
O
R
 
P 286 447 (449) 472 (474) 481 (483) 
P-CH2 272 433 (435) 458 (460) 467 (469) 
P-2H 284 445 (447) 470 (472) 479 (481) 
P-CH2-2H 270 431 (433) 456 (458) 465 (467) 
a Addition of nucleophile mass factoring in loss of 2H; Parentheses present addition of nucleophile mass 
without the loss of 2H 
b “P” refers to parent compound 
c Adducting species proposed by Deng et al.98; known to only form adduction products with Lys residues 
 
Screening samples were created according to the “Active Trapping Sample” specifications in 
Table 10.  Buffer, microsomes, substrate (cocaine, methamphetamine, morphine, or positive control), and 
trapping agent were added to an Eppendorf tube and pre-incubated at 37°C for 5 min followed by addition 
of NADPH and MgCl2, gentle mixing, and incubation for 1.5 h at 37°C (final sample volume 125 μL).  
Metabolism was ceased by addition of ice-cold acidified acetonitrile (5% v/v acetic acid) and proteins 
pelleted by centrifugation at 15,000 × g for 30 min at 4°C.  Supernatants were directly analyzed by LC-
38 
MS/MS.  Chromatographic separations were elicited by a biphasic system of eluents according to the 
“General adduct screening” gradient listed in Appendix 8. 
Table 10: Reactive metabolite trapping and control incubation specifications 
Component 
Reactive Metabolite Trapping and Control Incubations 
Active Trapping 
Sample 
Control 1 
(no NADPH) 
Control 2 
(no drug) 
Control 3 
(no trapping agent) 
Activating 
cofactor 2.0 mM NADPH N/A 2.0 mM NADPH 2.0 mM NADPH 
Substrate 100 μM drug 100 μM drug N/A 100 μM drug 
Trapping 
system 
20 mM trapping 
agent 
20 mM trapping 
agent 
20 mM trapping 
agent N/A 
Buffer 50 mM pH 7.4 potassium phosphate buffer 
Enzyme 1.0 mg/mL human liver microsomes 
Non-
activating 
cofactors 
3.0 mM MgCl2 
Samples in which MS/MS investigations provided evidence for the covalent adduction of drug to 
trapping agent underwent more thorough and rigorous investigations.  First, gradient elutions for 
chromatographic separation were optimized for individual substrate-trapping agent pairs (see Appendix 8 
for parameters corresponding to individually optimized methods).  Once optimized, control incubations 
were run in parallel to examine NADPH-dependence and reliance on the presence of drug and trapping 
molecule to clarify mechanism of formation (“Controls 1-3,” Table 10). 
Studies examining the influence of increasing incubation time and secondary supplementation 
with additional NADPH were performed to elicit maximal adduct formation for downstream analysis.  Data 
were collected for incubation times of 1.5, 3.0, 4.5, and 6.0 h, as well as an additional data point for 6.0 h 
incubation with an additional supplementation of 2.0 mM NADPH at t = 3.0 h (4.0 mM total NADPH). 
When irreversible adduction was determined to occur with one of the simple biomolecule model 
systems (i.e., NAC, NAK, or NAH), further probing of more complex trapping agents was performed to 
confirm analogous adduct structure across various nucleophilic protein models.  Substrates demonstrating 
adduction products resultant from binding to NAC were incubated with reactive metabolite trapping system 
containing the biological tripeptide, GSH, and a separate incubation containing a synthetic hexapeptide, 
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acetyl-Pro-Ala-Ala-Cys-Ala-Ala-OH (AcPAACAA).  Similarly, substrates demonstrating adduction 
potential with NAK or NAH were incubated with the synthetic hexapeptides, acetyl-Pro-Ala-Ala-Lys-Ala-
Ala-OH (AcPAAKAA) or acetyl-Pro-Ala-Ala-His-Ala-Ala-OH (AcPAAHAA), respectively.  LC-MS/MS 
methods for the analysis of resultant products are detailed in Appendix 8. 
 
3.7. Protein Adduct rhCYP Isoform Assays 
Determination of CYP isoform contributions to reactive metabolite/adduct formation were 
designated by in vitro incubation using heterologously expressed rhCYP bactosomes in place of human 
liver microsomes at 1.0 mg/mL rhCYP total protein (100 pmol/mL specific CYP isoform) concentration.  
All other parameters for incubations were analogous to the “Active Trapping Sample” in Table 10, with 
isoform assignments determined for all screening samples testing positive for covalent adduction (i.e., 
cocaine‒NAC and morphine‒NAC).  Samples were incubated for 1.5 h at 37°C, quenched by addition of 
ice-cold acidified acetonitrile (5% v/v acetic acid), centrifuged at 15,000 × g for 30 min at 4°C, and 
supernatants were directly analyzed via the LC-MS/MS analysis methods reported in Appendix 8. 
Isoform designation panels are presented both as raw data and also as data adjusted by multiplying 
by literature values for relative isoform concentrations in human liver samples and normalized to highest 
contributing isoform (similar to data transformation described in Section 3.5). 
 
3.8. Quantum Mechanical Calculations for Reactivity and Adduction Potential 
Calculations to approximate the properties of chemical potential (μ), chemical hardness (η), 
chemical softness (σ), electrophilicity index (ω), nucleophilicity index (φ), and reactivity index (ω-) were 
performed by determining the EHOMO and ELUMO for reactive electrophilic metabolites and nucleophilic 
structures modeling reactive sites within proteins.  The menu of compounds examined for their 
electrophilic/nucleophilic potential included cocaine; 2-, 3-, and 4-hydroxycocaine; cocaine-3,4-epoxide; 
morphine; morphinone; morphine quinone methide; Cys; His; Lys; NAC; NAH; NAK; and GSH.  Initial 
structure geometries were generated via molecular orbital package (MOPAC) optimization using Chem3D 
Ultra software (Version 8, CambridgeSoft Corporation) and were exported to Gaussian 03 software 
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(Gaussian, Inc.)108.  Iterative structural geometry optimization was carried out, and EHOMO and ELUMO were 
calculated at the density functional level using a B3LYP functional with 6-31G* basis set within Gaussian 
03.  Individual properties were calculated according to equations consistent with FOT and HSAB theory 
using EHOMO and ELUMO as presented in Section 2.5 (Equations 4-9).  
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4. RESULTS AND DISCUSSION 
4.1. Cocaine Metabolite Synthesis and Analytical Characterization 
The modified Steglich esterification procedure employed to synthesize nine monohydroxylated 
cocaine metabolites was found to be a fast, cost-effective method to assign chromatographic peaks, 
determine optimal ionization and fragmentation parameters, and obtain characteristic MS/MS spectra for 
comparison to in vitro assay-generated metabolic profiles.  As a result of the synthetic mechanism 
(involving activation of carboxylic acids by 1,3-dicyclohexylcarbodiimide followed by reaction with free 
alcohol groups; see Appendix 4 for mechanism), numerous side products were expected to be present in the 
final synthetic preparations.  Evidence of side product formation was seen in the low relative yields for 
those preparations containing multiple carboxylic acid and alcohol groups (i.e., hydroxybenzoylecgonine 
isomers).  However, even with sub-milligram quantities of desired product yield, complete MS/MS spectra 
that matched theory and literature were obtained for 2-, 3-, and 4-hydroxycocaine; 2-, 3-, and 4-
hydroxybenzoylecgonine; and 2-, 3-, and 4-hydroxycocaethylene.  These are presented in Figure 12, Figure 
13, and Figure 14, respectively. 
Chromatographic separation according to the gradient elution used for cocaine metabolites (see 
Appendix 8) was able to achieve baseline separation of each set of structural isomers (Figure 15).  Elution 
order on the reversed-phase LC system was also consistent within each set of isomers examined.109  The 4-
hydroxy isomers eluted first, followed by the 3-hydroxy and the 2-hydroxy isomers. 
MS/MS analysis revealed high similarity among isomeric structures.  The fragment at m/z 182 for 
hydroxycocaine is representative of the [M-OC(O)C6H4OH]+ ion and is a common ion monitored for 
MRM-based cocaine analysis methods.110,111  Structural identity of fragment ion m/z 200 for 
hydroxycocaine was investigated via pseudo-MS3 by means of in-source decay.  Figure 16a shows a 
representative spectrum of MS2 fragmentation obtained by inducing in-source decay of 4-hydroxycocaine.  
Fragment ions observed were comparable to authentic MS2 spectra for 4-hydroxycocaine (Figure 12c).  
Figure 16b and 16c are 4-hydroxycocaine pseudo-MS3 spectra of m/z 182 and 200, respectively, under in-
source decay conditions.  On the basis of qualitative similarity of pseudo-MS3 fragmentation, fragment ion 
m/z 200 is likely derived from the addition of water to the m/z 182 ion [M-OC(O)C6H4OH+H2O]+.  The 
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presence of ions from m/z 200 fragmentation maintaining a +18 mass shift concordant with water addition 
(designated by “*” in Figure 16c) provides further evidence supporting the chemical species identity as m/z 
182+H2O.  Analogous results were obtained for 2-hydroxycocaine, demonstrating conserved mechanisms 
of m/z 200 fragment ion formation regardless of hydroxylation position.   
However, under identical fragmentation conditions, characteristic differences between MS/MS 
spectra were noted for each isomer, allowing for unequivocal structural designation based on fragment ion 
peak ratios.  Figure 17 contains the MS/MS spectra of 2-, 3-, and 4-hydroxycocaine obtained under 
identical fragmentation parameters.  When fragmented at CE = 18 V, the ratios of m/z 182 to m/z 200 were 
dependent on the position of aromatic hydroxylation.  The ratios of these ions were 1:3 for 2-
hydroxycocaine, 1:0 (i.e., no m/z 200 peak) for 3-hydroxycocaine, and 1:0.2 for 4-hydroxycocaine.  Similar 
fragmentation patterns and ion ratios were observed for the ring-hydroxylated isomers of benzoylecgonine 
and cocaethylene.  The characteristic elution order, fragmentation patterns, and specific retention times 
allowed for definitive assignments of individual hydroxylated isomers. 
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Figure 12: MS/MS spectra of (a) 2-hydroxycocaine, (b) 3-hydroxycocaine, and (c) 4-hydroxycocaine 
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Figure 13: MS/MS spectra of (a) 2-hydroxybenzoylecgonine, (b) 3-hydroxybenzoylecgonine, and (c) 
4-hydroxybenzoylecgonine 
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Figure 14: MS/MS spectra of (a) 2-hydroxycocaethylene, (b) 3-hydroxycocaethylene, and (c) 4-
hydroxycocaethylene 
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Figure 15: Chromatographic separation of nine synthesized monohydroxylated cocaine metabolites 
Abbreviations: OH-BE, hydroxybenzoylecgonine; OH-CE, hydroxycocaethylene; OH-COC, 
hydroxycocaine 
3 2 6 5 9 8 4 71
1. 2-OH-BE
2. 3-OH-BE
3. 4-OH-BE
4. 2-OH-COC
5. 3-OH-COC
6. 4-OH-COC
7. 2-OH-CE
8. 3-OH-CE
9. 4-OH-CE
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* Designates fragment ions maintaining +18 mass unit addition 
Figure 16: Psuedo-MS3 analysis of 4-hydroxycocaine fragment ions 
**
a)
b)
c)
In-source decay pseudo-MS2
m/z 320scan
Pseudo-MS3
m/z 320182scan
Pseudo-MS3
m/z 320200scan
+18
+18
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Figure 17: Comparison of positional hydroxycocaine isomers under identical MS/MS conditions 
 
4.2. Metabolic Assays 
After processing, cocaine metabolism samples were reconstituted in DMSO in order to prevent 
nonenzymatic hydrolytic cleavage of labile ester bonds in cocaine and metabolites.  Other solvents were 
examined (acetonitrile and methanol), but were found to negatively impact retention time and peak shape 
on the chromatographic system.  Table 11 displays data showing the impact of solvent selection on analyte 
retention time, peak shape (evaluated by full width at half max peak height (FWHM) comparison), and any 
additional detriment imparted on the data collected using cocaine as a model for comparison.  Statistical 
comparisons of cocaine retention time among the solvent systems demonstrated that retention times were 
significantly different from that of cocaine in water when acetonitrile, methanol, and DMSO were 
employed as solvents for reconstitution (using 5 μL injections).  Injections of DMSO samples at 1 μL 
maintained chromatographic retention times statistically indistinguishable from cocaine in water.  
Likewise, 1 μL injection of DMSO was the only solvent system to not detrimentally affect FWHM (and 
therefore peak shape).  Reduction of injection volume for acetonitrile and methanol systems was discounted 
because of additional solvent system issues (i.e., contamination peaks with acetonitrile and split analyte 
peaks with methanol).  Cocaine metabolism samples dissolved in DMSO at 1 μL injection volumes were 
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therefore selected for future analysis.  While the decrease in injection volume did somewhat limit the 
sensitivity of this method, it was deemed necessary to maintain the integrity of metabolic profiles for each 
sample during time in the autosampler prior to analysis. 
Table 11: Comparison of solvents for cocaine analysis 
Solvent Cocaine Retention Time (min) 
FWHM 
(min) Note 
Water 4.116 ± 0.003a 0.073 N/A 
Acetonitrile 4.002b 0.162 Contamination Peaks 
Methanol 4.091b 0.135 Split Peak 
5 μL DMSO 4.081b 0.122 N/A 
1 μL DMSO 4.113 0.061 N/A 
a n=10 
b Denotes statistically significant difference from cocaine retention time using water solvent system 
 
Control incubations of methamphetamine and morphine in sodium phosphate buffer (pH 7.4) 
without addition of cofactors or enzymes did not produce any metabolic product within the anticipated 
profile for either drug.  Lack of passively generated metabolic products demonstrated the stability of both 
methamphetamine and morphine throughout the course of the assay procedure and, therefore, did not 
necessitate examination of substitute solvent systems to replace water during post-dry-down reconstitution 
to ensure metabolic profile integrity while in the autosampler. 
Activity of Phase I metabolic enzymes was confirmed via hydroxyzolpidem isomer production 
from control incubations containing zolpidem as target substrate (Figure 18).112  Similarly, Phase II 
glucuronidation pathway activity was determined by conjugation of nicotine to form nicotine-N-
glucuronide (Figure 19).113 
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Figure 18: Representative Phase I metabolism positive control showing the formation of 
hydroxyzolpidem isomers after 24 h incubation of zolpidem in HLM assay system 
 
 
Figure 19: Representative Phase II metabolism positive control showing the formation of nicotine-N-
glucuronide from nicotine after 24 h incubation in HLM assay system 
 
4.2.1. Cocaine 
Examination of metabolite profiles across in vitro systems showed distinct differences between 
assays arising from enzymatic components contained within each system.  Of the 50 compounds targeted 
by the analytical method, 13 were confirmed in one or more of the metabolic systems.  Metabolites 
detected include ecgonine; ecgonine methyl ester; benzoylnorecgonine; benzoylecgonine; norcocaine; 2-, 
3-, and 4-hydroxybenzoylecgonine; 3- and 4-hydroxynorcocaine; and 2-, 3-, and 4-hydroxynorcocaine.  As 
was expected, cocaethylene and the corresponding ethyl ester metabolites did not appear in any of the 
metabolic systems, since ethanol was not present in the reaction mixtures.  Table 12 details the relative 
levels of primary and secondary Phase I metabolites formed in the absence of enzyme and with each in 
NADPH added
Control (no NADPH added)
hydroxyzolpidem
isomers (P+O)
dihydroxyzolpidem
isomers (P+2O)
nicotine-N-glucuronide
UDP-GlcUAadded
Control (no UDP-GlcUAadded)
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vitro metabolic system after 24 h incubation.  The presence of benzoylecgonine and ecgonine in control (no 
enzyme) preparations and the lack of impact of metabolic enzyme inclusion on relative levels of these 
metabolites indicate that their formation was not dependent on enzymatic biotransformation but instead 
occurred primarily via nonenzymatic hydrolysis.  In addition, metabolite profiles noted in the cytosol-based 
systems were indistinguishable from control preparations, indicating that components of cytosol alone did 
not catalyze specific cocaine metabolism.  Aside from enhanced formation of ecgonine methyl ester, 
metabolite profiles in HLM+2 and S9+2 mixtures were also similar in profile to those with no enzyme.  In 
contrast, enzyme-mediated increases in relative metabolite concentrations were noted for ecgonine methyl 
ester, benzoylnorecgonine, norcocaine, and hydroxylated cocaine metabolites in the HLM and S9 systems.  
As expected, the metabolite profiles generated in HLM and S9 samples were qualitatively similar; 
quantitatively, the rate of metabolite generation was greater in HLM samples (see below).  Since HRP lacks 
the N-demethylase activity found in HLM and S9 assays, no norcocaine, benzoylnorecgonine, or secondary 
hydroxynorcocaine isomers were detected in HRP incubations (Table 12). 
The formation of hydroxylated cocaine metabolites did not occur in the absence of enzyme and 
was variably dependent upon the particular enzyme system tested (Table 12).  In total, eight distinct 
hydroxylated cocaine metabolites were detected amongst the assay systems examined.  Of the systems 
examined, hydroxylated metabolites were detected in those containing HLM, S9, or HRP.  Hydroxylation 
in HLM and S9 was found to be NADPH-dependent, as was expected for an enzymatic monooxygenase-
based Phase I metabolic process.  HRP appeared to be the enzyme system most effective in generating 
hydroxylated cocaine and benzoylecgonine metabolites, in that higher concentrations of such metabolites 
were noted as compared to any of the other assay systems examined (Table 12; Figure 20).  Systems 
derived from human liver fractions (HLM, S9) were found to exhibit regioselectivity in aromatic ring 
hydroxylation, forming hydroxylated products at the 3- and 4- positions, but not at the 2- position.  In 
contrast, the oxidative activity of the HRP system was found to be less selective, generating all three 
hydroxylated isomers.  Cytosol alone was not effective in the formation of any hydroxylated metabolites.  
In contrast to the formation of Phase I cocaine metabolites, no evidence was obtained for 
hydroxylated metabolite depletion consistent with Phase II metabolism in the present study.  This was the 
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case even after 24 h incubation in the presence of a Phase II metabolic cofactor (UDP-GlcUA).  In addition, 
no cocaine metabolite glucuronides were directly identified by LC-MS/MS analysis. 
Table 12: Distribution of cocaine metabolites across examined in vitro assay systems 
Metabolite N
o 
en
zy
m
e 
H
LM
+1
 
H
LM
+2
 
H
LM
+1
/2
 
C
Y
T+
1 
C
Y
T+
2 
C
Y
T+
1/
2 
S9
+1
 
S9
+2
 
S9
+1
/2
 
H
R
P+
 
Primary Metabolites 
BEa +++b +++ +++ +++ +++ +++ +++ +++ +++ +++ +++ 
EME + ++ ++ ++ + + + ++ ++ ++ + 
NC - ++ - ++ - - - ++ - ++ - 
2-OH-COC - - - - - - - - - - ++ 
3-OH-COC - + - + - - - + - + ++ 
4-OH-COC - + - + - - - + - + ++ 
Secondary Metabolites 
ECG + + + + + + + + + + + 
BNE - + - + - - - + - + - 
2-OH-BE - - - - - - - - - - ++ 
3-OH-BE - + - + - - - + - + ++ 
4-OH-BE - + - + - - - + - + ++ 
2-OH-NC - - - - - - - - - - - 
3-OH-NC - + - + - - - - - - - 
4-OH-NC - + - + - - - - - - - 
a Metabolite abbreviations: BE, benzoylecgonine; EME, ecgonine methyl ester; NC, norcocaine; OH-COC, 
hydroxycocaine; ECG, ecgonine; BNE, benzoylnorecgonine; OH-BE, hydroxybenzoylecgonine; OH-NC, 
hydroxynorcocaine. 
b Refers to qualitative prevalence of metabolite across all biotransformation systems tested; (+++) major 
metabolite, (++) intermediate metabolite, (+) minor metabolite, (-) not detected.  Criteria for classifications 
were as follows: major – dominated chromatograph, intermediate – visible in total ion chromatograph, 
minor – only visible through MRM filtering. 
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Figure 20: LC-MS chromatograms of (a) hydroxycocaine isomers and (b) hydroxybenzoylecgonine 
isomers in HLM and HRP assays 
Incubation times for published in vitro drug metabolism assays vary widely, with typical ranges 
from 5 min to 24 h.  In the present study, the impact of assay incubation time is illustrated by examining the 
production of norcocaine and benzoylnorecgonine.  Figure 21a presents data showing similar levels of 
norcocaine in HLM systems activated with NADPH at either 0.5 or 24 h.  In contrast, S9 systems activated 
with NADPH did not produce detectable quantities of norcocaine at the 0.5 h time point, but did after 24 h 
incubation.  Similar patterns were noted with other primary metabolites, including 3- and 4-hydroxycocaine 
(Figure 22b,c).  As with other primary metabolites of cocaine, 3- and 4-hydroxycocaine were produced 
rapidly (0.5 h incubation) in HLM incubations activated with NADPH, while detection in S9 assays 
required extended incubation time (24 h).  Benzoylnorecgonine, a secondary metabolite of cocaine, was not 
as rapidly generated by HLM.  Figure 21b shows that benzoylnorecgonine was not detectable in either the 
HLM or S9 systems at 0.5 h, but was present in both after 24 h incubation.  Likewise, the secondary 
metabolites 3- and 4-hydroxybenzoylecgonine and 3- and 4-hydroxynorcocaine showed similar trends, 
requiring extended incubation time for detection in both HLM and S9 assays (Figure 23 and Figure 24).   
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Figure 21: Comparison of (a) norcocaine and (b) benzoylnorecgonine formation across assay systems 
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Figure 22: Formation of (a) 2-hydroxycocaine, (b) 3-hydroxycocaine, and (c) 4-hydroxycocaine 
across assay systems 
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Figure 23: Formation of (a) 2-hydroxybenzoylecgonine, (b) 3-hydroxybenzoylecgonine, and (c) 4-
hydroxybenzoylecgonine across assay systems 
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Figure 24: Formation of (a) 3-hydroxynorcocaine and (b) 4-hydroxynorcocaine across assay systems 
 
4.2.2. Methamphetamine 
Methamphetamine demonstrated limited metabolism within the in vitro systems.  Of the 26 
metabolites targeted by this method, four were detected among the various assays examined.  These 
included the primary metabolites amphetamine and 2-, 3-, and 4-hydroxymethamphetamine.  No secondary 
metabolites of methamphetamine were detected in any assay system examined in this study.  Table 13 
presents the relative distribution of detected Phase I metabolites formed in the control incubation (absence 
of enzyme) and across all in vitro metabolic systems after incubation for 24 h.  Incubations activated solely 
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by UDP-GlcUA (i.e., HLM+2, CYT+2, S9+2) were indistinguishable from control samples, demonstrating 
no basal level of Phase II glucuronidation for methamphetamine without prior biotransformation via Phase 
I functionalization pathways.  Qualitative metabolic profiles were found to be similar in HLM, CYT, and 
S9 assays activated with NADPH (both +1 and +1/2 incubations), showing the formation of amphetamine, 
and 2-, 3-, and 4-hydroxymethamphetamine in each sample. 
N-Demethylation of methamphetamine to produce amphetamine was shown to occur in all liver 
fraction systems containing NADPH and was a minor metabolic pathway in the HRP assay activated by 
H2O2 (Table 13; Figure 25).  Maximal amphetamine production was found in the HLM system activated by 
NADPH, producing the metabolite at approximately nine-fold the yield generated by the CYT or S9 assays.  
Likewise, HLM+1 and HLM+1/2 incubations were the only assay systems to generate appreciable 
quantities of amphetamine after 0.5 h incubation. 
All enzymatic systems were qualitatively capable of performing the aromatic hydroxylation of 
methamphetamine to all three isomers when activated by either NADPH (for liver-based assays; +1 and 
+1/2) or H2O2 (HRP+) (Figure 26).  2-Hydroxymethamphetamine was found to be generated in similar 
amounts in both HLM and CYT assays activated by NADPH (HLM+1, HLM+1/2, CYT+1, and CYT+1/2) 
and was detected in greater quantities in S9 fractions activated by NADPH (presumably as a cumulative 
result of enzymatic action by both soluble and membrane-associated enzymes found in the CYT and HLM, 
respectively).  The HRP-containing assay activated with H2O2 demonstrated increased oxidative activity 
over all liver fraction assays, producing the 2-hydroxymethamphetamine isomer in much higher quantities.  
In all assay systems examined, 2-hydroxymethamphetamine was generated in larger quantities after 24 h 
incubation than 0.5 h incubation. 
Results obtained for the production of 3-hydroxymethamphetamine across assay systems were 
atypical for in vitro production of a Phase I metabolite.  The strongest oxidizing systems (i.e., HLM+1, 
HLM+1/2, and HRP+) did produce the metabolite rapidly (see 0.5 h time point, Figure 26b).  However, 3-
hydroxymethamphetamine concentrations decreased in the 24 h incubation samples.  Also unexpected for 
Phase I metabolic products, 3-hydroxymethamphetamine was produced in high levels within CYT-based 
systems activated with NADPH (i.e., CYT+1 and CYT+1/2).  Presumably, increased production of 3-
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hydroxymethamphetamine in S9+1 and S9+1/2 after 24 h incubation results from the action of CYT 
enzymes present in the S9 fraction. 
In contrast to the 3-hydroxy isomer, 4-hydroxymethamphetamine production in each in vitro 
system followed intuitive prediction.  General patterns of 4-hydroxymethamphetamine were similar to the 
2-hydroxy analog with minor distinctions.  First, CYT-based assays containing NADPH (i.e., CYT+1, 
CYT+1/2) were only capable of generating minor quantities of 4-hydroxymethamphetamine, while HLM-
based assay systems containing NADPH (i.e., HLM+1, HLM+1/2) produced the most metabolite from the 
liver-based fractions.  It is noteworthy that the 4-hydroxy isomer is generated rapidly within HLM-based 
assays activated with NADPH (i.e., HLM+1, HLM+1/2; demonstrating only minor increases in 
concentration between 0.5 and 24 h incubations) compared to 2-hydroxymethamphetamine.  As with 2-
hydroxymethamphetamine, the HRP assay activated with H2O2 showed greater oxidative strength than the 
other assays, producing more 4-hydroxymethamphetamine than any other assay system examined. 
Although documented previously in authentic urine and blood specimens, subsequent 
glucuronidation of hydroxymethamphetamine isomers was not definitively documented in this study.27  
While minor differences in quantities of hydroxylated metabolites were noted between assays containing 
the cofactors necessary to form glucuronide conjugates (+1/2) and those lacking UDP-GlcUA (+1), the 
analysis method did not directly detect the presence of glucuronic acid conjugated metabolites.  
Table 13: Distribution of methamphetamine metabolites across examined in vitro assay systems 
Metabolite N
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AMPa -b +++ - +++ + - + + - + + 
2-OH-MET - ++ - ++ + - + + - + +++ 
3-OH-MET - ++ - ++ + - + + - + +++ 
4-OH-MET - ++ - ++ + - + + - + +++ 
a Metabolite abbreviations: AMP, amphetamine; OH-MET, hydroxymethamphetamine 
b Refers to qualitative prevalence of metabolite across all biotransformation systems tested; (+++) major 
metabolite, (++) intermediate metabolite, (+) minor metabolite, (-) not detected.  Criteria for classifications 
were as follows: major – dominated chromatograph, intermediate – visible in total ion chromatograph, 
minor – only visible through MRM filtering. 
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Figure 25: Comparative biotransformation of methamphetamine to amphetamine across assay 
systems 
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Figure 26: Formation of (a) 2-hydroxymethamphetamine, (b) 3-hydroxymethamphetamine, and (c) 
4-hydroxymethamphetamine 
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4.2.3. Morphine 
Morphine displayed substantial metabolite production in vitro, but with limited diversity of 
products.  Of the 24 potential metabolites that were examined in this study, three were confirmed in one or 
more assay system.  The detected metabolites were the primary morphine metabolites normorphine, 
morphine-3-glucuronide, and morphine-6-glucuronide.  Secondary metabolites of morphine were not 
detected in any of the assays examined.  Table 14 displays the distribution of the three detected morphine 
metabolites in the control incubation (i.e., no enzyme) and in each active in vitro assay system after 24 h 
incubation.  Incubation samples CYT+1 and HRP+ did not form any of the three metabolites and were 
indistinguishable from control incubations, demonstrating no metabolic contributions from NADPH-
mediated metabolism in CYT or peroxide-initiated oxidative metabolism from HRP.  The HLM-based 
assays were able to elicit both Phase I and II metabolism, generating quantitatively superior profiles over 
the other assay systems.  CYT-containing assays only generated Phase II glucuronidation products for 
morphine, demonstrating no activity from soluble Phase I metabolizing enzymes within the CYT fraction.  
Like HLM, S9-based systems were able to produce both Phase I and II metabolites; however, product 
yields were diminished in comparison to analogous HLM incubations. 
N-Demethylation of morphine to normorphine (a minor Phase I metabolic pathway of morphine) 
was dependent on the presence of NADPH and was only produced in the HLM and S9 systems with the 
former producing an approximately five-fold yield over the latter (Figure 27).  No significant quantity of 
normorphine was produced in any CYT or HRP assay.   
Morphine-3-glucuronide dominated the metabolic profiles of HLM, CYT, and S9 systems 
activated with UDP-GlcUA (+2 and +1/2; Figure 28a).  Production of the glucuronide conjugate was 
maximal in the HLM system, followed by S9, and then CYT to a lesser extent.  The production of 
morphine-6-glucuronide followed a similar distribution among in vitro assays examined, but in lower 
quantities than morphine-3-glucuronide (assuming analogous ionization efficiency between isomers; Figure 
28b).   
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Table 14: Distribution of morphine metabolites across examined in vitro assay systems 
Metabolite N
o 
en
zy
m
e 
H
LM
+1
 
H
LM
+2
 
H
LM
+1
/2
 
C
Y
T+
1 
C
Y
T+
2 
C
Y
T+
1/
2 
S9
+1
 
S9
+2
 
S9
+1
/2
 
H
R
P+
 
NMa -b ++ - ++ - - - + - + - 
M3G - - +++ +++ - ++ ++ - ++ ++ - 
M6G - - ++ ++ - + + - + + - 
a Metabolite abbreviations: NM, normorphine; M3G, morphine-3-glucuronide; M6G, morphine-6-
glucuronide 
b Refers to qualitative prevalence of metabolite across all biotransformation systems tested; (+++) major 
metabolite, (++) intermediate metabolite, (+) minor metabolite, (-) not detected.  Criteria for classifications 
were as follows: major – dominated chromatograph, intermediate – visible in total ion chromatograph, 
minor – only visible through MRM filtering. 
 
 
Figure 27: Formation of normorphine from morphine across assay systems 
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Figure 28: Formation of (a) morphine-3-glucuronide and (b) morphine-6-glucuronide 
 
4.2.4. Discussion of Drug of Abuse In Vitro Metabolism Results 
In vitro metabolic systems are of great use for a variety of applications in drug development and 
monitoring, including metabolic profiling and toxicity assessment.30,114  The selection of the metabolic 
system itself in addition to variables such as cofactors and incubation time directly impacts the metabolic 
profile obtained.  Commonly incorporated metabolic components include microsomes, cytosol, S9 fraction, 
and purified biotransformation enzymes.  In addition, supplementation with additives can drastically impact 
the efficacy of these assays.  For example, divalent cations (e.g., Mg+2) and/or a NADPH regeneration 
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system can significantly improve the functionality of certain metabolic pathways.115  When Phase II 
glucuronide metabolites are desired, UDP-GlcUA must also be present as a cofactor.  In addition, since 
UGTs are membrane-bound enzymes with active pockets located within the lumen of the ER, introducing a 
means of traversing the ER membrane can dramatically increases system functionality.  The peptide 
antibiotic Alm is commonly employed for this purpose.35,37  The present study evaluated assay systems and 
the influence of time and cofactors in the in vitro metabolism of cocaine, methamphetamine, and morphine. 
Unlike in the case of licit drugs, few data have been reported on the application and utility of in 
vitro biotransformation systems for generating metabolites of drugs of abuse relevant to in vivo exposure.  
Recently, in vitro assays have been employed to determine major metabolites of “designer drugs,” 
including amphetamine, phencyclidine, and tetrahydrocannabinol analogs.116,117  These studies have 
facilitated the development of analytical detection methods for numerous emerging designer drug analogs 
whose in vivo metabolism has not been reported.  In the present study, several such systems were effective 
in producing a set of biotransformation products of cocaine, methamphetamine, and morphine, including all 
known major primary metabolites and numerous common secondary metabolites.  The data are generally 
consistent with the results of in vivo ADME studies for each important abused drug.104,118-120  The current 
approach was less effective in comprehensively identifying all of the minor metabolites reportedly formed 
in vivo (see Appendix 1, Appendix 2, and Appendix 3).  The inability to detect minor drug metabolites may 
be attributed to assay design and method sensitivity, which in the present study were optimized for rapid 
identification of major metabolites.   
 
4.2.4.1. Cocaine Metabolism Discussion 
The complete enzymology of each assay system was found to influence the rate and pathways of 
cocaine biotransformation.  Enzyme influence was illustrated by the differing relative levels of ecgonine 
methyl ester obtained in each assay system.  Enzyme-mediated ecgonine methyl ester production primarily 
involves hCE-2, an esterase bound to the ER membrane in the liver121, consistent with the finding of 
ecgonine methyl ester as an intermediate metabolite in assay systems containing ER membrane remnants 
(i.e., HLM and S9).  As the enzyme does not require activating cofactors such as NADPH, hCE-2 was able 
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to facilitate esterase activity in all HLM and S9 assay systems (i.e., +1, +2, and +1/2 mixtures) in the 
present study.  Low level formation of ecgonine methyl ester found in control (no enzyme), cytosol, and 
HRP assay systems likely represents non-specific hydrolysis, a phenomenon previously reported.122  In 
contrast, norcocaine production is mediated by CYP N-demethylase activity (also localized to the ER 
membrane), thereby accounting for its formation exclusively in HLM and S9 assays containing NADPH.  
NADPH is necessary for CYP activity and is included in the +1 and +1/2 assay systems employed here.  
Consequently, norcocaine is absent from no enzyme, CYT, and HRP systems and from HLM+2 and S9+2 
incubations.   
While regioselective ring metabolism has been well documented with numerous xenobiotics in the 
past123,124, this phenomenon has not been extensively investigated for drugs of abuse.  Comparisons of 
oxidative ring metabolism of cocaine in the present study revealed distinct differences between liver 
derived biotransformation components and non-liver derived HRP.  Specifically, regioselective 
hydroxylation pathways were noted for liver fractions, whereas hydroxylation by HRP was substantially 
less selective.  In addition, the relative levels of hydroxylated metabolites produced by the HRP system 
were considerably greater than the hepatic systems, reaffirming the strong oxidizing power of the 
HRP/H2O2 system.  The differences in isomer formation encountered with this system suggest that care 
must be taken in using the HRP assay as a model for hepatic oxidative metabolism.  However, the HRP 
assay may be a relevant model for endogenous peroxidases localized to individual tissue types other than 
liver31,125, and further studies examining the possible formation of 2-hydroxylated cocaine metabolites by 
tissue-specific peroxidases may validate this system as a predictor of non-hepatic in vivo metabolism. 
In the case of cocaine metabolism, distinct differences could be seen in the production of primary 
vs. secondary metabolites, stressing the importance of incubation time in experimental design.  Data from 
the current study demonstrate that, for norcocaine (a primary metabolite of cocaine), the HLM system is 
adept at producing the metabolite within 0.5 h, while S9 requires a longer incubation time to produce 
detectable quantities of norcocaine.  Since benzoylnorecgonine is a secondary metabolite (i.e., the result of 
further metabolism of the primary cocaine metabolites benzoylecgonine and norcocaine), production is 
slower in vitro.  These differences in metabolic profiles among assay systems and with differing incubation 
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times exemplify the need for adjusting assay parameters to the specific aim or desired outcome of each 
individual experiment.  For example, incubation time can be minimized when primary metabolites are the 
desired targets; however, if secondary or minor metabolites are of interest, increasing the incubation time 
beyond 30 min (especially with the S9 system) should be considered.  Minor or secondary metabolites may 
be of particular interest when examining the impact of toxicophore and reactive metabolite formation for 
consideration in idiosyncratic toxicity studies.69,126,127   
Similar metabolic studies on the pyrolytic cocaine product AEME reported by Toennes et al. and 
Fandino et al. are largely in agreement with findings from the present study regarding in vitro metabolism 
of cocaine.128,129  Investigations into hydrolytic degradation of AEME to anhydroecgonine demonstrated 
passive hydrolysis exacerbated by an increase in pH.  Additionally, enzymatic hydrolysis by 
butyrylcholinesterase was suggested on the basis of increases in anhydroecgonine production in human 
plasma as compared to buffer at physiological pH.  These data are concordant with observations of 
ecgonine methyl ester formation from cocaine, where assay systems with esterase activity (i.e., HLM and 
S9) demonstrated increased production of ecgonine methyl ester over other systems.  However, even 
systems without active esterases (i.e., no enzyme, CYT, and HRP) produced ecgonine methyl ester as a 
minor metabolite, likely by means of passive hydrolytic degradation.  Analysis of AEME after incubation 
with rat liver microsomal preparations128 showed qualitative similarity in metabolic pathways associated 
with AEME biotransformation as were observed in the current study with cocaine.  Fandino et al. did note 
appreciable variability of enzymatic activity between microsomal preparations derived from various 
tissues, specifically a lack of oxidative metabolite production in kidney- and brain-based assays.  However, 
as has been noted in other studies, xenobiotic metabolism can vary both qualitatively and quantitatively 
between species117,130, suggesting caution when drawing conclusions based on cross-species assays. 
The possible formation of Phase II cocaine metabolite glucuronides was also examined in the 
present study.  Results showed no evidence for glucuronide formation (either by direct MS detection or 
depletion of hydroxylated metabolites) in the in vitro systems studied, despite the presence of an active 
glucuronidation mechanism.  In contrast, Zhang et al. reported aryl-hydroxylated cocaine metabolites in 
authentic urine specimens after enzymatic hydrolysis, leading to their conclusion that hydroxylated 
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metabolites exist, at least in part, as Phase II conjugates.104  Since the extraction procedure used in their 
experiments hydrolyzed both glucuronide and sulfate conjugates, it is possible that hydroxylated cocaine 
metabolites exist primarily as sulfonated products, whose formation was not investigated in this study. 
 
4.2.4.2. Methamphetamine Metabolism Discussion 
 The hepatic metabolism of methamphetamine has been reported to be primarily mediated by CYP 
enzymes29,131 and FMOs29.  The current in vitro experiments, which are generally in agreement with the 
influence of membrane-bound CYP and FMO enzymes on methamphetamine metabolism, demonstrated a 
nine-fold increase in amphetamine production in microsomal systems activated with NADPH over any 
other system.  However, the appearance of amphetamine in CYT systems activated by NADPH suggests 
that not all methamphetamine metabolism is catalyzed by CYP enzymes and FMOs (which are found 
exclusively as membrane-coordinated enzymes in the HLM fraction).  Contamination of CYT fractions 
with CYP enzymes can be discounted, because the analogous zolpidem hydroxylation (positive control) 
was limited to HLM and S9 assays.  While the majority of the enzymatic components present in the CYT 
fraction mediate conjugative (Phase II) activities, soluble enzymes (such as methyltransferases) in the CYT 
fraction may contribute to the Phase I metabolism of methamphetamine.   
 While the oxidative activity of certain assay systems has been found to be regioselective with 
other drugs (including cocaine, as reported above)123,124, the oxidation of methamphetamine to form three 
arene-hydroxylated isomers did not demonstrate qualitative regioselectivity in the present study.  
Quantitative regioselectivity could not be definitively determined due to a lack of available calibrated 
standards.  Even though general assay regioselectivity was not observed, individual enzymatic components 
(e.g., CYP isozymes, CYP vs. FMO) may still display regioselective activity.   
 It is notable that analytical schemes for methamphetamine metabolite analysis typically only test 
for the presence of the 4-hydroxy isomer when hydroxymethamphetamine is examined.  Indeed, there is no 
mention of 2- or 3-hydroxymethamphetamine in human-based metabolism literature to date.  However, it is 
unclear whether the 2- or 3-hydroxy isomers have previously been targeted as potential metabolites.  4-
Hydroxymethamphetamine may be favored as the preferential hydroxyl metabolite because of its 
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comparatively rapid production (as demonstrated in the present study) or potential quantitative superiority 
over 2- and 3-hydroxy isomers.  Although the 2- and 3-hydroxy derivatives were clearly present, the 
present data are insufficient to assess quantitative distributions of hydroxymethamphetamine isomers 
among the assay systems examined.   
 Metabolism of methamphetamine to 3-hydroxymethamphetamine displayed characteristics 
atypical for aryl hydroxylation products.  First, data from systems typically exhibiting high oxidative 
activity (i.e., HLM+1, HLM+1/2, and HRP+) showed a decrease in the concentration of this metabolite 
from 0.5 to 24 h incubation.  The observed phenomenon may suggest preferential secondary oxidative 
metabolism of the 3-hydroxy isomer and/or molecular instability leading to further transformation of 
product.  Also atypical for oxidative products, the predominant human liver fraction producing 3-
hydroxymethamphetamine after 24 h incubation was determined to be CYT.  Oxidative metabolism is 
typically catalyzed by monooxygenases (e.g., CYPs, FMOs), which are almost exclusively located in the 
microsomal fraction.  These data suggest the possible influence of additional classes of enzymes outside the 
CYP and FMO superfamilies contributing to the comprehensive metabolism of methamphetamine 
biotransformation. 
 Literature reports have demonstrated the formation and direct detection of glucuronide and sulfate 
conjugates of aryl-hydroxylated metabolites of methamphetamine in authentic blood and urine specimens 
from drug users.27  In accordance, Phase II glucuronide products of methamphetamine metabolism were 
targeted by the comprehensive methamphetamine metabolism analysis method employed in the present 
study.  In contrast to human specimen data reported in previous work, direct LC-MS analysis in the present 
study was unable to detect methamphetamine metabolite glucuronide formation in any in vitro system 
examined, despite the presence of active Phase I oxidation and Phase II glucuronidation mechanisms.  
However, decreases in hydroxymethamphetamine isomer concentrations between assays containing only 
active Phase I systems and those with both active Phase I and II mechanisms were noted.  Observed 
discrepancies in hydroxymethamphetamine concentrations between assay systems containing UDP-GlcUA 
and those without would be consistent with secondary glucuronide conjugation.  Inability of the MS-based 
analytical method used in this study to directly detect glucuronide products may have been the result of less 
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than optimal ionization and fragmentation parameters, due to the lack of analytical standards for these 
metabolites.  
 
4.2.4.3. Morphine Metabolism Discussion 
 In contrast to the biotransformation of cocaine and methamphetamine, the metabolism of 
morphine by the four in vitro systems was primarily mediated by Phase II glucuronidation.  Glucuronide 
formation is generally known to be catalyzed by ER-bound UGT enzymes found mainly in the microsomal 
fraction, a fact corroborated by high concentrations of morphine-3- and morphine-6-glucuronide in 
HLM+2, HLM+1/2, S9+2, and S9+1/2 incubations in the present study.  However, the appearance of 
glucuronide metabolites in CYT assays containing the cofactor UDP-GlcUA also suggests the presence of 
glucuronide-forming enzymes in the cytosol.  This phenomenon may reflect either incomplete sequestering 
of UGT enzymes to the microsomal fraction during differential centrifugation or the existence of distinct 
enzymes in the cytosolic fraction that represent a minor contribution to the process of morphine 
glucuronidation.  In contrast, incubation of nicotine as a positive control did not reveal glucuronide 
production in CYT incubations; nicotine-N-glucuronide was exclusively produced in HLM and S9 assays 
containing UDP-GlcUA.  Lack of nicotine-N-glucuronide in CYT fractions activated with UDP-GlcUA 
suggests that incomplete sequestering of UGT enzymes to the microsomal fraction is unlikely to be the 
causal factor responsible for morphine glucuronidation in CYT assay systems.  These data suggest that 
morphine glucuronidation may be influenced by non-microsomal enzymes that have not been documented 
in morphine metabolism-based literature. 
 Though Phase I biotransformation represents only a small fraction of morphine metabolism, the N-
demethylation product normorphine was detected in HLM and S9 assays activated by NADPH.  This is 
consistent with previous reports demonstrating the influence of CYP enzymes on the N-dealkylation of 
morphine in humans.132  Furthermore, previous reports have demonstrated the formation of the morphine 
reduction product morphinone in human liver tissues.82  However, the intrinsic reactivity of compounds 
containing α,β-unsaturated carbonyls such as morphinone would likely result in binding to nucleophilic 
targets in cellular media in vivo (e.g., glutathione, free thiols within proteins).133,134  While morphinone was 
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not detected in free fraction by the methods used in this study, it may be that any morphinone produced 
would be protein bound, with the free fraction of morphinone remaining below the detection limits of this 
method. 
 
4.3. rhCYP Assays 
4.3.1. Positive Control Probes 
Isoform viability was confirmed using samples incubated with a cocktail of known substrates for 
each CYP isoform (melatonin, bupropion, amodiaquine, tolbutamide, omeprazole, and dextromethorphan).  
The production of anticipated metabolites from each substrate probe (see Table 7) was catalogued for each 
isoform (Figure 29).  While certain substrate-to-metabolite transformations were conserved across multiple 
isoform incubations (i.e., N-demethylation of omeprazole to desmethylomeprazole, Figure 29), maximal 
formation of each resultant metabolite was as anticipated on the basis of published CYP isoform data. 
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Figure 29: rhCYP positive control assays 
Expected metabolic event from literature: CYP1A2, melatonin6-hydroxymelatonin; 
CYP2B6, bupropionhydroxybupropion; CYP2C8, amodiaquinedesethylamodiaquine; 
CYP2C9, tolbutamidehydroxytolbutamide; CYP2C19, omeprazole 
desmethylomeprazole; CYP2D6, dextromethorphandextorphan; CYP3A4, omeprazole 
omeprazole sulfone.  Dark bars designate CYP isoform targeted by each specific metabolic 
transformation. 
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4.3.2. Cocaine 
 Concordant with existing reports of cocaine ester cleavage resulting from various esterases (e.g., 
carboxylesterases, cholinesterases), assay data demonstrated that none of the CYP isoforms examined 
significantly influenced the hydrolytic pathways of cocaine biotransformation. 
 Norcocaine production is known to be mediated by CYP enzymes, with reports having designated 
CYP3A4 as a contributing isoform in humans for oxidative N-demethylation.135  Results from the present 
study confirmed the generation of norcocaine from cocaine by CYP3A4 and determined that the CYP2C 
family (i.e., 2C8, 2C9, 2C19) also plays a significant role in the N-demethylation of cocaine.  Figure 30 
displays data collected for the contribution of each CYP isoform examined to norcocaine production. 
 The pathways responsible for the aromatic hydroxylation of cocaine have the potential to be 
complex due to regioselective oxidative activity documented in some CYP enzymes.123,136  Therefore, the 
phenotyping of biotransformation pathways responsible for each hydroxylated isomer was examined 
individually.  As such, the reactions of 2-, 3-, and 4-hydroxylated isomers of cocaine were phenotyped 
separately.  As was reported above (Section 4.2.1), 2-hydroxycocaine is not a metabolite generated via 
hepatic biotransformation processes in humans.  In accordance with these previous findings, the present 
experiment showed that 2-hydroxycocaine is not formed by any of the human CYP isozymes examined in 
the phenotyping panel.  Likewise, 3-hydroxycocaine production could not be attributed to any of the 
isoforms studied, suggesting the possible influence of other enzyme classes (e.g., FMOs) or one of the CYP 
isoforms not investigated in this study.  4-Hydroxycocaine production was found to be almost exclusively 
mediated by CYP2C19 with minor influences from CYPs 2C9 and 3A4 (Figure 30).  
Incorporating existing knowledge with the data presented herein, Figure 31 displays a 
comprehensive list of known enzymatic contributors (focusing on individual CYP isoforms) for the primary 
Phase I biotransformation pathways affecting cocaine metabolism. 
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Figure 30: Cytochrome P450 isoform panel for cocaine primary metabolite formation 
(a) and (c) present raw data for norcocaine and 4-hydroxycocaine formation within the CYP 
isoform panel.  (b) and (d) present the same data after transformation to account for relative 
CYP concentrations in human liver tissue. 
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Figure 31: Enzymology of primary cocaine biotransformation pathways in humans 
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4.3.3. Methamphetamine 
 Since methamphetamine and amphetamine typically undergo analogous biotransformation 
processes due to structural similarity, it was anticipated that methamphetamine could undergo α-
hydroxylation to form ephedrine in the same way that amphetamine has been documented to undergo α-
hydroxylation to form norephedrine in humans and other species.137,138  However, in vitro rhCYP assay 
incubations of methamphetamine did not demonstrate CYP-mediated formation of ephedrine.  Indeed, this 
data is in agreement with microsomal incubation results (see Section 4.2.2) where neither ephedrine nor 
norephedrine were detected in any in vitro metabolic model system examined. 
The primary Phase I metabolic pathway of methamphetamine metabolism in humans is N-
demethylation to form the pharmacologically active product amphetamine.  Existing literature has 
demonstrated the contribution of CYP2D629,131 in the metabolism of methamphetamine to amphetamine; 
however, complete reaction phenotyping with other major CYP isoforms has not been reported.  Data 
collected here corroborated the primary impact of CYP2D6 previously reported in the literature.  
Additionally, CYPs 2C9 and 2C19 were found to mediate the N-demethylation of methamphetamine to 
amphetamine (Figure 32).   
Existing literature reporting the aromatic hydroxylation of methamphetamine and other 
phenethylamine congeners has unilaterally focused on the 4-hydroxylated product without mentioning 
either the 2- or 3-hydroxylated isomers.  These reports have also identified CYP2D6 as a contributor to the 
production of 4-hydroxymethamphetamine; however, as with CYP designation for amphetamine, 
comprehensive examinations of contributions from other CYP isoforms were not performed.  As a result of 
data from the present study indicating the formation of all three hydroxymethamphetamine isomers within 
in vitro microsomal metabolic model systems (see Section 4.2.2), the biotransformation of 
methamphetamine to each hydroxymethamphetamine isomeric product was phenotyped individually.  
While minor quantities of the 2- and 3-hydroxylated isomers were formed in many of the CYP assays, no 
specific mediating isoform could be determined for the production of either 2- or 3-
hydroxymethamphetamine.  In contrast, the production of 4-hydroxymethamphetamine was found to be 
mediated by numerous CYP isoforms.  Data collected in the current study confirmed the primary role of 
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CYP2D6 concordant with existing literature, but also catalogued the influences of CYP3A4 and the 
CYP2C subfamily (CYPs 2C8, 2C9, and 2C19; see Figure 32).   
Incorporating existing knowledge with data presented herein, Figure 33 displays a comprehensive 
list of known enzymatic contributors (focusing on individual CYP isoforms) for the primary Phase I 
biotransformation pathways affecting methamphetamine metabolism. 
 
Figure 32: Cytochrome P450 isoform panel for methamphetamine primary metabolite formation 
(a) and (c) present raw data for amphetamine and 4-hydroxyamphetamine formation within 
the CYP isoform panel.  (b) and (d) present the same data after transformation to account 
for relative CYP concentrations in human liver tissue. 
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Figure 33: Enzymology of primary methamphetamine biotransformation pathways in humans 
 
4.3.4. Morphine 
As was documented in microsomal incubations, morphine undergoes minimal Phase I 
biotransformation detectable via the direct analysis methods utilized in these experiments (see Section 
4.2.3).  However, it is known that catalytic oxidation of the C6 hydroxyl group on morphine to form the 
α,β-unsaturated carbonyl metabolite, morphinone, is facilitated by the enzyme morphine-6-dehydrogenase 
and free hydroxyl radicals.  Consistent with data from microsomal incubations performed earlier in this 
project (see Section 4.2.3), morphinone was not detected in any CYP isoform incubation performed, further 
supporting the singular role of the enzyme morphine-6-dehydrogenase in catalyzing the transformation of 
morphine to morphinone.82-84 
Previous research by Projean et al. investigated the isoforms responsible for N-demethylation of 
morphine to normorphine using rhCYP extrapolated enzyme kinetics and microsomal inhibition data, 
confirming the primary influence of CYPs 3A4 and 2C8 and minor influences by CYPs 2C9, 2C19, and 
2D6.132  Results obtained by in vitro incubation of morphine with individual rhCYP isozymes in the current 
study determined the primary influence of CYPs 2C8 and 3A4 with minor influences of CYPs 2C9 and 
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2C19 (Figure 34).  Thus, the data obtained are generally concordant with existing literature for the N-
demethylation of morphine, demonstrating the usefulness of the simplified reaction phenotyping procedure 
used in this study for designation of the principal CYP isoforms mediating individual biotransformation 
pathways. 
Incorporating existing knowledge with data presented herein, Figure 35 displays a comprehensive 
list of known enzymatic contributors (focusing on individual CYP isoforms) for the primary Phase I 
biotransformation pathways affecting morphine metabolism. 
 
Figure 34: Cytochrome P450 isoform panel for morphine primary metabolite formation 
(a) presents raw data for normorphine formation within the CYP isoform panel.  (b) 
presents the same data after transformation to account for relative CYP concentrations in 
human liver tissue. 
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Figure 35: Enzymology of primary morphine biotransformation pathways in humans 
 
4.3.5. Discussion of Results from Drug of Abuse rhCYP Reaction Phenotyping 
Results obtained from CYP phenotyping of the metabolic pathways associated with primary 
metabolites of cocaine, methamphetamine, and morphine demonstrated the variety of enzymatic 
contributors that can play a role in the metabolism of a xenobiotic.  Specific knowledge of the primary CYP 
isoforms responsible for metabolic pathways can be critical during exposure to multiple drugs.  While 
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cocaine and methamphetamine are not typically prescribed medically, administration of morphine with 
other pharmaceuticals is common.  Likewise, clinicians prescribing pharmaceuticals to individuals illegally 
abusing cocaine, methamphetamine, or morphine could greatly benefit from such phenotyping data, as the 
chronic use and high doses often associated with drug abuse can have a severe impact on the patient’s 
physiology and therapeutics.139  Additionally, known genetic predispositions (i.e., enzymatic 
overexpression, under expression, or variance in enzyme function) can act as biomarkers of susceptibility 
to effects associated with drug impact on pharmacokinetics, pharmacodynamics, toxic metabolite 
production, and other toxicological descriptors. 
 Data collected in this study for morphine are in good agreement with existing literature describing 
the CYP phenotyping of N-demethylation pathways that generate the Phase I metabolic product 
normorphine.  While the present study did not determine CYP2D6 to be a contributing isoform based on 
criteria utilized, the combination of Michaelis-Menten kinetic parameters determined by Projean et al. (i.e., 
relatively high Km of 10.1 mM and low Vmax of 6.57 pmol/min/pmol CYP)132 coupled with the relatively 
low expression of CYP2D6 in human liver (i.e., 2.0% total CYP content in liver) could explain this 
discrepancy with existing literature.  In contrast, the simplified method utilized here was successful in 
assigning the influence of CYPs 2C8, 3A4, 2C9, and 2C19 in concordance with existing literature, again 
demonstrating the value of the assay. 
 In the case of the important drug of abuse cocaine, CYP3A4 has previously been catalogued as a 
major contributor to the overall metabolism of this drug in humans.  Data reported above confirm the 
impact of CYP3A4 on biotransformation pathways responsible for norcocaine and 4-hydroxycocaine.  
Additionally, norcocaine and 4-hydroxycocaine production were determined to be mediated by the CYP2C 
subfamily, with CYPs 2C19, 2C8, and 2C9 contributing to the N-demethylation of cocaine and CYPs 2C19 
and 2C9 as contributors to regioselective hydroxylation to 4-hydroxycocaine.  Interestingly, while 
individual isoform contribution to hydroxylation at the 4-position of the benzoyl ring could be attributed to 
specific CYP isoforms, analogous reaction to form 3-hydroxycocaine was not determined to be mediated 
by any of the CYPs examined.  In concordance with data presented in Section 4.2.1, individual CYP 
phenotyping did not demonstrate the formation of 2-hydroxycocaine in any of the human CYP-containing 
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assays examined, supporting the conclusion that regioselective enzyme activity in human liver tissue does 
not allow for the hydroxylation of cocaine at the 2-position of the cocaine benzoyl moiety.  Also in support 
of existing data, the formation of the esterase products benzoylecgonine and ecgonine methyl ester was not 
exacerbated by any CYP isoform examined in this study.  While benzoylecgonine and ecgonine methyl 
ester were detected as products in rhCYP isoform assays, their presence can reasonably be attributed to the 
passive hydrolytic cleavage of labile cocaine ester bonds (see Section 4.2.1).  Levels of the hydrolysis 
products in systems containing NADPH and control samples (i.e., no NADPH added) were 
indistinguishable, demonstrating the lack of influence of NADPH-initiated CYP monooxygenase activity 
on their formation. 
 Designation of CYP2C19 as a mediating factor in 4-hydroxycocaine production may have 
implications on cocaine-associated pathology and its relationship to genetic predisposition for addiction.  It 
has been suggested that the cascade associated with cocaine addiction is mediated by the binding of cocaine 
to dopamine transporters and downstream physiological effects that result from this binding.140-142  Singh et 
al. have demonstrated that 2- and 4-hydroxycocaine have 9.9- and 1.6-fold higher affinity, respectively, for 
dopamine transporter binding as compared with cocaine (3-hydroxycocaine has only 0.2-fold the affinity 
for dopamine transporters compared to cocaine).143  In compliance with the dopamine transporter binding 
theory of cocaine addiction, increased concentration of 4-hydroxycocaine in humans would elicit stronger 
dopaminergic response, thereby stimulating the addiction pathway.  Individual genetic or epigenetic factors 
causing increases or decreases in CYP2C19 expression and/or activity may act as biomarkers of 
susceptibility for the development of cocaine addiction.  While production of 2-hydroxycocaine would 
result in more dramatic shifts in addiction pathology (as its dopamine transporter binding is 9.9-fold more 
potent than cocaine and 6.1-fold more potent than 4-hydroxycocaine), data from this study suggests that 2-
hydroxycocaine is not a metabolic product of human CYP enzymes after cocaine exposure.  However, non-
hepatic oxidative enzymes (e.g., tissue-specific peroxidases) may bring about oxidation at the 2-position of 
the cocaine arene moiety, causing localized production of 2-hydroxycocaine and possible downstream 
impact on dopamine transporter binding and addiction. 
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 Like cocaine, limited reports of individual isoform contribution to methamphetamine metabolism 
are available in the literature to suggest the involvement of CYP2D6 on the biotransformation pathways 
that result in amphetamine and 4-hydroxymethamphetamine production in humans.  Data collected in this 
study confirm and extend existing data, designating CYP2D6 as the major CYP isoform responsible for 
both amphetamine and 4-hydroxymethamphetamine production.  Additionally, results demonstrate that the 
N-demethylation of methamphetamine to amphetamine is also mediated by CYPs 2C19 and 2C9, while 
hydroxylation to 4-hydroxymethamphetamine can be attributed to contributions by CYPs 2C19, 3A4, 2C8, 
and 2C9.  As was the case with cocaine oxidation, the production of hydroxylated isomers aside from 4-
hydroxymethamphetamine (i.e., 2- and 3-hydroxymethamphetamine) could not be attributed to any specific 
CYP isoform examined in this study.  On the basis of the observation that both 2- and 3-
hydroxymethamphetamine are formed in human liver microsomal incubations (see Section 4.2.2), it is 
probable that either the FMO superfamily of monooxygenase enzymes are responsible for the microsomal 
production of these products or that one of the CYP isoforms not examined in the present study (e.g., 
CYP2E1) is the catalytic enzyme in these biotransformation pathways.  Lastly, the production of ephedrine 
was examined as a possible metabolic route for methamphetamine catalyzed by CYP enzymes.  In 
agreement with data from microsomal incubations, where ephedrine was not detected in any in vitro 
metabolic model system examined, rhCYP isoform assays also did not generate detectable concentrations 
of ephedrine.  Lack of ephedrine detection supports the assertion that the aliphatic hydroxylation of 
methamphetamine to ephedrine may not be a metabolic process that occurs in humans, even though there is 
documented evidence for the formation of norephedrine (purportedly from the aliphatic hydroxylation of 
amphetamine as a secondary metabolite of methamphetamine biotransformation) in humans.138 
 
4.4. Reactive Metabolite Trapping and Protein Adduction Model Systems 
Positive control incubations in the presence of clozapine or benzyl bromide confirmed the 
formation of postulated covalent adduction products of these drugs (see Figure 36 and Figure 37).144,145  
Trapped reactive electrophiles within positive control incubations included a combination of reactive parent 
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compound and/or reactive metabolites, demonstrating the functionality of both pathways within these 
assays. 
 
Figure 36: Positive control incubation demonstrating passive and metabolism-mediated adduction by 
clozapine 
 
Figure 37: Positive control incubation demonstrating passive adduction by benzyl bromide 
 Abbreviation: BB, benzyl bromide 
Preliminary screening of drug of abuse substrates (i.e., cocaine, methamphetamine, or morphine) 
for adduction potential in the presence of an active Phase I metabolic system and trapping agent (i.e., NAC, 
NAK, or NAH) showed the presence of numerous adduction products consistent with the m/z values of the 
hypothetical products presented in Table 9.  Subsequent MS/MS investigation of each suspected adduction 
product further narrowed the pool of potential candidates by eliminating compounds when MS2 
fragmentation data was not consistent with a conjugated product resulting from substrate-trapping agent 
interaction.  Table 15 presents a summary of preliminary screening assay data, where only cocaine/NAC 
clozapine/NAC adducts
hydroxyclozapine/NAC adducts
Active trapping sample
Control 1 (no NADPH)
Control 2/3 (no drug/no NAC)
NAC + benzyl bromide
NAK + benzyl bromide
NAH + benzyl bromide
Control (no benzyl 
bromide added)
NAC-BB 1
NAC-BB 2
NAH-BB 1
NAH-BB 2
NAK-BB 2
NAK-BB 1
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and morphine/NAC systems were found to produce adduction products with corroborating MS/MS spectra.  
All potential compounds detected in systems containing methamphetamine, NAK, or NAH were eliminated 
because of MS/MS data that was unsupportive of adduction products containing respective 
substrate/trapping agent moieties. 
 Rigorous investigations into the structure and mechanism of formation for putative adducts were 
performed according to the stepwise method optimization and probing assays described in the Methods 
section (see Section 3.6).  Data and analysis are presented in the following section, organized according to 
individual substrate/trapping molecule systems.  Chromatographic methods corresponding to each 
substrate/trapping molecule system are summarized in Appendix 8. 
Table 15: Summary of preliminary screening assays for potential adduction products 
Drug Substrate Trapping Agent Conjugation Products with MS/MS Data Consistent with Adduction 
Cocaine 
NAC m/z 483 
NAK NDa 
NAH ND 
Methamphetamine 
NAC ND 
NAK ND 
NAH ND 
Morphine 
NAC m/z 447, 449 
NAK ND 
NAH ND 
a ND = none detected 
 
4.4.1. Cocaine Adduction Products 
4.4.1.1. Cocaine‒N-Acetylcysteine Adduction 
Chromatographic separation via UHPLC resulted in the designation of eight distinct analytes 
arising from interaction between cocaine and N-acetylcysteine (labeled COC-NAC 1-8 in Figure 38).  
Exact mass analysis performed by QTOF-MS of each analyte revealed qualitatively similar molecular mass 
and formula (molecular formula for all analytes determined to be C22H30N2O8S via Agilent MassHunter 
software; see Table 16).  MS/MS fragmentation of parent ions resulted in similar spectra, with a 
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representative spectrum presented in Figure 39.  Fragmentation of m/z 483 precursor ions yielded fragments 
consistent with hydroxycocaine isomers, specifically m/z 121 (Figure 39 inset), a mass indicative of 
[OCC6H4OH]+, an ion designating hydroxylation on the arene ring.  Likewise, the fragment ion at m/z 182 
is indicative of an intact methyl ester tropane, discounting the potential for formation by means of N-
oxidative processes (i.e., nitrosonium ion adduction).  In accordance, the eight analytically determined 
products of cocaine‒N-acetylcysteine adduction were assigned as isomers of the structure presented in 
Figure 40.  Thiol-adduction products similar to that shown in Figure 40 have been previously characterized 
(e.g., with benzylamine)107, demonstrating the stability of conjugated enols that do not undergo subsequent 
dehydration to re-establish aromaticity. 
Adduction products were not detected in three control samples incubated without NADPH, 
cocaine, and NAC, respectively, demonstrating that adduct formation is NADPH-, cocaine-, and NAC-
dependent.  NADPH-mediated adduct formation suggests the involvement of CYP and/or FMO enzyme 
families.   
 
Figure 38: Chromatographic separation of cocaine‒N-acetylcysteine adducts (labeled COC-NAC 1-
8; inset is expansion to show dominance of COC-NAC 3) 
 
 
 
COC-NAC 1
COC-NAC 2
COC-NAC 4
COC-NAC 5
COC-NAC 6
COC-NAC 7
COC-NAC 8
COC-NAC 3
COC-NAC 3
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Table 16: Comparison of theoretical and observed [M+H]+ ions for cocaine‒N-acetylcysteine adducts 
Adduction 
Product 
Retention Time 
(min) 
Theoretical Mass 
(m/z) Observed Mass (m/z) 
Difference 
(ppm) 
COC-NAC 1 3.41 483.1796 483.1794 0.41 
COC-NAC 2 4.34 483.1796 483.1797 0.21 
COC-NAC 3 4.61 483.1796 483.1801 1.03 
COC-NAC 4 4.90 483.1796 483.1797 0.21 
COC-NAC 5 5.91 483.1796 483.1793 0.62 
COC-NAC 6 6.11 483.1796 483.1800 0.83 
COC-NAC 7 6.30 483.1796 483.1797 0.21 
COC-NAC 8 7.42 483.1796 483.1796 0.00 
Average - 483.1796 483.1797 ± 0.0003 0.21 
 
 
Figure 39: MS/MS spectrum of cocaine‒N-acetylcysteine adduct 
 
Figure 40: Fragmentation pattern of cocaine‒N-acetylcysteine adduct 
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 Investigation into the effect of varying incubation time and secondary supplementation with 
additional NADPH are summarized in Figure 41 using COC-NAC 3 as a model (analogous trends were 
documented across all eight COC-NAC isomers).  Data demonstrated a linear relationship between 
incubation time and adduct production, with the 6 h incubation generating maximal adduct levels.  In 
addition, it was found that, overall, a 6 h incubation with secondary NADPH supplementation at 3 h was 
more effective at quantitative generation of adduction products, generating 230% the amount of adduct than 
a 1.5 h incubation without supplementation (assuming a linear relationship between peak area count and 
adduct concentration). 
 
Figure 41: COC-NAC 3 formation as a factor of incubation time and secondary NADPH 
supplementation 
  
4.4.1.2. Cocaine‒N-Acetylcysteine Adduct Cytochrome P450 Enzyme Designation 
Examination of cocaine‒N-acetylcysteine adduct formation within rhCYP assay systems revealed 
that CYPs 1A2, 2C19, and 2D6 were the primary contributing isoforms.  While slight differences in 
quantitative isomer distribution between isoforms were observed, all contributing CYP isoforms were 
capable of producing each of the eight cocaine‒N-acetylcysteine isomers.  Figure 42 displays the relative 
quantities of adduct generated between in vitro assays using COC-NAC 3 as a model (labeled “Raw Data”) 
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and the calculated relative contribution of each isoform expected in human liver tissue based on native 
isoform concentrations (labeled “Liver”).  It is noteworthy that isoform panels examining 3- and 4-
hydroxycocaine formation did not coincide with cocaine‒N-acetylcysteine adduct formation even though 
hypothesized mechanisms for both rely on the same postulated cocaine-3,4-epoxide reactive intermediate.  
While CYP2C19 was conserved as a mediating isoform for both the 4-hydroxycocaine metabolite and 
cocaine adduction products, observed differences in isoform panels may be the result of enzymatic factors, 
specifically a preference for adduct formation over hydroxylated metabolite formation (for CYPs 1A2 and 
2D6) or enzyme-substrate interactions influencing reaction kinetics within in vitro systems.  The absence of 
CYP3A4 as a mediating factor in the formation of cocaine‒N-acetylcysteine adducts does suggest that 
tropane nitrogen oxidation (known to be CYP3A4-mediated; demonstrated in norcocaine rhCYP assay, see 
Figure 30) is not a likely formation mechanism.  While this data does confirm the influence of CYP 
enzymes in the production of metabolically induced cocaine thiol adduction, it does not preclude the 
contribution of the FMO superfamily of enzymes within microsomal assays. 
 
Figure 42: Cytochrome P450 isoform panel for cocaine‒N-acetylcysteine adduct formation 
(a) presents raw data for cocaine‒N-acetylcysteine adduct formation within the CYP 
isoform panel.  (b) presents the same data after transformation to account for relative CYP 
concentrations in human liver tissue. 
 
4.4.1.3. Putative Mechanism for Cocaine-Derived Thiol Adduction 
Structural designation of monohydroxylation at the arene moiety on cocaine in addition to 
knowledge of NADPH-mediated formation suggests that bioactivation of the benzoyl group yields a 
reactive electrophilic intermediate capable of reacting with a nucleophilic agent such as the sulfhydryl 
group on cysteine.  Epoxide intermediate formation via FMO- or CYP-mediated oxidation (well-known 
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mechanisms resulting in the hydroxylation of arenes) is concordant with all data on mechanism and 
structure accrued in this study (Figure 43).  Specific designation of the CYP isoforms 1A2, 2C19, and 2D6 
confirm the role of CYPs in the adduction mechanism but do not preclude a potential influence of FMOs in 
the comprehensive adduction scheme.  Adduct formation via an arene epoxide intermediate would involve 
the nucleophilic attack of the reactive epoxide intermediate by a cysteine thiol, resulting in epoxide ring 
opening and reduction of the oxygen to form a monohydroxylated thiol-adducted product with a stable 
conjugated enone.  As nucleophilic attack of the epoxide can occur from numerous directions, this 
mechanism is also concordant with the generation of several structural isomers varying by site of 
hydroxylation and thiol attachment on the arene moiety. 
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Figure 43: Proposed mechanism for cocaine metabolism to reactive intermediate and thiol adduction 
 
4.4.1.4. Cocaine‒Glutathione Adduction 
In vitro incubations supplemented with GSH as a reactive metabolite trapping agent revealed a 
series of cocaine‒GSH adduction products consistent with the formation mechanisms proposed for 
cocaine‒NAC adducts.  LC-QQQ-MS analysis resulted in designation of three adduction products 
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(designated COC-GSH 1-3, Figure 44; native GSH MS/MS fragmentation included for reference in 
Appendix 9a).  Isocratic elution at 4% B revealed COC-GSH 1-3 to be unresolved peaks (most likely 
arising from co-eluting structurally similar isomers; see Figure 44 inset).  However, since MS/MS analysis 
of all peaks revealed uniform spectra (representative spectrum presented in Figure 45) and baseline 
separation could not be achieved even under isocratic conditions, attempts to better separate isomeric 
structures were not pursued, since MS/MS spectra alone are insufficient to designate individual structural 
isomers.  Exact mass analysis by QTOF-MS revealed similar masses, with an average [M+H]+ m/z of 
627.2329 ± 0.0020.  Agilent MassHunter software estimated the molecular formula to be C27H38N4O11S 
with empirical data deviating 0.32 ppm from theoretical mass (m/z 627.2331). 
Control incubations which sequentially eliminated NADPH, cocaine, and GSH did not generate 
any cocaine‒GSH adduction products.  Data demonstrated cocaine‒glutathione adduction to be NADPH-, 
cocaine-, and GSH-mediated, analogous to cocaine‒NAC adduction.  An adduction mechanism requiring 
coordination of NADPH, cocaine, and GSH, in addition to exact mass data and analysis of MS/MS spectra, 
led to the designation of COC-GSH 1-3 as structural isomers of the compound displayed in Figure 46 
(MS/MS fragmentation also justified in Figure 46). 
 
Figure 44: Chromatographic separation of cocaine‒ glutathione adduction products (labeled COC-
GSH 1-3; inset shows unresolved co-eluting peaks using isocratic elution) 
COC-GSH 1
COC-GSH 2
COC-GSH 3
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Figure 45: MS/MS spectrum of cocaine‒ glutathione adduct 
 
Figure 46: Fragmentation pattern of cocaine‒ glutathione adduct 
 
4.4.1.5. Cocaine‒AcPAACAA Adduction  
Covalent adduction of cocaine to higher order biological thiols was confirmed by assessment of 
binding to a model hexapeptide containing a central cysteine residue (AcPAACAA; MS/MS fragmentation 
of native peptide included for comparison in Appendix 9b).  Increasing macromolecular complexity as 
compared to cocaine‒NAC and cocaine‒GSH adduction products resulted in diminishing capacity of the 
chromatographic system to separate potential isomeric structures.  As such, only two distinguishable 
products were isolated utilizing the separation conditions described in Appendix 8 (designated COC-PEP 1 
and 2, Figure 47).  Exact mass analysis of products revealed an empirical average [M+H]+ ion of 864.3776 
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± 0.0007 Da,  deviating from the theoretical [M+H]+ of 864.3808 Da (C39H57N7O13S) by 3.70 ppm.  As 
before, COC-PEP 1 and 2 produced qualitatively similar MS/MS spectra, displaying characteristic peptide 
fragmentation patterns in conjunction with ions consistent with the primary fragmentation of 
hydroxycocaine (Figure 48).  Indeed, MS/MS fragmentation patterns support analogous adduction 
mechanisms for covalent binding of cocaine to higher order biological thiols as were observed for NAC 
and GSH assays (Figure 49). 
 
Figure 47: Chromatographic separation of cocaine‒AcPAACAA adduction products (labeled COC-
PEP 1-2) 
 
Figure 48: MS/MS spectrum of cocaine‒AcPAACAA adduct 
COC-PEP 1
COC-PEP 2
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Figure 49: Fragmentation pattern of cocaine‒AcPAACAA adduct 
 
4.4.1.6. Discussion of Cocaine Thiol Adduction Results 
Data collected from in vitro assay incubations of cocaine in the presence of thiol-containing 
trapping agents (i.e., NAC, GSH, and AcPAACAA) in conjunction with MS/MS-based structural 
investigations suggest a novel metabolic pathway in the metabolism of cocaine that is of particular interest 
to analytical and forensic toxicologists and pathologists.  While investigations were performed to examine 
the interaction of cocaine metabolites with other know nucleophilic amino acids in addition to cysteine 
(i.e., histidine and lysine), no evidence was found in the current study to suggest binding of cocaine 
biotransformation products to biological nucleophiles other than sulfhydryls.  Chromatographic and mass 
spectrometric investigations of products arising from cocaine interaction with biological thiols revealed the 
production of numerous stereospecific analytes.  Each sulfhydryl-containing trapping agent generated more 
than one chromatographically distinct product that maintained high MS/MS qualitative similarity among 
each trapping agent product group.  As such, it was determined by means of exact mass analysis and 
MS/MS fragmentation patterns that the resulting products represented structural isomers.  Step-wise assay 
modification determined the adduction products to be NADPH-dependent, suggesting monooxygenase 
(e.g., CYP and/or FMO superfamilies) contributions to the metabolic activation and subsequent adduction 
mechanism.  Indeed, rhCYP assay incubations conclusively demonstrated the influence of CYPs 1A2, 
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2C19, and 2D6 in the production of the observed adduction products arising from cocaine 
biotransformation.  FMOs can often accomplish oxidative events analogous to CYP biotransformation; as 
such, designation of CYP influences on adduct production does not preclude the contribution of the FMO 
superfamily within the hepatocellular microenvironment. 
The proposed formation of irreversibly bound oxidation products from cocaine biotransformation 
is not a novel toxicological finding per se, with previous research groups having documented their 
existence (see summary in Figure 11).  However, data collected from the current study are not consistent 
with any proposed mechanism of covalent cocaine adduction that exists in the literature.  In contrast, 
rigorous exact mass MS and MS/MS investigations coupled with CYP isoform designation yielded 
evidence for a novel metabolic pathway and covalent attachment mechanism.  The data support oxidative 
bioactivation of cocaine to an aryl epoxide reactive electrophilic intermediate, followed by nucleophilic 
thiol-induced ring opening resulting in the formation of a monohydroxylated thiol-adducted product.  The 
observed MS/MS product ions m/z 121 and 182 of NAC-bound cocaine metabolites are indicative of 
hydroxylation on the arene ring and an intact methyl ester tropane, respectively.  Because of the observed 
product ions, oxidative activation of the tropane nitrogen was discounted as a potential mechanism of 
adduct formation.  Indeed, oxidation of the cocaine aryl group purports the existence of a reactive 
intermediate (i.e., an aryl epoxide) directly resulting in nucleophile binding at the site of oxidation.   
Investigation of adduction products arising from nitrogen oxidation as well as methyl ester 
activation as reported in the literature23,95-99 were performed in the current study; however, the in vitro 
systems utilized were unable to confirm these previously proposed mechanisms.  Other research has 
employed immunogenic detection using antibodies raised against tropane nitrogen haptenized cocaine as 
evidentiary support for adduct formation via tropane nitrogen oxidation.95,96  Myriad factors may have 
contributed to the lack of detected products arising from this route of biotransformation in the present 
study, including electrophilic interaction with nucleophilic sites on proteins other than those examined, 
differences in ionization states of nucleophilic residues in vivo vs. in vitro (e.g., impact of the immediate 
microenvironment on ionization state), low stoichiometric binding leading to product concentration below 
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method detection limits, adduction product structure with a molecular ion outside the menu utilized within 
this study (see Table 9), or the combined effects of more than one of these factors. 
 Likewise, studies by Deng et al. utilized MS and nuclear magnetic resonance (NMR) analysis to 
designate the structure of an adduction product putatively arising from the interaction of a self-acid-
catalyzed electrophilic ester with nucleophilic lysine residues.98  Since autoradiography and Western blot 
immunodetection were the primary methods utilized, it is possible that the present approach was unable to 
detect the expected product due to analyte abundance below the method detection limit.  While attempts 
were made to boost the yield of lysine adduction products by increasing the incubation pH to increase the 
percent of NAK in the reactive neutral state, modification of pH above the pKa of cocaine’s tropane 
nitrogen (pKa of 8.6) would significantly decrease the proportion of cocaine molecules with the protonated 
ammonium tropane.  Since the ammonium tropane is necessary for self-acid-catalyzed ester activation, 
increasing media pH would still be detrimental to the adduction process even if it resulted in the increased 
concentration of neutral reactive lysine residues.  However, lysine residues in vivo with depressed pKa 
values are not uncommon, which suggests that this mechanism could be more relevant to in vivo cocaine 
metabolism than is suggested by the in vitro results of the present study. 
 The novel pathway for cocaine adduction to biological thiols described in this study has 
significant implications for cocaine-associated toxicity and the sequelae associated with cocaine 
biotransformation.  Numerous toxicity studies investigating cocaine biotransformation have catalogued the 
depletion of hepatocellular GSH, with the mechanism responsible for this event purported to involve 
oxidative stress.23,94  While generation of reactive oxygen species during the CYP-catalyzed metabolism of 
cocaine is likely and expected as a result of “leaky” oxidative pathways (see Figure 2), data from the 
current study suggests that specific targeting of GSH thiols by reactive cocaine intermediates is also a 
possible compounding mechanism behind in vivo GSH depletion.  Additionally, covalent binding to 
reactive thiols present within the structure of endogenous proteins may be detrimental to protein activity or 
cause complete protein deactivation, especially when the adducted thiol is imperative to protein function.  
Indeed, macromolecular binding and GSH depletion may be causal factors in the observed hepatocellular 
necrosis in chronic cocaine abusers.23,146 
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4.4.2. Morphine Adduction Products 
4.4.2.1. Morphine‒N-Acetylcysteine Adduction 
UHPLC chromatographic separation and MS analysis demonstrated the presence of seven 
distinguishable analytes resultant from NAC interaction with morphine (designated MOR-NAC 1-7, Figure 
50).  The products MOR-NAC 1-4 had parent [M+H]+ ions with m/z 447 and were determined to have the 
chemical formulaC22H26N2O6S by Agilent MassHunter software based on exact mass data from QTOF-MS 
(see Table 17).  MS/MS fragmentation of MOR-NAC 1-4 parent ions (m/z 447) yielded two distinct subsets 
of fragments, with Figure 51a depicting a representative spectrum for MOR-NAC 1 and 3 and Figure 51b 
showing a representative spectrum for MOR-NAC 2 and 4.  Three minor products were determined to have 
nominal masses of 448 Da and molecular formulas approximated as C22H28N2O6S in the same manner as 
above (see Table 17).  The three minor products (MOR-NAC 5-7) were found to have extremely similar 
MS/MS fragmentation patterns.  A representative MS/MS spectrum obtained from parent ion (m/z 449) 
fragmentation of MOR-NAC 5-7 is presented in Figure 51c.  It is noteworthy that, qualitatively, the 
representative spectrum for MOR-NAC 5-7 closely resembles that of MOR-NAC 2 and 4 with a mass shift 
of m/z +2 for most fragments.  Spectral similarity suggests that compounds MOR-NAC 5-7 are structurally 
related to MOR-NAC 2 and 4 by the addition of 2H (accounting for the shift of parent ion [M+H]+ from 
m/z 447 to 449 and mass shifts of m/z +2 for many prominent daughter ions of m/z 449 compared to m/z 
447). 
 Control incubations without NADPH, morphine, and/or NAC provided further insight into 
possible mechanisms of product formation.  All adduction products (MOR-NAC 1-7) were found to be 
dependent upon the presence of both morphine and NAC.  However, only MOR-NAC 1 and 3 were found 
to be NADPH-dependent.  MOR-NAC 2, 4, 5, 6, and 7 were generated in the absence of NADPH, 
suggesting reaction mechanisms not involving the CYP and FMO enzyme superfamilies.   
Previous studies involving morphine’s covalent adduction to biological sulfhydryls using NMR 
spectrometry have described two distinct products, one involving thiol attachment at C-10 of morphine88,90 
and the other at C-880,82,83 (represented by Figure 52a and b, respectively; see Section 2.6).  Correia et al. 
determined that adduction at the C-10 position was CYP-mediated in rats, requiring NADPH as a cofactor 
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to elicit metabolic activation of morphine, although no specific mechanistic explanation was proposed.88  
Indeed, NADPH-mediated adduction of morphine with the model thiol, NAC, was catalogued in the 
present study for MOR-NAC 1 and 3, suggesting that these derivatives are the result of structural isomer 
formation by thiol addition at the C-10 position on morphine, resulting in the stereo isomers 10α- and 10β-
S-(N-acetylcysteinyl)morphine.  More complete NMR- or chiral-based analysis methods are required to 
definitively assign MOR-NAC 1 and 3 as 10α- and 10β-S-(N-acetylcysteinyl)morphine; however, the 
mechanisms of formation and MS/MS fragmentation patterns are consistent with these putative 
designations.  It is noteworthy that isomeric structures were not identified in the studies performed by 
Correia et al. (i.e., only the 10α- species was confirmed via NMR).  The putative appearance of the 10β- 
isomeric structure in the current study may be the result of differences in species-specific regioselective 
thiol addition or variance in quantitative or qualitative adduct formation between in vitro and in vivo 
environments, or may be a product of technological advances in chromatographic separations allowing for 
higher resolution than was available at the time the earlier experiments were performed.   
Extensive characterization of thiol adduction products at C-8 of morphine was performed to 
determine adduct structure and mechanism of formation.  Reduction of the C-6 hydroxyl moiety yields 
morphinone, a Phase I metabolic product of morphine containing a Type-2 alkene in the form of an α,β-
unsaturated carbonyl.  This reduction event is catalyzed by the enzyme morphine-6-dehydrogenase and is 
not mediated by the CYP or FMO enzyme superfamilies (making the event atypical in the realm of Phase I 
xenobiotic biotransformation).82,83  In place of NADPH, morphine-6-dehydrogenase utilizes NAD(P)+ as an 
activating cofactor (with bias toward NAD+ activation over NADP+ in many species, including humans).82  
Research has also demonstrated the formation of morphinone from interaction with hydroxyl radicals.84  In 
the current study, formation of MOR-NAC 2 and 4 is in good agreement with the structure and mechanisms 
described in previous studies for products resulting from morphinone adduction to thiols at C-8, being 
readily produced even in the absence of NADPH.   
Published literature has postulated morphinone-derived adduct reduction to re-hydrogenate the C-
6 keto group via biological reducing agents (e.g., NADPH, GSH); however, no literature exists in which 
reduced products were isolated or characterized.  Formation of MOR-NAC 5-7 within in vitro incubations 
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is consistent with reduction of morphinone-derived thiol adducts (see Figure 52c for reduction product 
structure and fragmentation).  Concordance of MOR-NAC 5-7 with the hypothesized C-6 keto reduction 
products was confirmed by their production in the absence of NADPH and by qualitative MS/MS spectral 
similarity with MOR-NAC 2 and 4 fragmentations (see Figure 51b and 51c).  Such reduction could be 
elicited by NAD(P)H generated by morphine-6-dehydrogenase during conversion of morphine to 
morphinone, but more likely results from reducing activity of free thiols (i.e., NAC) within the samples.  
Theoretically, reduction could yield two stereo isomers from each morphinone-based adduct (yielding a 
total of four isomeric products).  Detection of three distinct products (instead of the predicted four) may be 
the result of insufficient chromatographic separation causing coelution, stereo-selectivity in hydrogenation 
products, or a specific biochemical process diminishing the production of a specific adduction product 
isomer. 
 
Figure 50: Chromatographic separation of morphine‒N-acetylcysteine adducts from in vitro 
incubation sample (labeled MOR-NAC 1-7; inset shows expansion of m/z 449 chromatograph) 
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Table 17: Comparison of theoretical and observed [M+H]+ ions for morphine‒N-acetylcysteine 
adducts 
Adduction 
Product 
Retention Time 
(min) 
Theoretical Mass 
(m/z) Observed Mass (m/z) 
Difference 
(ppm) 
MOR-NAC 1 2.66 447.1584 447.1589 1.12 
MOR-NAC 2 3.56 447.1584 447.1587 0.67 
MOR-NAC 3 5.70 447.1584 447.1590 1.34 
MOR-NAC 4 6.41 447.1584 447.1588 0.89 
1-4 Average - 447.1584 447.1589 ± 0.0001 1.12 
MOR-NAC 5 2.32 449.1741 449.1744 0.67 
MOR-NAC 6 2.48 449.1741 449.1743 0.45 
MOR-NAC 7 5.10 449.1741 449.1739 0.45 
5-7 Average - 449.1741 449.1742 ± 0.0003 0.22 
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Figure 51: MS/MS spectra of morphine‒N-acetylcysteine adducts (a) MOR-NAC 1 and 3, (b) MOR-
NAC 2 and 4, and (c) MOR-NAC 5-7 
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Figure 52: Fragmentation patterns of morphine‒N-acetylcysteine adducts (a) MOR-NAC 1 and 3, 
(b) MOR-NAC 2 and 4, and (c) MOR-NAC 5-7 
 
 Morphine-derived adduct production was found to be variably dependent on incubation time.  
Figure 53 displays data with MOR-NAC 1 and 4 acting as representative models for NADPH-mediated and 
non-NADPH-mediated adduction products, respectively.  Figure 54 shows data with MOR-NAC 5 as a 
representative model for all non-NADPH-mediated secondary reduction products.  Maximum levels of all 
morphine-based NAC adduction products were found to be present under conditions of secondary 
supplementation with NADPH and 6 h incubation time.  This effect was particularly apparent for the 
secondary reduction products MOR-NAC 5-7 (see Figure 54), where it is likely that supplemental NADPH 
acts as a reducing agent for oxidation products produced during the first 3 h of incubation.    
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Figure 53: MOR-NAC 1 and 4 formation as a factor of incubation time and NADPH 
supplementation 
 
Figure 54: MOR-NAC 5 formation as a factor of incubation time and NADPH supplementation 
 
4.4.2.2. Morphine‒N-Acetylcysteine Adduct Cytochrome P450 Enzyme Designation 
As a result of data demonstrating the NADPH-independent formation of MOR-NAC 2 and 4-7, 
investigation of CYP isoform influences on adduct formation was performed solely for MOR-NAC 1 and 
3.  Qualitative and quantitative profiles of individual isoform contribution to MOR-NAC 1 and 3 formation 
were similar, further supporting the common mechanism of formation purported in Section 4.4.2.1 (Figure 
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55).  Raw data demonstrated very minor contributions from the CYP2C subfamily (i.e., 2C8, 2C9, 2C19), 
with CYPs 2D6 and 3A4 being the major isoforms responsible for NADPH-mediated morphine adduction 
to thiols.  After correction for relative enzyme concentrations in human liver, it is evident that CYP3A4 is 
almost entirely responsible for the CYP-mediated formation of morphine‒NAC adduction products 
(although this does not necessarily preclude FMO contributions to this metabolic cascade). 
 
Figure 55: Cytochrome P450 isoform panel for morphine‒N-acetylcysteine adduct formation 
(a) presents raw data for morphine‒N-acetylcysteine adducts formation within the CYP 
isoform panel.  (b) presents the same data after transformation to account for relative CYP 
concentrations in human liver tissue. 
 
4.4.2.3. Putative Mechanisms for Morphine-derived Thiol Adduction 
In combination with existing structural and mechanistic data from literature, data from this study 
suggests two distinct mechanisms of protein adduct formation arising from Phase I morphine 
biotransformation (Figure 56).  The first mechanism is consistent with dehydrogenation of the C-6 
hydroxyl group by means of enzymatic oxidation by morphine-6-dehydrogenase or hydroxyl radicals to 
yield the known reactive metabolite, morphinone (Pathway (a), Figure 56).  Subsequent biomolecular 
adduction of morphinone involves nucleophilic attack of the electrophilic C-8 site by a thiol resulting in 1,4 
Michael addition.  Tautomerism of the resultant enol to the stable keto form leads to observation of a 3,4 
addition product (keto structure confirmed by previous NMR studies85).  Secondary reduction of the C-6 
keto group of adducted morphinone subsequently yields a series of enantiomeric compounds.   
The second mechanism of morphine metabolism and adduction is consistent with the enzymatic 
oxidation of the C-3 hydroxyl moiety via FMO- or CYP-catalyzed biotransformation (Pathway (b), Figure 
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56).  rhCYP investigation confirmed the almost exclusive influence of CYP3A4 in facilitating this 
pathway, but does not preclude the potential role of FMOs in the complete enzymology for this reaction.  
Redistribution of aromatic electrons within the conjugated ring structure of the oxidized product generates 
a quinone methide, a Type 2 alkene structure known to possess reactive electrophilic properties.147  
Nucleophilic attack by biological thiols on the electron-depleted C-10 site, followed by electron 
rearrangement along the conjugated quinone methide structure causes reduction of the C-3 oxygen (via 1,6 
Michael addition). 
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Figure 56: Proposed mechanisms for morphine metabolism to reactive metabolites and thiol 
adduction 
 
4.4.2.4. Morphine‒Glutathione Adduction 
Incubation of morphine with GSH resulted in the appearance of four adduction products 
(designated MOR-GSH 1-4, Figure 57; MS/MS fragmentation of native peptide included for comparison in 
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Appendix 9a).  Exact mass QTOF-MS analysis of each adduction product revealed m/z consistent with the 
chemical formula C27H34N4O9S (Table 18).  MS/MS analysis of each analyte revealed two sets of products 
with qualitatively similar spectra: MOR-GSH 1 and 2 yielded spectra represented by Figure 58a, while 
Figure 58b is a representative spectrum of MOR-GSH 3 and 4 fragmentations. 
Control incubations in which NADPH, morphine, and GSH were sequentially removed from 
assays revealed that all products were reliant on the presence of morphine and GSH while only MOR-GSH 
1 and 2 required the presence of NADPH (i.e., formation of MOR-GSH 3 and 4 is not NADPH-dependent).  
In consideration of the putative mechanisms determined by morphine incubations with NAC, it is 
postulated that MOR-GSH 1 and 2 are the result of CYP-mediated activation of C-10 to form 10α- and 
10β- isomers (Figure 59a).  Likewise, NADPH-independent formation of MOR-GSH 3 and 4 is consistent 
with morphine-6-dehydrogenase-mediated production of 8α- and 8β- adduction product isomer formation 
via the reactive metabolite, morphinone (Figure 59b).  In contrast to assays containing NAC, no secondary 
reduction products were detected in samples containing GSH.  Inability to detect such secondary reduction 
products may be the result of decreased production of primary adduction products in assays containing 
GSH (vs. those using NAC as trapping agent) thereby decreasing reduced product levels below method 
detection limits.  Another possible factor could be steric interference directly resulting from addition of the 
bulky tripeptide GSH, resulting in hindered access to the C-6 keto group for reducing agents. 
 
Figure 57: Chromatographic separation of morphine‒ glutathione adducts (labeled MOR-GSH 1-4) 
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Table 18: Comparison of theoretical and observed [M+H]+ ions for morphine‒glutathione adducts 
Adduction 
Product 
Retention Time 
(min) 
Theoretical Mass 
(m/z) Observed Mass (m/z) 
Difference 
(ppm) 
MOR-GSH 1 0.98 591.2119 591.2083 6.09 
MOR-GSH 2 1.36 591.2119 591.2092 4.57 
MOR-GSH 3 2.02 591.2119 591.2112 1.18 
MOR-GSH 4 2.16 591.2119 591.2063 9.47 
1-4 Average - 591.2119 591.2088 ± 0.0020 5.24 
 
 
Figure 58: MS/MS spectra of morphine‒ glutathione adducts (a) MOR-GSH 1 and 2 and (b) MOR-
GSH 3 and 4 
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Figure 59: Fragmentation patterns of adducts between glutathione and (a) MOR-GSH 1 and 2 and 
(b) MOR-GSH 3 and 4 
 
4.4.2.5. Morphine‒AcPAACAA Adduction 
Irreversible adduction of morphine to higher order biological thiols was confirmed via assessment 
of binding to the model hexapeptide AcPAACAA (MS/MS fragmentation of native peptide included for 
comparison in Appendix 9b).  As with previous studies in this project, the increase in macromolecular 
complexity resulted in diminished capacity of the chromatographic system to separate potential isomeric 
structures.  In the case of morphine incubations with the AcPAACAA trapping agent, only one 
distinguishable product was isolated, employing the separation conditions from Appendix 8 (designated 
MOR-PEP 1, Figure 60).  Exact mass analysis by QTOF-MS determined an empirical [M+H]+ ion of m/z 
828.3566, deviating from theoretical [M+H]+ m/z 828.3597 (C39H53N7O11S) by 3.74 ppm.  A representative 
MS/MS spectrum for MOR-PEP 1 is presented in Figure 61, displaying characteristic peptide 
fragmentation patterns in conjunction with ions consistent with the primary fragmentation of morphine.  
While MS/MS fragmentation patterns are not enough to distinguish between the proposed structures 
analogous to NAC and GSH adducts, results of collision induced dissociation of MOR-PEP 1 are consistent 
with either structure presented in Figure 62a and b (or possible coelution of both products). 
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Figure 60: Chromatographic separation of morphine‒AcPAACAA adduction products (labeled 
MOR-PEP 1) 
 
Figure 61: MS/MS spectrum of MOR-PEP 1 
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Figure 62: Structure and MS/MS fragmentation pattern of (a) morphine quinone methide-derived 
adduct and (b) morphinone-derived adduct 
 
4.4.2.6. Discussion of Morphine Thiol Adduction Results 
Results of the above studies from the in vitro trapping studies suggest a series of Phase I metabolic 
pathways that result in irreversible binding to biological thiol moieties.  Covalent adduction products 
described by data in the present study are consistent with the formation of two electrophilic reactive entities 
resulting from the Phase I biotransformation of morphine: morphinone and morphine quinone methide.  
Covalent protein binding via morphinone has been documented in the literature as formation of 8α-
morphinonyl thiol adducts.85  However, results from the current study have elaborated on the mechanism of 
covalent attachment and the nature of resulting adduction products.  Incubation of morphine with NAC 
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demonstrated the formation of five distinct products of morphine/NAC interaction that are not reliant on 
NADPH activated metabolism, consistent with morphinone production by the enzyme morphine-6-
dehydrogenase.  Two of these chromatographically distinguishable compounds have a molecular ion of m/z 
447, while three have a molecular ion of m/z 449.  The two m/z 447 compounds have similar MS/MS 
spectra, suggesting similar structures.  Their mechanism of formation is consistent with the bioactivation of 
morphine to morphinone followed by the 1,4 Michael addition of thiol nucleophile with subsequent 
rearrangement of the enol to the tautomeric keto form, resulting in the formation of both the 8α- and 8β- 
stereo products.  This accounts for the manifestation of two chromatographic peaks with identical MS/MS 
spectra.  While previous literature only reported the formation of the 8α- isomer, chromatographic 
assessment of the products in those studies was performed via UV detection, which would not have allowed 
distinction of coeluting peaks.  In contrast, improvement in chromatographic analysis and MS detection in 
the present study allowed for mass-to-charge filtering and consequential designation of coeluting analytes 
with differing molecular masses.   
Existing literature does suggest the possibility of secondary reduction products resulting from 
hydrogenation of the C-6 keto group of morphinone; however, no specific identification of such products 
has been reported to date.  The three detected adduction products with molecular ions of m/z 449 are 
consistent with secondary reduction of bound morphinone-derived adducts.  MS/MS fragmentation patterns 
of each m/z 449 product are qualitatively similar and closely resemble the fragmentation patterns of the 
morphinone-derived adduction products with minor shifts in fragment masses resultant from the 
hydrogenation of the C-6 keto group.  Theory predicts the existence of four isomeric structures resulting 
from the hydrogenation of the 8α- and 8β- morphinone stereo adduction products.  Data from the present 
study conclusively demonstrated three such isomers via chromatographic methodology.  The unaccounted 
for isomer in the present study may be the result of stereospecificity along the mechanistic pathway or may 
be caused by insufficient chromatographic resolving power or coelution with one of the major products of 
m/z 447 and consequential masking by carryover from the M+2 isotope peak. 
In conjunction with the aforementioned products that are the result of the reactive morphine 
metabolite morphinone, a second pathway was examined in this study (i.e., two distinct products with m/z 
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447).  Consistent with the NADPH-mediated dehydrogenation of the C-3 hydroxyl group and subsequent 
electron shift to generate a quinone methide functional group, products of this pathway have previously 
been suggested, but without a purported mechanism to account for their formation.  Results from the 
current study demonstrated the formation of two chromatographically separable products arising from NAC 
interaction with morphine having a molecular ion of m/z 447 that require the addition of monooxygenase 
activating cofactor NADPH.  MS/MS fragmentation patterns of the two products show extreme similarity, 
again suggesting structural similarity.  On the basis of NADPH-mediated formation, similarity in MS/MS 
spectra, and exact mass analysis, these two structurally similar products are proposed to be the 10α- and 
10β- stereoisomers of 10-S-(N-acetylcysteinyl)morphine.  The 10α- isomer has been conclusively 
characterized by NMR structural analysis in literature.90  As with morphinone-derived adduction products, 
analysis of products arising from this mechanistic pathway were chromatographically separated and 
detected via UV absorbance, which may have masked additional stereoproducts beneath signals from other 
more abundant metabolic products of morphine. 
While previous research has proposed an electrophilic reactive metabolite that is responsible for 
the formation of NADPH-mediated irreversible morphine adduction products, no specific pathway of 
activation has been proposed to date to account for such products.  The purported reactivity of the 
hypothesized progenitor(s) of NADPH-mediated adduction products makes them difficult to identify by 
means of free-fraction analysis; therefore, conclusive designation of this pathway may be difficult by 
analytical methods.  However, this study has clarified myriad aspects surrounding the formation of 
irreversible thiol adducts arising from monooxygenase activity on morphine.  Indeed, rhCYP assay 
incubations conclusively determined the almost exclusive influence of CYP3A4 in the production of the 
NADPH-mediated adduction products cataloged in this study that arise from morphine biotransformation.  
While these data substantiate the role of CYP monooxygenase within this mechanism, they do not 
necessarily preclude the influence of FMO activity. 
The two pathways of irreversible morphine adduction to biological thiols identified in this study 
expand the existing pool of knowledge and more completely describe the potential metabolic fate of 
morphine after human exposure.  The data provide evidence for novel routes of toxicophore activation in 
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morphine and suggest that the breadth of products arising from the covalent interaction of morphine 
biotransformation products with biological thiols may be more diverse than postulated in existing literature.  
In fact, they may contribute to the discrepancy in mass balance for morphine metabolism and may be a 
major component of the mechanism of depletion of cellular GSH following morphine exposure.83  
Macromolecular covalent binding may also contribute to the sequelae that result in cellular damage and 
tissue necrosis, especially that localized to hepatic tissue, which is the primary site of reactive morphine 
metabolite formation.148 
 
4.4.3. Use of Adducts as Cocaine and Morphine Biomarkers 
 In conjunction with providing insights into drug-induced toxicities, detection methods for GSH 
and NAC adduction products can serve as viable alternatives to direct testing of biological matrices for 
parent drug and metabolites.  GSH conjugates are commonly excreted in bile, but there is precedence for 
the extraction and detection of GSH conjugates from the blood.149,150  Perhaps more relevant to non-
invasive analysis for drug of abuse exposure are NAC conjugates (also called mercapturates).  Being the 
post-conjugation processed product of Phase III metabolic activity on GSH conjugates, mercapturates are 
preferentially excreted in the urine, an ideal matrix for minimally invasive confirmation of xenobiotic 
exposure.15,16 
 The data collected and methods developed within the present body of research form the foundation 
of an analytical scheme to detect both GSH conjugates and mercapurates arising from cocaine and 
morphine exposure.  Complete MS/MS characterization of each product allows for sensitive MRM 
detection to be employed for the evaluation of such adducts.  Furthermore, chromatographic methods 
established in this work may be translated to other laboratories with commercial LC-MS/MS 
instrumentation, making the validation of GSH- and NAC-bound drug metabolites feasible for forensic and 
medical investigations. 
While less conventional among drug of abuse detection methods, the examination of protein 
adduction products may be an attractive future tract for forensic toxicological analysis.  Analytical methods 
to detect and identify bound adducts commonly rely on enzymatic digestion and chromatographic 
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designation of a peptide fragment from the original protein containing an adducted moiety.151  While 
protein extraction, digestion, and analytical designation of adducted thiol-containing peptides can be time-
consuming, the potential to extend the window of detection for cocaine and morphine from days (the 
current timeline for parent drug and metabolites in the free fraction) to weeks/months (depending on the in 
vivo life-time of the protein target) is an attractive proposal for toxicologists.  Such adducts may therefore 
be useful as longer-term and/or retrospective exposure biomarkers for these important drugs of abuse.  
Similarly, identification of individual protein targets and specific sites of covalent adduction by cocaine or 
morphine via the mechanisms described above would be useful in further illuminating the comprehensive 
metabolism of cocaine and morphine as well as the milieu of toxic responses attributed to each drug in the 
human body. 
Data from the current study suggests that detection methods utilizing macromolecular biomarkers 
are technically feasible for both cocaine and morphine adducts.  The studies presented herein describe 
adduction mechanisms, nucleophilic targets on proteins, and MS/MS-characterized identities of adducted 
moieties for cocaine- and morphine-derived adducts.  In conjunction with existing proteomic technologies 
and peptide mapping techniques, the above results are translatable into an analytical scheme useful in 
characterizing the cocaine and morphine “adductome”152 in the human body. 
 
4.5. In Silico Estimations of Chemical Reactivity and Adduction Potential 
4.5.1. Nucleophilicity of Reactive Amino Acids 
Calculation of molecular HOMO and LUMO energies by means of DFT calculations revealed 
significant differences in the nucleophilic reaction potential of model nucleophiles that are directly 
mediated by pH/pKa-dependent ionization states, a property well-documented with in vivo biological 
nucleophile research.  Table 19 contains HOMO and LUMO energies determined using DFT calculations 
and molecular properties calculated from HOMO and LUMO energies including chemical potential (μ), 
hardness (η), softness (σ), electrophilicity index (ω), and nucleophilicity index (φ).  The calculated 
properties are concordant with in vitro data generated in the present study, demonstrating increased 
nucleophilicity index when Cys is in the ionized thiolate form and when His and Lys are in their 
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deprotonated (un-charged) states.  Cys-containing nucleophiles demonstrated increased chemical potential 
and decreased chemical hardness in their thiolate forms compared to the uncharged state.  Basic His and 
Lys nucleophiles also showed increased chemical potential when deprotonated, but both basic residues 
exhibited increases in chemical hardness when un-charged.  In general, nucleophiles containing thiolate 
Cys moieties were the softest among those examined, with glutathione in the thiolate form (GSH (-1)) 
being the softest nucleophile, exemplifying the axiomatic designation of Cys thiols as the softest biological 
nucleophiles.  Concurrently, the highest calculated nucleophilicity index was GSH (-1), supporting GSH’s 
role as a nucleophilic reservoir for reactive electrophilic species within intra- and inter-cellular media. 
Table 19: Quantum mechanical parameters for biological nucleophiles 
Nucleophile ELUMO (eV) EHOMO (eV) µ (eV) η (eV) σ (eV-1) ω (eV) φ (eV-1) 
Cys (0)a -0.03 -6.86 -3.44 3.42 0.293 1.74 0.576 
Cys (-1) 4.05 0.21 2.13 1.92 0.521 1.18 0.845 
His (+1) -4.88 -10.31 -7.60 2.71 0.368 10.64 0.094 
His (0) -0.28 -6.08 -3.18 2.90 0.345 1.75 0.572 
Lys (+1) -4.58 -8.98 -6.78 2.20 0.455 10.45 0.096 
Lys (0) 0.10 -6.26 -3.08 3.18 0.314 1.49 0.670 
NAC (0) -0.10 -6.70 -3.40 3.30 0.303 1.75 0.570 
NAC (-1) 3.79 -0.13 1.83 1.96 0.510 0.85 1.170 
NAH (+1) -5.07 -9.96 -7.52 2.44 0.409 11.56 0.087 
NAH (0) -0.33 -6.24 -3.28 2.96 0.338 1.82 0.549 
NAK (+1) -4.54 -8.88 -6.71 2.17 0.460 10.37 0.096 
NAK (0) 0.20 -6.34 -3.07 3.27 0.306 1.44 0.694 
GSH (0) -0.80 -6.60 -3.70 2.90 0.345 2.36 0.424 
GSH (-1) 1.54 -0.06 0.74 0.80 1.250 0.34 2.925 
a Ionization state of molecule is presented in parentheses 
 
4.5.2. Electrophilicity of Reactive Drug Intermediates and Metabolites 
 To thoroughly examine the mechanisms of formation for each adduction product detected in this 
research, reactivity parameters of postulated electrophilic species were determined.  Calculated descriptors 
for mechanisms of cocaine adduct formation included those for the parent compound (cocaine), the 
hypothesized reactive intermediate (cocaine-3,4-epoxide), and the resultant stable metabolites in humans 
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(3- and 4-hydroxycocaine) (see Table 20).   While variations in chemical potential and chemical hardness 
were minimal between parent, reactive intermediate, and stable metabolic products, the higher order 
parameter describing electrophilicity showed an increase in molecular electrophilicity for the reactive 
epoxide over the stable parent and metabolites.  Stereoisomeric forms of cocaine-3,4-epoxide were found to 
have HOMO and LUMO energies that were quantitatively identical, demonstrating that stereochemistry of 
the epoxide does not modify electrophilicity.  Comparisons of HOMO and LUMO energies between 2-, 3-, 
and 4-hydroxycocaine metabolites revealed modest differences in thermodynamic and kinetic stability 
between isomeric products.  Large HOMO-LUMO energy gaps (exemplified by larger η values) are 
characteristic of hard electrophiles, which exhibit thermodynamic stability.  Similarly, high-lying LUMO 
shells coupled with low-lying HOMO shells are characteristic of chemically inert species resistant to both 
self-reaction and kinetic reactions with Lewis acids and bases.  Comparison of HOMO-LUMO gaps and 
relative energies between hydroxycocaine isomers suggests increased molecular stability for the 2- and 4-
hydroxycocaine isomeric products in comparison to 3-hydroxycocaine.  Relative thermodynamic stability 
may be a contributing factor to the observed preferential formation of 4-hydroxycocaine over 3-
hydroxycocaine as reported with authentic samples.153-155 
 Similar in silico studies were repeated for morphine-derived adducts using the parent compound 
(morphine), known reactive metabolite, morphinone, and postulated reactive metabolite, morphine quinone 
methide (see Table 20).  The reactive metabolites morphinone and morphine quinone methide were found 
to have increased electrophilic chemical potential and decreased hardness in comparison to morphine.  
Calculation of the electrophilicity index demonstrated substantial increases in electrophilic potential as a 
function of electronic factors, with the postulated metabolite morphine quinone methide possessing the 
highest electrophilicity index among the electrophiles examined. 
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Table 20: Quantum mechanical parameters for drug electrophiles 
Electrophile ELUMO (eV) EHOMO (eV) µ (eV) η (eV) σ (eV-1) ω (eV) 
COC (+1)a,b -3.86 -9.29 -6.57 2.72 0.368 7.95 
2-OH-COC (+1)c -3.71 -8.54 -6.13 2.41 0.414 7.78 
3-OH-COC (+1) -3.82 -8.43 -6.12 2.31 0.434 8.13 
4-OH-COC (+1) -3.72 -8.59 -6.16 2.44 0.410 7.78 
COC-3,4-epoxide (+1)d -4.22 -8.85 -6.54 2.23 0.431 9.21 
MOR (+1) -3.27 -8.36 -5.82 2.55 0.393 6.65 
MN (+1) -4.93 -8.71 -6.82 1.89 0.530 12.32 
MQM (+1) -6.10 -9.47 -7.78 1.69 0.593 17.98 
a Electrophile Abbreviations: COC, cocaine; OH-COC, hydroxycocaine; MOR, morphine; MN, 
morphinone; MQM, morphine quinone methide 
b Ionization state of molecule is presented in parentheses 
c While 2-OH-COC is not generated in human hepatocytes, data is included for comparisons of relative 
stability between OH-COC isomers 
d Postulated reactive intermediates and metabolites are highlighted for distinction from precursors and 
stable metabolites 
 
4.5.3. In Silico Estimation of Nucelophile-Electrophile Interactions 
 While in silico estimations of individual nucleophile and electrophile reactivity are vital to the 
study of adduction potential for reactive molecules, they are limited by their unilateral view of each in 
isolation without consideration of nucleophile-electrophile interaction, which is a major component in 
HSAB theory.  Simulations of system reactivity were performed by inclusion of nucleophile and reactive 
electrophile descriptors of chemical potential and hardness according to Equation 9 in Section 2.5.  The 
data presented in Table 21 are higher-order descriptors of electrophile‒ nucleophile reactivity as a function 
of electronic interaction between frontier molecular orbitals.  The reactive metabolites cocaine-3,4-epoxide, 
morphinone, and morphine quinone methide are predicted to show increased reactivity with the thiolate 
forms of Cys and NAC as well as with unprotonated (un-charged) His, Lys, NAH, and NAK.  In the case of 
GSH, morphinone and morphine quinone methide were determined to be more reactive with the thiolate 
form, while cocaine-3,4-epoxide was calculated to have higher reactivity with the uncharged thiol.  
Quantitative comparisons suggests that the most reactive nucleophile‒ electrophile pair is Cys (-1)/ 
morphinone.  However, morphinone was not unanimously the most reactive species among morphine 
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metabolites.  Morphine quinone methide displayed a greater predicted reaction potential for GSH (-1), the 
neutral basic amino acids His (0) and Lys (0), and the analogous neutral basic N-acetylated amino acids 
NAH (0) and NAK (0).  The reactive cocaine metabolite cocaine-3,4-epoxide was predicted to have an 
increased reaction potential with the harder basic nucleophiles than either of the reactive morphine 
metabolites. 
Table 21: Calculated reaction indices (ω-) for electrophile reactions with possible nucleophilic targets 
Nucleophile 
ω- (eV) 
COC-3,4-epoxide (+1)a,b MN (+1) MQM (+1) 
Cys (0)a 13.55 8.35 10.74 
Cys (-1) 456.66 72,214.25 1,703.02 
His (+1) 9.80 1.20 0.04 
His (0) 48.26 18.76 20.82 
Lys (+1) 4.64 0.02 4.20 
Lys (0) 25.40 13.27 15.69 
NAC (0) 16.92 9.72 12.20 
NAC (-1) 542.45 13,314.57 1,181.47 
NAH (+1) 74.36 1.92 0.15 
NAH (0) 38.47 16.23 18.55 
NAK (+1) 1.54 0.16 5.29 
NAK (0) 21.61 12.02 14.44 
GSH (0) 34.61 13.83 16.43 
GSH (-1) 9.19 19.31 37.08 
a Ionization state of molecule is presented in parentheses 
b Abbreviations: COC, cocaine; MN, morphinone; MQM, morphine quinone methide 
 
4.5.4. Discussion of Calculated Reactivity Data 
The use of in silico techniques to model complex chemical systems has found great utility 
recently, as technological advances have minimized the cost of computing systems necessary to perform 
iterative processes associated with such methods.  In this study, in silico techniques were utilized to model 
the electronic reactivities of relevant nucleophiles and electrophiles associated with protein adducts formed 
with cocaine and morphine metabolic products.  Data collected are in good agreement with existing 
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knowledge of nucleophile reactivity, especially as a property mediated by pH/pKa-derived ionization states, 
demonstrating the applicability of these calculation-based estimators.  In silico analysis of purported 
reactive electrophiles (i.e., cocaine-3,4-epoxide, morphinone, and morphine quinone methide) revealed 
increases in molecular electrophilicity compared to parent molecules and stable metabolic products.  When 
the electronic reactivity was exclusively based on HOMO and LUMO energies, the reactive products of 
morphine metabolism (i.e., morphinone and morphine quinone methide) were found to be more reactive 
than cocaine-3,4-epoxide.  However, these calculations do not fully account for the steric strain present in 
an aryl epoxide like cocaine-3,4-epoxide.  Consequently, overall reactivity of a system involving a cocaine-
derived reactive epoxide may be increased as compared to that predicted from the above data. 
One motivation behind performing in silico reactivity estimations in the present study was to 
assess the feasibility of morphine quinone methide as a possible reactive electrophile and its potential role 
as the metabolite responsible for NADPH-mediated thiol adducts described in this study.  The calculated 
electrophilicity of 17.98 eV for morphine quinone methide is of similar magnitude to that for the 
electrophile morphinone (ω = 12.32 eV), supporting not only the putative assignment of morphine quinone 
methide as a reactive biotransformation product of morphine, but also accounting for its formidable 
reactivity and consequential inability to be detected in the free fraction by methods employed in this study.  
Additionally, quantum mechanical calculations suggest that morphine quinone methide is a relatively soft 
electrophile, which would support the selectivity for reaction with Cys thiols (soft nucleophiles) as opposed 
to His or Lys residues (moderately hard nucleophiles) observed in in vitro incubations performed for adduct 
screening purposes.   
The “reactivity index (ω-)” modeling interactions between individual electrophile‒ nucleophile 
pairs were in good agreement with general trends predicted by HSAB theory.  The soft electrophiles 
morphinone and morphine quinone methide were found to have high reactivity with cysteine-based 
thiolates, especially Cys (-1) and NAC (-1).  These data are concordant with adduct formation observed by 
LC-MS/MS as reported above, where adduction products were detected in systems with cysteine-
containing nucleophilic trapping agents (i.e., NAC, GSH, AcPAACAA) but were not detected in samples 
containing other nucleophiles (i.e., NAH, NAK).  Morphine quinone methide’s designation as a soft 
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electrophile with high preferential reactivity for biological thiols is consistent with descriptions of the 
unknown reactive morphine metabolite in earlier literature and explains the structure of the resultant 
adduction products. 
Even though epoxides are classified as soft electrophiles and cocaine-3,4-epoxide is a softer 
electrophile than its progenitor, cocaine, it is evident from in silico calculations that cocaine-3,4-epoxide is 
a harder electrophile than either morphine biotransformation product.  Reactivity indices for cocaine-3,4-
epoxide demonstrated preferential interaction with soft cysteine thiolates Cys (-1) and NAC (-1), while 
displaying calculated reactivity data uncharacteristic of a soft electrophile when paired with harder 
nucleophiles (i.e., His, Lys, NAH, NAK).  While conventional analysis of nucleophile reactivity generally 
designates neutral basic amino acids as the more reactive species, reaction indices calculated for cocaine-
3,4-epoxide showed the protonated basic amino acids (i.e., His (+1), Lys (+1), NAH (+1), NAK (+1)) to be 
more likely to be adducted.  Similarly, in silico calculations determined the thiol form of GSH to be more 
reactive with cocaine epoxide than the thiolate.  Data from in vitro incubations of cocaine with nucleophilic 
trapping agents are concordant with the prediction that cysteine thiols have preferential reactivity with the 
cocaine epoxide intermediate, in that adduction products involving oxidation of the aryl moiety were only 
detected in thiol-containing systems (i.e., NAC, GSH, AcPAACAA).  However, predicted reactivity indices 
for the cocaine epoxide and GSH deviate from the accepted designation of deprotonated thiolates as 
preferential nucleophilic targets over protonated thiols.  Even though the predicted electronic reactivity for 
the epoxide/GSH system deviates from generally accepted HSAB principles, compounding factors aside 
from those relying on electronic descriptors of molecular reactivity (e.g., steric factors, influence of GST 
enzymes) offer a potential explanation for adduct formation between GSH and reactive cocaine epoxide 
intermediates in assay samples. 
While the electronic potentials of each nucleophile are vital parameters in their respective 
reactivities, the distribution of charge states as a function of pH of the microenvironment directly controls 
the availability of electronically “active” forms of each nucleophile.  Table 22 presents generally accepted 
pKa values for each nucleophile along with the percent existing in each of the ionization states at pH 7.4, 
based on Henderson-Hasselbalch calculations.  With the exception of His and NAH, the more 
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electronically reactive form of the nucleophile is not prevalent at physiological pH, thus limiting the 
reservoir of reactive sites within biological media.  However, occurrences of catalytic diads and other pKa-
modifying anomalies can shift ionization state distributions by depressing functional pKa values of specific 
nucleophiles, consequently increasing the availability of favorable reaction sites.56,57 
Table 22: Nucleophile ionization state distribution at physiological pH 
Nucleophile pKa % at pH 7.4 
Cys (0)a 8.15 85 
Cys (-1) 8.15 15 
His (+1) 6.04 4 
His (0) 6.04 96 
Lys (+1) 10.79 99.96 
Lys (0) 10.79 0.04 
NAC (0) 9.52 99.25 
NAC (-1) 9.52 0.75 
NAH (+1) 7.00 28 
NAH (0) 7.00 72 
NAK (+1) 15.9 100 
NAK (0) 15.9 ~0 
GSH (0) 8.56 93.5 
GSH (-1) 8.56 6.5 
a Ionization state of molecule is presented in parentheses 
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5. SUMMARY AND PROSPECT 
This study was successful in utilizing LC-MS/MS technologies in conjunction with in vitro 
metabolic assays to deliver a more complete understanding of the metabolic fate of cocaine, 
methamphetamine, and morphine in humans.  Investigations of in vitro assay conditions demonstrated 
marked shifts in metabolic profiles obtained for these drugs that were directly mediated by additive 
supplementation and incubation time.  In all cases, the in vitro assays systems tested were capable of 
metabolizing each drug of abuse to the anticipated major metabolic products based on literature reports of 
the enzymatic components present.  Minor and trace biotransformation products were minimally detected 
by the methods utilized, most likely due to their optimization for rapid production of major metabolites.  
However, comparisons among the metabolic model systems examined did offer novel insight into 
regioselective hydroxylation events for cocaine, in addition to new data on the enzymatic contributions to 
N-demethylation of methamphetamine and glucuronidation of morphine.  Results from these experiments 
not only lead to improvements in the efficacy of in vitro metabolic model systems for the controlled 
production of metabolic profiles for drugs of abuse, but also demonstrate their usefulness in examining 
specific routes of biotransformation and designation of the impact of enzyme class on individual metabolic 
transformations. 
Utilizing rhCYP-based in vitro assay systems, biotransformation processes yielding the primary 
Phase I metabolic products for cocaine, methamphetamine, and morphine were phenotyped for each drug.  
Results of this study demonstrated CYP isoform specificity for substrate and metabolic process, 
designating the contributions of individual CYP isozymes for cocaine and methamphetamine not 
previously catalogued in existing literature.  Particular attention was given to the aryl hydroxylation 
products of cocaine (2-, 3-, and 4-hydroxycocaine) and methamphetamine (2-, 3-, and 4-
hydroxymethamphetamine), where it was found that formation of the 4-hydroxy isomers of both drugs is 
mediated by regioselective CYP activity.  Conversely, the formation of 3-hydroxycocaine and 2- and 3-
hydroxymethamphetamine could not be attributed to one of the CYP isoforms studied, suggesting 
contributions from either the FMO superfamily of enzymes or one of the CYP isoforms not examined in 
this study.  In vitro phenotyping incubations did not demonstrate the formation of 2-hydroxycocaine or 
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ephedrine, supporting the conclusion that CYP-mediated oxidation does not result in the production of 
either metabolite in humans after exposure to cocaine or methamphetamine, respectively.   
The main portion of this research examined the potential for cocaine, methamphetamine, and 
morphine to form irreversible adduction products with endogenous proteins, by means of biomolecular 
trapping agents added to the in vitro metabolic systems to model reactive protein nucleophilic sites.  The 
analysis methods used were unable to demonstrated covalent adduction products from methamphetamine 
with and of the model nucleophiles tested, or from cocaine or morphine with model nucleophiles 
containing lysine or histidine.  However, clear evidence for covalent adduction products with cocaine and 
morphine and free cysteine thiols was obtained.  In addition, it was demonstrated that cocaine adduct 
formation is mediated by CYPs 2C19, 1A2, and 2D6, via a novel mechanism involving reactive aryl 
epoxide formation and subsequent nucleophilic attack by reactive sulfhydryl groups, resulting in a stable 
monohydroxylated cocaine adduction moiety.   
Data from morphine investigations demonstrated two distinct pathways that result in covalent 
adduction products with cysteine thiols.  The first pathways involves the bioactivation of morphine to the 
known reactive metabolite morphinone, forming 8-S-(cysteinyl)morphinone adducts by means of 1,4-
Michael-type addition.  This data corroborated existing knowledge of non-NADPH-mediated formation of 
morphinone by morphine-6-dehydrogenase with no significant influence from CYP-catalyzed oxidative 
activity.  In addition, a second metabolic pathway was determined, involving production of a novel 
morphine metabolite, morphine quinone methide, and subsequent 1,6-Michael addition resulting in 10-S-
(cysteinyl)morphine adduction products.  Reaction phenotyping for the formation of morphine quinone 
methide adduction products confirmed a NADPH-mediated oxidative process almost exclusively catalyzed 
by CYP3A4.  Data on the formation of reactive electrophilic morphine metabolites corroborate existing 
knowledge of morphine bioactivation and binding and provide novel insight into mechanisms responsible 
for the adduction process and structural characteristics associated with thiol-bound products. 
Further probing of the mechanisms of covalent adduction by cocaine and morphine with biological 
thiols was performed via computational analysis of postulated reactive intermediates/metabolites in 
conjunction with model nucleophiles.  Calculated reactive indices for electrophile‒ nucleophile interactions 
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were generally in good agreement with the in vitro data collected in the study, designating biological thiols 
as the preferential targets for adduct formation resulting from cocaine epoxide intermediates, morphinone, 
and morphine quinone methide.  While focusing primarily on electronic factors involved in the adduction 
process, the results obtained further support the feasibility of putative mechanisms for irreversible protein 
binding by cocaine and morphine, including the participation of the novel morphine metabolite, morphine 
quinone methide.   
The protein adduction processes described by this research represent novel routes for cocaine and 
morphine biotransformation with significant implications for the toxicology associated with each of these 
important and heavily abused drugs.  In addition to providing medical professionals with a more complete 
understanding of possible mechanisms behind drug-induced toxicity, results of this research open the door 
for analytical and forensic scientists to develop methodologies for detecting cocaine- and morphine-derived 
conjugates that unequivocally confirm exposure to either drug of abuse.  Likewise, detection of 
macromolecular protein targets for the covalent binding of cocaine and morphine would give insight into 
downstream toxicodynamics associated with each drug, but also could be utilized by forensic scientists to 
extend the timeline of detection for cocaine and morphine from days to months without having to rely on 
alternative (and potentially problematic) specimens such as hair.  In summary, data collected in this project 
describe novel metabolic events for several important drugs of abuse, culminating in detection methods and 
mechanistic descriptors useful to both medical and forensic investigators when examining the toxicology 
associated with cocaine, methamphetamine, and morphine exposure in humans. 
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APPENDICES 
Appendix 1: Biotransformation of cocaine 
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Cocaine Biotransformation Pathway Enzymes/Mechanisms 
# Process Enzyme/Mechanism Source # 
1 N-Oxidation FMO 29 
2 Aromatic oxidation Enzymatic oxidation 129 
3 Ester hydrolysis hCE-2, serum cholinesterase, minor non-enzymatic hydrolysis 24, 29, 122 
4 N-Dealkylation CYP (CYP3A4) 29, 135 
5 Ester hydrolysis Non-enzymatic hydrolysis, hCE-1 122, 24 
6 Transesterification hCE-1 in presence of ethanol, FAES in presence of ethanol 29, 24, 20 
7 Pyrolysis Pyrolytic decomposition 20 
8 N-Dealkylation Enzymatic oxidation 129 
9 Ester hydrolysis hCE-2 129 
10 Ester hydrolysis Postulated - 
11 Aromatic oxidation Enzymatic oxidation 129 
12 Ester hydrolysis hCE-1 129 
13 N-Oxidation FMO, CYP 23, 156 
14 N-Oxidation CYP 130, 23, 156 
15 Aromatic oxidation Postulated enzymatic oxidation 129 
16 N-Oxidation Postulated - 
17 Ester hydrolysis Not available in literature 20 
18 Aromatic oxidation Postulated - 
19 N-Dealkylation CYP 129 
20 Ester hydrolysis hCE-2, serum cholinesterase 156 
21 N-Dealkylation Postulated - 
22 Aromatic oxidation Enzymatic oxidation 129 
23 Ester hydrolysis Non-enzymatic hydrolysis, hCE-1 20, 24, 121 
24 N-Dealkylation Enzymatic oxidation 129 
25 Ester hydrolysis hCE-1 129 
26 Ester hydrolysis hCE-2 129 
27 Ester hydrolysis Postulated - 
28 Ester hydrolysis hCE-2 129, 121 
29 Aromatic oxidation Postulated - 
30 N-Oxidation Postulated - 
31 Ester hydrolysis Not available in literature 20 
32 N-Dealkylation Postulated - 
33 Aromatic oxidation Postulated - 
34 Aromatic oxidation Enzymatic oxidation 129 
35 Ester hydrolysis Not available in literature 20 
36 Pyrolysis Pyrolytic decomposition 20 
37 Transesterification Not available in literature 128 
38 Ester hydrolysis Not available in literature 128 
39 N-Oxidation Not available in literature 128 
40 N-Dealkylation Not available in literature 128 
41 N-Dealkylation Postulated - 
42 N-Dealkylation Not available in literature 128 
II Phase II conjugation Indirect evidence of UGT and SULT 104 
* Protein adduction 1,4-Michael addition on α,β-unsaturated carbonyl 99 
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Appendix 2: Biotransformation of methamphetamine 
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Methamphetamine Biotransformation Pathway Enzymes/Mechanisms 
# Process Enzyme/Mechanism Source # 
1 N-Dealkylation CYP (CYP2D6), FMO 131 
2 Aromatic oxidation CYP (CYP2D6) 131 
3 Aliphatic oxidation Postulated - 
4 Aliphatic oxidation Not available in literature 26, 138, 137 
5 Aromatic oxidation CYP (CYP2D6) 131 
6 Oxidative deamination Not available in literature 26, 138, 137 
7 N-Oxidation Postulated - 
8 N-Dealkylation Not available in literature 138, 137 
9 Aliphatic oxidation Postulated - 
10 Aromatic oxidation Postulated - 
11 N-Dealkylation Postulated - 
12 Aromatic oxidation Not available in literature 26, 138, 137 
13 Aliphatic oxidation Not available in literature 26, 138, 137 
14 Side chain oxidation Not available in literature 26, 138, 137 
II Phase II conjugation UGT, SULT 27 
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Appendix 3: Biotransformation of morphine 
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Morphine Biotransformation Pathway Enzymes/Mechanisms 
# Process Enzyme/Mechanism Source # 
1 N-Dealkylation CYP (CYPs 3A4, 2C8) 132 
2 Alcohol oxidation Morphine-6-dehydrogenase, OH radicals 82, 83, 84 
3 Alkene reduction Morphinone reductase 157 
4 N-Dealkylation Not available in literature 158 
5 Ketone reduction Not available in literature 159 
6 Ketone reduction Not available in literature 159 
7 N-Dealkylation Not available in literature 159 
8 N-Dealkylation Not available in literature 159 
II Phase II conjugation UGT (UGT2B7), SULT 159, 160 
* Protein adduction 1,4-Michael addition on α,β-unsaturated carbonyl 80, 83 
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Appendix 4: Steglich esterification mechanism 
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Appendix 5: Cocaine metabolism MRM ionization and dissociation parameters 
Compound (Abbreviation) [M+H]+ Fragmentor (V) Transitionsa Collision Energy (V) RT (min)b,c 
norecgonine* 
     (NE) 172.1 110 
172.1 
172.1 
 
 
154 
68 
18 
26 N.D. 
ecgonine 
     (ECG) 186.1 110 
186.1 
186.1 
 
 
168 
82 
18 
26 0.295 ± 0.002 
norecgonine methyl ester* 
     (NEME) 186.1 105 
186.1 
186.1 
 
 
168 
68 
14 
26 N.D. 
ecgonine methyl ester 
     (EME) 200.1 105 
200.1 
200.1 
 
 
182 
82 
14 
26 0.288 ± 0.000 
norecgonine ethyl ester* 
     (NEEE) 200.1 115 
200.1 
200.1 
 
 
182 
68 
14 
26 N.D. 
ecgonine ethyl ester 
     (EEE) 214.1 115 
214.1 
214.1 
 
 
196 
82 
14 
26 0.389 ± 0.001 
benzoylnorecgonine* 
     (BNE) 276.1 120 
276.1 
276.1 
 
 
154 
68 
14 
30 3.005 ± 0.003 
benzoylecgonine 
     (BE) 290.1 120 
290.1 
290.1  
 
 
168 
105 
14 
30 2.940 ± 0.001 
norcocaine 
     (NC) 290.1 110 
290.1 
290.1 
 
 
168 
136 
10 
22 4.454 ± 0.002 
2-hydroxybenzoylnorecgonine* 
     (2-OH-BNE) 292.1 120 
292.1 
292.1 
 
 
172 
154 
14 
30 N.D. 
3-hydroxybenzoylnorecgonine* 
     (3-OH-BNE) 292.1 120 
292.1 
292.1 
 
 
154 
68 
14 
30 N.D. 
4-hydroxybenzoylnorecgonine* 
     (4-OH-BNE) 292.1 120 
292.1 
292.1 
 
 
154 
68 
14 
30 N.D. 
N-hydroxybenzoylnorecgonine* 
     (N-OH-BNE) 292.1 120 
292.1 
292.1 
 
 
170 
84 
14 
30 N.D. 
cocaine 
     (COC) 304.2 120 
304.2 
304.2 
 
 
182 
82 
14 
30 4.164 ± 0.003 
norcocaethylene 
     (NCE) 304.2 125 
304.2 
304.2 
 
 
182 
68 
18 
30 5.550 ± 0.007 
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Compound (Abbreviation) [M+H]+ Fragmentor (V) Transitionsa Collision Energy (V) RT (min)b,c 
norcocaine nitroxide* 
     (NC-NO) 305.1 110 
305.1 
305.1 
 
 
169 
151 
10 
22 N.D. 
2-hydroxybenzoylecgonine 
     (2-OH-BE) 306.1 115 
306.1 
306.1 
 
 
186 
168 
14 
30 3.199 ± 0.003 
2-hydroxynorcocaine* 
     (2-OH-NC) 306.1 110 
306.1 
306.1 
 
 
186 
168 
10 
22 4.613 ± 0.005 
3-hydroxybenzoylecgonine 
     (3-OH-BE) 306.1 120 
306.1 
306.1 
 
 
168 
121 
18 
26 2.322 ± 0.002 
3-hydroxynorcocaine* 
     (3-OH-NC) 306.1 110 
306.1 
306.1 
 
 
168 
150 
10 
22 3.014 ± 0.000 
4-hydroxybenzoylecgonine 
     (4-OH-BE) 306.1 120 
306.1 
306.1 
 
 
168 
121 
15 
35 2.030 ± 0.003 
4-hydroxynorcocaine* 
     (4-OH-NC) 306.1 110 
306.1 
306.1 
 
 
168 
150 
10 
22 2.639 ± 0.003 
N-hydroxynorcocaine* 
     (N-OH-NC) 306.1 110 
306.1 
306.1 
 
 
168 
150 
10 
22 N.D. 
cocaethylene 
     (CE) 318.2 130 
318.2 
318.2 
 
 
196 
82 
18 
30 5.284 ± 0.002 
2-hydroxycocaine 
     (2-OH-COC) 320.1 115 
320.1 
320.1 
 
 
200 
182 
18 
30 4.302 ± 0.005 
2-hydroxynorcocaethylene* 
     (2-OH-NCE) 320.1 125 
320.1 
320.1 
 
 
200 
182 
18 
30 N.D. 
3-hydroxycocaine 
     (3-OH-COC) 320.1 135 
320.1 
320.1 
 
 
182 
82 
18 
40 2.813 ± 0.003 
3-hydroxynorcocaethylene* 
     (3-OH-NCE) 320.1 125 
320.1 
320.1 
 
 
182 
68 
18 
30 N.D. 
4-hydroxycocaine 
     (4-OH-COC) 320.1 135 
320.1 
320.1 
 
 
182 
121 
18 
34 2.466 ± 0.000 
4-hydroxynorcocaethylene* 
     (4-OH-NCE) 320.1 125 
320.1 
320.1 
 
 
182 
68 
18 
30 N.D. 
cocaine nitroxide* 
     (CNO) 320.1 120 
320.1 
320.1 
 
 
198 
82 
14 
30 N.D. 
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Compound (Abbreviation) [M+H]+ Fragmentor (V) Transitionsa Collision Energy (V) RT (min)b,c 
N-hydroxynorcocaethylene* 
     (N-OH-NCE) 320.1 125 
320.1 
320.1 
 
 
198 
84 
18 
30 N.D. 
N-hydroxy-2-hydroxynorcocaine* 
     (N-OH-2-HO-NC) 322.1 110 
322.1 
322.1 
 
 
202 
184 
10 
22 N.D. 
N-hydroxy-3-hydroxynorcocaine* 
     (N-OH-3-HO-NC) 322.1 110 
322.1 
322.1 
 
 
184 
152 
10 
22 N.D. 
N-hydroxy-4-hydroxynorcocaine* 
     (N-OH-4-HO-NC) 322.1 110 
322.1 
322.1 
 
 
184 
152 
10 
22 N.D. 
2-hydroxycocaethylene 
     (2-OH-CE) 334.2 130 
334.2 
334.2 
 
 
214 
196 
14 
30 5.424 ± 0.003 
3-hydroxycocaethylene 
     (3-OH-CE) 334.2 130 
334.2 
334.2 
 
 
196 
82 
18 
34 3.658 ± 0.002 
4-hydroxycocaethylene 
     (4-OH-CE) 334.2 130 
334.2 
334.2 
 
 
196 
82 
18 
34 3.214 ± 0.002 
dihydroxycocaine (isomers)* 
     (dOH-COC) 336.1 120 
336.1 
336.1 
 
 
182 
82 
14 
30 
0.625 ± 0.013 
1.788 ± 0.004 
2.937 ± 0.003 
N-hydroxy-2-hydroxynorcocaethylene* 
     (N-OH-2-OH-NCE) 336.1 125 
336.1  
336.1 
 
 
216 
198 
18 
30 N.D. 
N-hydroxy-3-hydroxynorcocaethylene* 
     (N-OH-3-OH-NCE) 336.1 125 
336.1 
336.1 
 
 
198 
84 
18 
30 N.D. 
N-hydroxy-4-hydroxynorcocaethylene* 
     (N-OH-4-OH-NCE) 336.1 125 
336.1 
336.1 
 
 
198 
84 
18 
30 N.D. 
dihydroxycocaethylene (isomers)* 
     (dOH-CE) 350.2 130 
350.2 
350.2 
 
 
196 
82 
18 
30 
1.125 ± 0.012 
2.402 ± 0.007 
3.758 ± 0.004 
hydroxybenzoylnorecgonine glucuronide* 
     (OH-BNE-G) 468.1 120 
468.1 
468.1 
 
 
292 
154 
14 
30 N.D. 
hydroxybenzoylecgonine glucuronide* 
     (OH-BE-G) 482.1 120 
482.1  
482.1  
 
 
306 
168 
14 
30 N.D. 
hydroxynorcocaine glucuronide* 
     (OH-NC-G) 482.1 110 
482.1  
482.1 
 
 
306 
168 
10 
22 N.D. 
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Compound (Abbreviation) [M+H]+ Fragmentor (V) Transitionsa Collision Energy (V) RT (min)b,c 
hydroxycocaine glucuronide* 
     (OH-COC-G) 496.1 120 
496.1  
496.1 
 
 
320 
182 
14 
30 N.D. 
hydroxynorcocaethylene glucuronide* 
     (OH-NCE-G) 496.1 125 
496.1  
496.1 
 
 
320 
182 
18 
30 N.D. 
hydroxycocaethylene glucuronide* 
     (OH-CE-G) 510.2 130 
510.2 
510.2  
 
 
334 
196 
18 
30 N.D. 
dihydroxynorcocaine diglucuronide* 
     (dOH-NC-dG) 674.1 110 
674.1 
674.1  
 
 
498 
322 
10 
22 N.D. 
dihydroxynorcocaethylene diglucuronide* 
     (dOH-NCE-dG) 688.1 125 
688.1  
688.1  
 
 
512 
336 
18 
30 N.D. 
benzoylecgonine-D3 (IS) 
     (BE-D3) 293.2 120 
293.2 
293.2 
 
 
171 
105 
14 
30 2.934 ± 0.002 
* parameters determined theoretically, not by direct optimization 
a bold = quantifier; plain text = qualifier 
b N.D. = not detected and no standard 
c n=10 
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Appendix 6: Methamphetamine metabolism MRM ionization and dissociation parameters 
Compound (Abbreviation) [M+H]+ Fragmentor (V) Transitionsa Collision Energy (V) RT (min)b,c 
phenylacetone* 
     (PHA) 135.1 75 
135.1 
135.1 
 
 
91 
119 
16 
4 0.987 ± 0.010 
amphetamine 
     (AMP) 136.1 75 
136.1 
136.1 
 
 
91 
119 
16 
4 2.043 ± 0.003 
methampethamine 
     (MET) 150.1 80 
150.1 
150.1 
 
 
91 
119 
16 
4 2.684 ± 0.005 
2-hydroxyamphetamine* 
     (2-OH-AMP) 152.1 75 
152.1 
152.1 
 
 
107 
135 
16 
4 1.381 ± 0.002 
3-hydroxyamphetamine* 
     (3-OH-AMP) 152.1 75 
152.1 
152.1 
 
 
107 
135 
16 
4 0.876 ± 0.002 
4-hydroxyamphetamine* 
     (4-OH-AMP) 152.1 75 
152.1 
152.1 
 
 
107 
135 
16 
4 0.690 ± 0.002 
N-hydroxyamphetamine* 
     (N-OH-AMP) 152.1 75 
152.1 
152.1 
 
 
91 
119 
16 
4 N.D. 
norephedrine 
     (NEPH) 152.1 75 
152.1 
152.1 
 
 
134 
117 
5 
17 0.975 ± 0.002 
2-hydroxymethamphetamine* 
     (2-OH-MET) 166.1 80 
166.1 
166.1 
 
 
107 
135 
16 
4 1.824 ± 0.002 
3-hydroxymethamphetamine* 
     (3-OH-MET) 166.1 80 
166.1 
166.1 
 
 
107 
135 
16 
4 1.053 ± 0.003 
4-hydroxymethamphetamine* 
     (4-OH-MET) 166.1 80 
166.1 
166.1 
 
 
107 
135 
16 
4 0.788 ± 0.002 
ephedrine 
     (EPH) 166.1 80 
166.1 
166.1 
 
 
148 
117 
9 
17 1.425 ± 0.003 
2-hydroxynorephedrine* 
     (2-OH-NEPH) 168.1 75 
168.1 
168.1 
 
 
150 
133 
5 
17 0.803 ± 0.002 
3-hydroxynorephedrine* 
     (3-OH-NEPH) 168.1 75 
168.1 
168.1 
 
 
150 
133 
5 
17 0.470 ± 0.001 
4-hydroxynorephedrine* 
     (4-OH-NEPH) 168.1 75 
168.1 
168.1 
 
 
150 
133 
5 
17 0.378 ± 0.000 
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Compound (Abbreviation) [M+H]+ Fragmentor (V) Transitionsa Collision Energy (V) RT (min)b,c 
dihydroxyamphetamine* 
     (di-OH-AMP) [major isomer] 168.1 75 
168.1 
168.1 
 
 
123 
151 
16 
4 0.459 ± 0.004 
2-hydroxyephedrine* 
     (2-OH-EPH) 182.1 80 
182.1 
182.1 
 
 
164 
133 
9 
17 1.120 ± 0.003 
3-hydroxyephedrine* 
     (3-OH-EPH) 182.1 80 
182.1 
182.1 
 
 
164 
133 
9 
17 0.586 ± 0.001 
4-hydroxyephedrine* 
     (4-OH-EPH) 182.1 80 
182.1 
182.1 
 
 
164 
133 
9 
17 0.426 ± 0.001 
dihydroxymethamphetamine* 
     (di-OH-MET) [major isomer] 182.1 80 
182.1 
182.1 
 
 
123 
151 
16 
4 0.508 ± 0.002 
dihydroxynorephedrine* 
     (di-OH-NEPH) [major isomer] 184.1 75 
184.1 
184.1 
 
 
166 
149 
5 
17 0.375 ± 0.003 
dihydroxyephedrine* 
     (di-OH-EPH) [major isomer] 198.1 80 
198.1 
198.1 
 
 
180 
149 
9 
17 0.394 ± 0.005 
hydroxyamphetamine-β-D-glucuronide* 
     (OH-AMP-G) 328.1 75 
328.1 
328.1 
 
 
152 
107 
4 
16 N.D. 
N-hydroxyamphetamine-β-D-glucuronide* 
     (N-OH-AMP-G) 328.1 75 
328.1 
328.1 
 
 
152 
91 
4 
16 N.D. 
hydroxymethamphetamine-β-D-glucuronide* 
     (OH-MET-G) 342.2 80 
342.2 
342.2 
 
 
166 
107 
4 
16 N.D. 
hydroxynorephedrine-β-D-glucuronide* 
     (OH-NEPH-G) 344.1 75 
344.1 
344.1 
 
 
168 
150 
5 
17 N.D. 
hydroxyephedrine-β-D-glucuronide* 
     (OH-EPH-G) 358.2 80 
358.2 
358.2 
 
 
182 
164 
9 
17 N.D. 
methamphetamine-D5 (IS) 
     (MET-D5) 155.2 85 
155.2 
155.2 
 
 
92 
121 
17 
5 2.721 ± 0.004 
* parameters determined theoretically, not by direct optimization 
a bold = quantifier; plain text = qualifier 
b N.D. = not detected and no standard 
c n=10 
  
148 
Appendix 7: Morphine metabolism MRM ionization and dissociation parameters 
Compound (Abbreviation) [M+H]+ Fragmentor (V) Transitionsa Collision Energy (V) RT (min)b,c 
normorphine 
     (NM) 272.1 140 
272.1 
272.1 
 
 
165 
181 
38 
38 0.511 ± 0.001 
norhydromorphone 
     (NHM) 272.1 130 
272.1 
272.1 
 
 
185 
157 
27 
50 0.821 ± 0.003 
nordihydroisomorphine* 
     (NdHiM) 274.1 130 
274.1 
274.1 
 
 
185 
157 
27 
50 N.D. 
nordihydromorphine* 
     (NdHM) 274.1 130 
274.1 
274.1 
 
 
185 
157 
27 
50 N.D. 
morphinone* 
     (MN) 284.1 160 
284.1 
284.1 
 
 
185 
227 
38 
38 0.799 ± 0.005 
hydromorphone 
     (HM) 286.1 160 
286.1 
286.1 
 
 
185 
157 
33 
45 0.942 ± 0.003 
morphine 
     (MOR) 286.1 150 
286.1 
286.1 
 
 
165 
157 
45 
41 0.601 ± 0.002 
dihydroisomorphine* 
     (dHiM) 288.2 160 
288.2 
288.2 
 
 
185 
157 
33 
45 N.D. 
dihydromorphine* 
     (dHM) 288.2 160 
288.2 
288.2 
 
 
185 
157 
33 
45 N.D. 
norhydromorphone-3-β-D-glucuronide* 
     (NHM3G) 448.2 165 
448.2 
448.2 
 
 
272 
185 
33 
50 N.D. 
normorphine-3-β-D-glucuronide* 
     (NM3G) 448.2 145 
448.2 
448.2 
 
 
272 
165 
33 
50 N.D. 
normorphine-6-β-D-glucuronide* 
     (NM6G) 448.2 145 
448.2 
448.2 
 
 
272 
165 
33 
50 N.D. 
nordihydroisomorphine-3-β-D-glucuronide* 
     (NdHiM3G) 450.2 145 
450.2 
450.2 
 
 
274 
185 
33 
50 N.D. 
nordihydromorphine-3-β-D-glucuronide* 
     (NdHM3G) 450.2 145 
450.2 
450.2 
 
 
274 
185 
33 
50 N.D. 
hydromorphone-3-β-D-glucuronide 
     (HM3G) 462.2 165 
462.2 
462.2 
 
 
286 
185 
33 
50 0.464 ± 0.003 
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Compound (Abbreviation) [M+H]+ Fragmentor (V) Transitionsa Collision Energy (V) RT (min)b,c 
morphine-3-β-D-glucuronide 
     (M3G) 462.2 145 
462.2 
462.2 
 
 
286 
201 
33 
50 0.398 ± 0.002 
morphine-6-β-D-glucuronide 
     (M6G) 462.2 145 
462.2 
462.2 
 
 
286 
201 
33 
50 0.553 ± 0.005 
dihydroisomorphine-3-β-D-glucuronide* 
     (dHiM3G) 464.2 145 
464.2 
464.2 
 
 
288 
185 
33 
50 N.D. 
dihydromorphine-3-β-D-glucuronide* 
     (dHM3G) 464.2 145 
464.2 
464.2 
 
 
288 
185 
33 
50 N.D. 
dihydroisomorphine-6-β-D-glucuronide* 
     (dHiM6G) 464.2 145 
464.2 
464.2 
 
 
288 
185 
33 
50 N.D. 
dihydromorphine-6-β-D-glucuronide* 
     (dHM6G) 464.2 145 
464.2 
464.2 
 
 
288 
185 
33 
50 N.D. 
normorphine-3,6-di-β-D-glucuronide* 
     (NM36dG) 624.2 145 
624.2  
624.2 
 
 
448 
272 
33 
50 N.D. 
morphine-3,6-di-β-D-glucuronide* 
     (M36dG) 638.2 145 
638.2 
638.2 
 
 
462 
286 
33 
50 N.D. 
dihydroisomorphine-3,6-di-β-D-glucuronide* 
     (dHiM36dG) 640.3 145 
640.3 
640.3 
 
 
464 
288 
33 
50 N.D. 
dihydromorphine-3,6-di-β-D-glucuronide* 
     (dHM36dG) 640.3 145 
640.3 
640.3 
 
 
464 
288 
33 
50 N.D. 
morphine-D3 (IS) 
     (MOR-D3) 289.2 155 
289.2 
289.2 
 
 
165 
157 
50 
45 0.600 ± 0.002 
* parameters determined theoretically, not by direct optimization 
a bold = quantifier; plain text = qualifier 
b N.D. = not detected and no standard 
c n=10 
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Appendix 8: LC-MS/MS Methods 
A:  2 mM ammonium formate and 0.1% formic acid in H2O 
Cocaine metabolism 
B:  90/10/0.1 acetonitrile:H2O:formic acid 
Flow Rate:  0.5 mL/min  Injection Volume:  1 μL 
   Post-run Equlibration:  3.5 min at 5% B 
   MS Mode:  QQQ; Dynamic MRM 
Run Time:  12.5 min  MS Parameters:  See Appendix 5 
 
A:  2 mM ammonium formate and 0.1% formic acid in H2O 
Methamphetamine metabolism 
B:  90/10/0.1 acetonitrile:H2O:formic acid 
     Flow Rate:  0.5 mL/min  Injection Volume:  5 μL 
   Post-run Equlibration:  3.5 min at 5% B 
   MS Mode:  QQQ; Dynamic MRM 
Run Time:  9.0 min      MS Parameters:  See Appendix 6 
     
 
A:  2 mM ammonium formate and 0.1% formic acid in H2O 
Morphine metabolism 
B:  90/10/0.1 acetonitrile:H2O:formic acid 
  Flow Rate:  0.5 mL/min    Injection Volume:  5 μL 
   Post-run Equlibration:  3.5 min at 5% B 
  MS Mode:  QQQ; Dynamic MRM 
Run Time:  9.0 min  MS Parameters:  See Appendix 7 
 
 
Time (min) % B 
0.0 5 
7.0 30 
8.0 95 
9.0 95 
Time (min) % B 
0.0 5 
3.5 5 
4.5 95 
5.5 95 
Time (min) % B 
0.0 5 
3.5 5 
4.5 95 
5.5 95 
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A:  2 mM ammonium formate and 0.1% formic acid in H2O 
rhCYP bactosome isoform viability cocktail 
B:  90/10/0.1 acetonitrile:H2O:formic acid 
  Flow Rate:  0.5 mL/min    Injection Volume:  5 μL 
   Post-run Equlibration:  3.5 min at 5% B 
  MS Mode:  QQQ; Dynamic MRM 
Run Time:  10.5 min  MS Parameters:  See Table 7 
 
A:  10 mM ammonium acetate (pH 4.0) 
General adduct screening 
B:  Methanol 
  Flow Rate:  0.3 mL/min  Injection Volume:  10 μL 
   Post-run Equlibration:  6.0 min at 4% B 
   MS Mode:  QQQ; SIM of theoretical m/z values & Product Ion of  
Run Time:  28.0 min   suspected adduction products 
    MS Parameters:  Frag 120 V (COC), 90 V (MET), 160 V (MOR);  
CE 10, 20, 30, 40 V 
 
A:  10 mM ammonium acetate (pH 4.0) 
Cocaine‒N-acetylcysteine adduct 
B:  Methanol 
  Flow Rate:  0.3 mL/min  Injection Volume:  10 μL 
   Post-run Equlibration:  6.0 min at 4% B 
   MS Mode:  QTOF; Targeted MS/MS of m/z 483.18 
     MS Parameters:  Frag 120 V; CE 10, 20, 30, 40 V 
Run Time:  19.0 min 
Time (min) % B 
0.0 5 
5.0 65 
6.0 95 
7.0 95 
Time (min) % B 
0.0 4 
0.5 4 
20.0 90 
22.0 90 
Time (min) % B 
0.0 4 
0.5 4 
10.0 15 
11.0 90 
13.0 90 
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A:  10 mM ammonium acetate (pH 4.0) 
Cocaine‒ glutathione adduct 
B:  Methanol 
  Flow Rate:  0.3 mL/min    Injection Volume:  10 μL 
   Post-run Equlibration:  6.0 min at 4% B 
  MS Mode:  QQQ; SIM & Product Ion of m/z 627 
     MS Parameters:  Frag 150 V; CE 10, 20, 30, 40, 50 V 
Run Time:  14.0 min 
 
A:  10 mM ammonium acetate (pH 4.0) 
Cocaine‒AcPAACAA adduct 
B:  Methanol 
  Flow Rate:  0.3 mL/min   Injection Volume:  10 μL 
   Post-run Equlibration:  6.0 min at 4% B 
   MS Mode:  QQQ; SIM & Product Ion of m/z 864 
     MS Parameters:  Frag 140 V; CE 20, 30, 40, 50 V 
Run Time:  20.0 min 
 
A:  10 mM ammonium acetate (pH 4.0) 
Morphine‒N-acetylcysteine adduct 
B:  Methanol 
Flow Rate:  0.3 mL/min  Injection Volume:  10 μL 
   Post-run Equlibration:  6.0 min at 4% B 
   MS Mode:  QTOF; Targeted MS/MS of m/z 447.16 & 449.17 
     MS Parameters:  Frag 160 V; CE 10, 20, 30, 40, 50 V 
Run Time:  16.0 min 
Time (min) % B 
0.0 4 
0.5 4 
5.0 26 
6.0 90 
8.0 90 
Time (min) % B 
0.0 4 
0.5 4 
11.0 50 
12.0 90 
14.0 90 
Time (min) % B 
0.0 4 
0.5 4 
7.0 7.5 
8.0 90 
10.0 90 
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A:  10 mM ammonium acetate (pH 4.0) 
Morphine‒ glutathione adduct 
B:  Methanol 
Flow Rate:  0.3 mL/min  Injection Volume:  10 μL 
   Post-run Equlibration:  6.0 min at 4% B 
   MS Mode:  QQQ; SIM & Product Ion of m/z 591 
Run Time:  14.0 min  MS Parameters:  Frag 160 V; CE 10, 20, 30, 40, 50 V 
       
A:  10 mM ammonium acetate (pH 4.0) 
Morphine‒AcPAACAA adduct 
B:  Methanol 
Flow Rate:  0.3 mL/min  Injection Volume:  10 μL 
   Post-run Equlibration:  6.0 min at 4% B 
   MS Mode:  QQQ; SIM & Product Ion of m/z 823 
     MS Parameters:  Frag 160 V; CE 10, 20, 30, 40, 50 V 
Run Time:  20.0 min 
Time (min) % B 
0.0 4 
5 4 
6.0 90 
8.0 90 
Time (min) % B 
0.0 4 
0.5 4 
11.0 50 
12.0 90 
14.0 90 
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Appendix 9: MS/MS fragmentation of native peptides (a) GSH and (b) AcPAACAA 
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